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CHAPTER 1: INTRODUCTION 
1.1 CARDIOVASCULAR AND KIDNEY DISEASE  
 
 
Cardiovascular disease (CVD) encompasses a wide range of acute and chronic pathologies, 
specifically atherosclerotic, myocardial, valvular and pericardial disease as well as cardiac 
arrhythmias. Kidney disease likewise incorporates a myriad of vascular, glomerular, tubulo-
interstitial and obstructive nephropathies, presenting either abruptly as an acute kidney injury 
(AKI) or progressing insidiously in chronic kidney disease (CKD). Co-existence of 
cardiovascular and kidney disease is a frequent clinical finding, determined by shared 
aetiologies and numerous bidirectional pathological interactions, which confers additional 
risk and which carries an ominous prognosis.  
 
The traditional risk factors associated with cardiovascular disease, namely advanced age, male 
gender, Asian ethnicity, diabetes mellitus, hypertension, dyslipidaemia as well as lifestyle 
factors including smoking, physical inactivity and obesity, overlap considerably with the risk 
factors for CKD (Table 1). In studies of patients with established CKD, up to 20% have 
concurrent diabetes mellitus and 50% suffer from hypertension1.  Similarly in patients with 
established diabetes or hypertension, the prevalence of CKD has been found to be  as high 
as 26% and 37% respectively2. Throughout the world these risk factors are now epidemic, 
with one in seven people treated for hypertension3 and one in twelve people diagnosed with 
diabetes4. These totals are projected to increase by 50% over the next decade and the 
prevalence of CKD is expected to rise accordingly. 
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As would be expected by way of shared aetiology alone, notwithstanding the independently 
deleterious effect that CKD has on the cardiovascular system, CVD is highly prevalent in 
renal patients and is directly proportional to the severity of renal dysfunction. One in three 
patients with moderate to severe CKD will suffer from coronary artery disease (CAD) and a 
third develop chronic heart failure (CHF).1  
 
Similarly a considerable proportion of patients with CVD have co-existent CKD, found in a 
third of patients undergoing coronary angiography5-7 and in a third with chronic heart failure. 
Co-existent CVD and CKD leads to exacerbation of disease progression in both conditions 
and considerably increases morbidity and mortality. A systematic review by Tonelli et al8, 
including 100,064 patients with mild to moderate CKD, found that at age 50 years, the 
relative risk of cardiovascular mortality was 3.4 (95% CI 2.1 to 5.5) whereas at 70 years, the 
relative risk was 1.5 (95% CI 0.96 to 2.3). By the onset of end stage renal disease (ESRD) 
and dialysis, even after stratification for age, gender, race and diabetes, cardiovascular 
mortality is 10 to 20 times higher than that of the general population9. 
 
Pre-existing CKD or the onset of AKI significantly increases the risk of serious adverse 
events following cardiovascular investigations and therapies. A prototypical example of this 
is ‘contrast induced nephropathy’ (CIN) which describes an acute kidney injury caused by 
exposure to the intravascular radio-contrast media administered during coronary 
angiography (CA) and which is associated with significant major adverse cardiac events 
(MACE) . Clinical concerns regarding the increased risks brought about by CIN following 
CA based cardiac investigations may lead to delay or even withdrawal of prognostic therapies 
which must be carefully balanced against the potential benefits in this high risk cohort. In 
light of these concerns, patients with both CVD and CKD are optimally managed by 
multidisciplinary teams with experience of the complexities within this clinical field. 
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Table 1: Common risk factors for CVD and CKD 
 
 
CKD specific risks Shared CVD and CKD 
risks 
CVD specific risks 
 
Autoimmune disease 
Vasculitic disease 
Cirrhotic liver disease 
Polycystic Kidney Disease 
Pyelonephritis 
Glomerulonephritis 
Nephrotoxic agents 
Urinary outflow 
obstruction 
 
Age 
Male sex 
Black/Asian ethnicity 
Hypertension 
Diabetes 
Dyslipidaemia 
Smoking 
Obesity 
 
Genetic disease 
Infectious disease 
Pulmonary disease 
Thrombophilia 
Chemotherapy 
Radiotherapy 
Physical inactivity 
Dietary factors 
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1.1.1 ACUTE KIDNEY INJURY AND CHRONIC KIDNEY DISEASE 
 
 
The manifold aetiologies of both AKI and CKD can be broadly categorised into pre-renal, 
renal and post-renal processes.  
 
Pre-renal insults involve disruption of renal perfusion due to a reduction in circulating blood 
volume (e.g. haemorrhage or over-diuresis), reduction in cardiac output (e.g. cardiogenic 
shock or low output cardiac failure), renal arterial compromise (e.g. renal artery stenosis or 
excessive vasoconstriction) or venous congestion (e.g. venous thrombosis or congestive 
heart failure).  
 
Renal (or intrinsic) aetiologies are caused by primary parenchymal disease, which can be 
subdivided by the structures principally affected, notably the glomerulus, tubules or 
interstitium as well as those secondary to systemic disease processes (e.g. diabetes mellitus 
and autoimmune disease) or specific to the kidney (e.g. polycystic kidney disease or 
pyelonephritis).  
 
Post renal pathologies involve obstruction of urinary outflow from the kidney either at a 
tubular (e.g. crystal deposition) or anatomical level (e.g. prostatic hypertrophy). Severe AKI 
in which permanent renal injury occurs may herald the onset of CKD, with loss of renal 
auto-regulatory processes and development of systemic complications secondary to kidney 
dysfunction (e.g. hypertension) leading to ongoing renal injury and a progressive decline in 
glomerular filtration rate (GFR) (Table 2).  
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Following an acute renal insult, the diagnosis of AKI typically relies upon an initial reduction 
in urinary output lasting at least 6 to 12 hours followed by a rise in serum creatinine (SCr), 
or a fall in estimated glomerular filtration rate (eGFR - calculated using SCr and adjusted for 
variables such as age, gender, ethnicity and weight). Elevations in SCr are maximal after 48 
hours and may persist for one to two weeks before gradually falling, although if significant 
injury has occurred SCr levels may never return to baseline. A number of graded classification 
systems for AKI exist as summarised in Table 3.  
 
The diagnosis of CKD is dependent on a persistent reduction in eGFR for a minimum of 
three months, to under 60ml/min/1.73m2, or under 90ml/min/1.73m2 in the presence of 
structural kidney abnormality, albuminuria, or genetic disease. The Kidney Disease Outcome 
Quality Initiative (K/DOQI), classification of CKD consists of five categories that 
correspond with the severity of disease, therapeutic modalities and prognosis (Table 4)10.   
17 
 
 
 
 
1.1.1.1     GFR, serum creatinine and estimated GFR measurement 
 
 
 
Currently all standard clinical investigations for assessment of renal function have limitations 
and do not correlate well with true GFR, defined as the volume of fluid filtered from the 
renal glomerular capillaries into the Bowman's capsule per unit of time. Differential basal 
tone of the afferent and efferent glomerular arterioles provides homeostasis of GFR, 
regulated by neuronal and hormonal mediators. GFR is equal to the ‘Clearance Rate’ of a 
solute, if freely filtered and neither reabsorbed nor secreted by the kidney. Serum creatinine 
(SCr), formed by the breakdown of creatine phosphate in muscle tissue, is freely filtered by 
the glomerulus but also actively secreted in small amounts by the peritubular capillaries, 
leading to an overestimation of GFR of between 10% and 20%. SCr measurement is a widely 
available investigation, limited by dependence on a number of non-renal factors such as total 
body pool of creatine phosphate (total muscle mass), creatine phosphate generation rate, 
conversion rate of creatine phosphate to creatinine, dietary sources of creatinine, hydration 
status, renal tubular secretion rate of creatinine, urinary flow rate and assay interference. As 
such different SCr concentrations can occur between individuals with the same renal 
function due to differing age, gender and ethnicity and other factors.  Several calculations 
have been developed to provide a more accurate estimation of true GFR by incorporating 
known clinical variables, for example that of the Modified Diet in Renal Disease (MDRD) 
study group11. 
 
eGFR MDRD = 186 x (SCr / 88.4)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if black) 
 
Criticisms of this formula include the absence of total body weight, as in the original 
Cockcroft-Gault formula12, as well as reduced accuracy in patients with GFR >60ml/min. 
As such adoption of the more accurate CKD-EPI formula13 is now commonplace, which 
has also been shown to correlate more precisely with cardiovascular endpoints14. 
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Table 2: Aetiology of AKI and CKD 
 
 
 
                    
                       Acute Kidney Injury                              Chronic Kidney Disease 
 
Pre- 
Renal 
Acute hypo-perfusion 
 Haemorrhage/dehydration 
 Sepsis/cardiogenic shock 
Vascular 
 Embolism 
 Vasoconstriction (drugs/Ca2+) 
 Renal vein thrombosis 
 
Chronic hypo-perfusion 
 Liver cirrhosis/hypoalbuminemia 
 Chronic heart failure 
Vascular 
 Hypertension 
 Renal artery stenosis 
 
 
Renal 
 
Acute Glomerulonephritis 
 IgA/haemolytic uremic 
syndrome 
Acute Tubular Necrosis 
 Contrast induced nephropathy 
 Nephrotoxic 
Acute Interstitial Nephritis 
 Allergic  
 
Polycystic Kidney disease 
Inflammatory Glomerulonephritis 
 Systemic lupus erythematosis 
Non-inflammatory Glomerulonephritis 
 Minimal change 
 Focal segmental/membranous 
Metabolic 
 Diabetes Mellitus 
 
Post- 
Renal 
Acute Urinary Retention 
 Ureteric/prostatic/urethral 
 Urolithiasis, malignancy 
Tubular Obstruction 
 Crystal/drug deposition 
Infective 
 Pyelonephritis 
 
Chronic Urinary Retention 
 Benign prostatic hypertrophy 
 Neuropathic bladder 
 Urolithiasis/malignancy 
Tubular Obstruction 
 Crystal/Protein 
Vesico-ureteric reflux 
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Table 3: Three classification systems for severity of AKI 
 
RIFLE15  
 
AKIN16 KDIGO17 All 
Stage SCr/eGFR 
(7 days) 
 SCr (48 hr)  SCr (48hr) Urine output 
Risk SCr x 1.5 
eGFR< 25% 
1 SCr x 1.5-2  
or 
>0.3mg/dl 
1 SCr x 1.5 -1.9 
or >0.3mg/dl 
<0.5ml/kg/hr  
for 6hr 
Injury SCr x 2 
eGFR <50% 
2 SCR x 2-3  
 
2 SCr x 2-2.9  
 
<0.5ml/kg/hr  
for 12 hr 
Failure SCr x 3 (or 
>0.5mg/dl 
if baseline 
>4mg/dl) 
eGFR <75% 
3 SCr x 3>  
or 
>0.5mg/dl 
if baseline 
>4mg/dl) 
or RRT 
3 SCr x 3>  
or >4mg/dl 
or RRT 
<0.3ml/kg/hr 
for 24 hr or 
anuria for 
12hr 
Loss AKI >4 
weeks 
 
ESRD ESRD >3 
months 
 
 
 
SCr – Serum Creatinine, eGFR = estimated glomerular filtration rate, RRT = Renal replacement therapy, AKI = Acute 
kidney injury, ESRD = End stage renal disease, hr = hour 
 
 
 
Table 4: The K/DOQI Chronic kidney disease classification system 
 
K/DOQI10 
Stage 
GFR 
ml/min 
Description Treatment 
I >90  Normal kidney function 
with urinary, structural 
or genetic abnormality 
Observation, blood pressure and 
cardiovascular risk management 
II 60-89  Mild reduction in kidney 
function 
As above 
IIIa 
 
IIIb 
45-59  
 
30-44  
Moderate reduction in 
kidney function 
As above 
IV 15-29  Severe reduction in 
kidney function 
As above, planning for end stage 
kidney failure,  
V <15  
Dialysis 
Very severe or ‘end 
stage’ renal disease 
Haemodialysis, Renal transplant, 
anaemia, calcium, cardiovascular  
risk management 
P/T/D P = Proteinuria, T= Renal Transplant, D= Dialysis 
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1.1.2 CORONARY ARTERY DISEASE 
 
 
Coronary artery disease (CAD), otherwise known as ischaemic heart disease (IHD) or 
coronary heart disease (CHD) encompasses a spectrum of clinical presentations including 
stable angina, the acute coronary syndromes (ACS) namely unstable angina (UA), non-ST 
elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI) 
as well as sudden cardiac death (SCD). CAD is characterised by atherosclerosis of one or 
more of the coronary arteries, which may limit coronary blood flow causing myocardial 
ischaemia, or lead to myocardial infarction following atherosclerotic plaque rupture and 
thrombotic occlusion of the vascular lumen.  
 
CAD remains the leading cause of mortality in the world, responsible for almost 30% of all 
deaths18. In the last decade in the United Kingdom, cancer has overtaken myocardial 
infarction as the leading cause of death in men, however it remains the primary cause of 
death in women19.  The rising global incidence of CAD risk factors and an aging population 
will ensure that CAD remains the major future challenge facing health care systems in both 
the developed and developing world. 
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1.1.3 CORONARY ARTERY DISEASE AND CHRONIC KIDNEY DISEASE 
 
 
Accelerated atherosclerosis of the coronary arteries, and indeed of any artery, is pathognomic 
of the interaction between CVD and CKD. Beginning in Stage I CKD,  low-grade micro-
albuminuria, defined as a urine albumin creatinine ratio (UACR) of ≥ 2.5 mg/mmol in men 
and ≥ 3.5 mg/mmol in women, is associated with an increased risk of adverse cardiovascular 
outcomes, even in non-diabetic, non-hypertensive patients and is now recognised as an 
independent cardiovascular risk factor20. As eGFR declines, CAD risk has been shown to 
increase proportionately21 with a twofold increase in the rate of CAD progression22 and an 
increased risk of death following MI in patients with moderate to severe CKD23. In patients 
with established renal disease, cardiovascular mortality is 10-30 times higher,1  and is a more 
likely to occur than progression to end-stage renal disease (ESRD)24. 
 
The rapid progression of CAD seen in CKD is a direct result of the complex  
pathophysiology inherent in renal dysfunction with promotion of vascular calcification25 and 
endothelial dysfunction secondary to factors such as renin-angiotensin dysregulation, hyper-
uricaemia, hyper-parathyroidism and hyper-phosphataemia26,  increased oxidative stress, 
systemic inflammation27, and hyper-homocysteinaemia28. In addition physiological stressors 
such as hypertension, hypervolaemia, malnutrition and anaemia29 as well as pro-thrombotic 
states30 are highly contributory elements. As with all preventive strategies employed against 
CAD, a multidisciplinary approach to control the progression of both renal and 
cardiovascular disease is essential to reduce the excessively high morbidity and mortality rate 
in this patient cohort.31 
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1.1.4 THE ‘CARDIO-RENAL’ SYNDROME 
 
 
The complex bidirectional pathophysiological interaction between the heart and kidney has 
been termed the ‘cardio-renal syndrome’32 (CRS), which is further classified based upon 
primary organ dysfunction and chronicity (see table 5).  In primary cardiac dysfunction, an 
acute (type 1) or chronic (type 2) reduction in cardiac output compromises renal arterial 
blood flow, whilst venous congestion, commonly seen in both systolic and diastolic heart 
failure, reduces the renal perfusion gradient and increases the risk of renal ischaemia33.   
 
In primary renal disease an acute (type 3) or chronic (type 4) reduction in renal function leads 
to neuro-hormonal dysregulation, electrolyte and calcium disturbances, anaemia, 
hypertension, volume overload, oxidative stress and activation of inflammatory cascades. 
This in turn has a deleterious effect on cardiac function, in both an acute (e.g. decompensated 
heart failure, myocardial infarction and arrhythmia) and a chronic fashion (e.g. accelerated 
coronary artery disease (CAD), left ventricular hypertrophy (LVH), and vascular 
calcification). Type 5 CRS occurs when both organ systems are simultaneously affected by 
severe systemic disease processes such as sepsis and toxaemia.  It is important to recognise 
that following the onset of CRS, a negative feedback loop may exist where dysfunction of 
the secondary organ further exacerbates dysfunction of the primary organ. 
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Table 5: The ‘cardio-renal’ syndrome, adapted from the 2010 ADQI conference32 
 
 Inciting event 
Secondary 
disturbance 
Example 
Type 1 
Acute cardio-
renal syndrome 
Acute cardiac 
dysfunction 
Acute kidney injury 
Acute cardiogenic 
shock or acute 
decompensation of 
chronic heart failure 
Type 2  
Chronic cardio-
renal syndrome 
 
Chronic cardiac 
dysfunction 
Chronic kidney 
disease 
Chronic heart failure 
Type 3 
Acute reno-
cardiac syndrome 
Acute kidney 
injury 
Acute cardiac 
dysfunction  
(e.g. heart failure or 
arrhythmia) 
Contrast induced 
nephropathy 
Type 4  
Chronic reno-
cardiac syndrome 
Chronic kidney 
disease 
Chronic cardiac 
dysfunction and/or 
increased risk of 
MACE 
Diabetic renal disease 
Type 5 
Secondary cardio-
renal syndrome 
 
 
Systemic 
disease 
 
Cardiac and renal 
dysfunction 
 
Systemic lupus, sepsis 
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1.2 CORONARY ANGIOGRAPHY & PERCUTANEOUS 
CORONARY INTERVENTION 
 
Invasive coronary angiography was pioneered in 1958 in the United States by Sones and 
Proudfit 34 and remains the gold standard for coronary artery imaging. Under local 
anaesthesia an arterial sheath is sited into either the femoral, brachial or radial artery to allow 
introduction of the cardiac catheter. This is a long, flexible, specifically shaped radio-opaque 
tube, which is guided into the ascending aorta and engaged into the ostium of either the right 
or left coronary artery under x-ray video fluoroscopy. Once engaged, radio-opaque contrast 
media (CM) is injected into the coronary artery to directly visualise the coronary anatomy. 
CM may also be injected into the left ventricle to assess myocardial and valvular function 
(left ventriculography) and into the aorta to visualise aortic anatomy (aortography). 
Haemodynamic pressure measurements within the aorta and left ventricle as well as 
continuous ECG recordings are acquired during the procedure in order to assess patient 
stability and allow additional cardiovascular diagnosis.  
 
Percutaneous coronary intervention (PCI), otherwise known as percutaneous transluminal 
coronary angioplasty (PTCA) was developed by Andreas Gruntzig35 in 1977 as a minimally 
invasive intervention to treat coronary artery stenoses in order to restore normal coronary 
blood flow.  Following on from coronary angiography, a guide catheter and guide wire is 
used to position a balloon tipped catheter within the ‘target’ coronary stenosis, which is then 
inflated to restore patency of the arterial lumen. This technique has since been modified to 
allow deployment of metallic stents directly within coronary stenoses in order to stabilise 
atherosclerotic plaque and to structurally support the lumen of the vessel;  this development 
has been shown to be superior to balloon angioplasty alone36 and is now the treatment of 
choice unless stent insertion is not possible (e.g. contra-indication to dual antiplatelet therapy 
required for maintenance of stent patency). 
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1.2.1 COMPLICATIONS OF CORONARY ANGIOGRAPHY AND PCI 
 
 
Diagnostic CA carries a relatively low risk of adverse events, although this is highly 
dependent on patient factors such as advanced age, left ventricular dysfunction, hypotension, 
peripheral vascular disease and renal dysfunction. In general CA involves an approximate 
2% risk of major complications including MI, cerebrovascular accident (CVA), emergency 
CABG, ventricular arrhythmia, major haemorrhage or vascular injury and a 0.08% risk of 
death37. PCI carries a greater risk, related to patient specific factors in the same way as CA, 
but also related to procedural factors such as the urgency of the procedure and complexity 
of the target coronary lesions38.  
 
1.2.2 COMPLICATIONS OF CONTRAST MEDIA ADMINISTRATION 
 
Approximately 0.2% of patients receiving modern non-ionic CM may experience a Type 1 
(Mast Cell/Histamine/IgE mediated) allergic reaction, particularly if a prior history of 
asthma or atopy, allergy to CM or Iodine exists39. This can precipitate an urticarial rash, 
angioedema, acute asthma, allergic vasculitis and rarely anaphylaxis (0.02%). This is usually 
prevented or treated with antihistamines and steroid medications40 and if severe allergy 
occurs, airway management, β-agonist bronchodilators, intravenous crystalloids and 
epinephrine may be required.  
 
In susceptible individuals, intravascular administration of highly viscous and often 
hyperosmolar radio-contrast media may lead to an acute kidney injury (AKI) known as 
contrast induced nephropathy (CIN), which will be examined comprehensively in the 
following chapter. Because CIN provides a predictable model of renal ischaemia reperfusion 
injury (IRI) and remains a significant iatrogenic clinical problem, it is an attractive target for 
basic and clinical research into novel prophylactic interventions. 
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1.3 CONTRAST INDUCED NEPHROPATHY 
 
 
Contrast induced nephropathy (CIN), also commonly referred to as contrast induced acute 
kidney injury (CIAKI), is an iatrogenic kidney injury that follows intravascular administration 
of radiopaque CM in at risk patients. The first cases of CIN were identified in the 1950’s, 
after intravenous pyelography was performed in patients with multiple myeloma associated 
renal disease, leading to acute renal failure and death41, 42.  Even today, CIN continues to be 
responsible for a third of all cases of hospital acquired AKI43, 44 affecting up to 1-2% of all 
patients and occurring in up to 50% of higher risk patients undergoing CA or PCI45.  
 
At present in Europe approximately one third of patients undergoing CA or PCI will have 
stage III-V CKD which is recognised as the main risk factor for CIN.  The mean rate of 
CIN in at risk patients undergoing CA or PCI using optimal prophylactic measures is 
between 10% and 15%46. In the UK approximately 400,000 people undergo CA or PCI47 per 
year, equating to 120,000 patients at risk of CIN, of which 12-18,000 are estimated to develop 
CIN.  In most cases of CIN, renal function will completely recover however in an estimated 
2400 to 3600 cases an irreversible deterioration in renal function will occur. A small number 
of these patients will, as a result, require long-term renal dialysis which is a serious adverse 
outcome and carries significant costs for the NHS. Taking into consideration the cost of 
extra bed days alone, the average length of stay (LOS) for a patient who undergoes CA or 
PCI and develops CIN is 6.8±7.1 days vs. 2.3±2.5 days for patients without CIN48.  
Assuming the cost of a bed day in the UK is £22527, the estimated index hospital costs due 
to CIN, not including dialysis, readmissions, or mortality is £1012 per CIN patient; which 
constitutes a total cost to the NHS of approximately £12.1-18.2 million per year.  
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A wide number of modern cardiac imaging and interventional procedures require 
administration of intravascular CM, including CT coronary angiography (CTCA), trans-
catheter aortic valve Implantation (TAVI) as well as cardiac resynchronisation therapy 
pacemaker (CRTP) implantation.  Primary PCI, developed for the emergency treatment of 
acute myocardial infarction (AMI), has revolutionised cardiovascular outcomes, albeit at the 
expense of increased rates of CIN. This is due to the presence of unknown pre-procedural 
CIN risk factors, such as reduction in eGFR, as well as known risk factors such as the time 
dependent inability to provide adequate i.v. pre-hydration, peri-procedural hypotension and 
larger volumes of CM required49.   
 
CM is also commonly used in many non-cardiac imaging modalities such as CT pulmonary 
angiography (CTPA) and indeed any plain or CT imaging of a vascular bed (e.g. femoral 
angiography, CT cerebral angiography etc.) or of the urological system (e.g. intravenous 
urography). In addition to the greatly expanded number of imaging modalities requiring CM, 
the population undergoing CM based investigations are at an inherently greater risk of CIN 
due to the greater incidence of patients with advanced age and co-morbidity, with the result 
that CIN remains a growing and significant clinical problem50.  
 
Patient specific risk for the development of CIN can be estimated using known demographic, 
clinical and peri-procedural factors. Although the classical risk factor for CIN is the presence 
of chronic kidney disease (CKD) stage III or worse10 (Table 4), numerous additional risk 
factors are also highly contributory to CIN 45, many of which are perhaps less well recognised 
in clinical practice.  Cohort studies investigating CIN51, 52 have led to the development of 
several risk scoring systems, enabling early prediction of CIN and prompting provision of 
additional prophylactic measures. The predictable and serious nature of CIN continues to 
encourage a wealth of basic and clinical research into this common iatrogenic complication.  
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1.3.1 DEFINITION AND DIAGNOSIS OF CIN 
 
 
A relative 25% increase in serum creatinine (SCr), or an absolute increase of 0.5 mg/dl 
(44µmol/L) from baseline SCr, within 72 hours of contrast exposure without alternative 
explanation, is the most commonly used definition of CIN53. This definition has been 
criticised as even minor increases in SCr have been shown to correlate with significant renal 
injury and adverse events54, 55 and no reference is made to early functional reductions in urine 
output, such as in the RIFLE15, AKIN16 and KDIGO17 classification systems (Table 4). 
However this definition is easy to implement in clinical practice and has been widely adopted 
as the primary endpoint in most CIN studies and as such has been convincingly associated 
with adverse clinical outcomes. Harjai et al56 have further refined the classical CIN definition 
using three grades of relative and absolute creatinine increase, including minor changes in 
SCr (<25% or 0.5mg/dl), which have also been shown to correlate with adverse clinical 
outcomes (Table 6). 
 
 
 
Table 6: CIN Grades, adapted from Harjai et al56 
 
CIN Grade 
 
Change in Serum Creatinine 6 month Outcomes 
Grade 0 SCr increase <25% and <0.5 mg/dL 
above baseline 
MACE 12.4% 
Mortality 10.2% 
Grade 1 SCr increase >/= 25% and <0.5 mg/dL 
above baseline 
MACE 19.4% 
Mortality 10.4% 
Grade 2 SCr increase >/= 0.5 mg/dL 
above baseline 
MACE 28.6% 
Mortality 40.9% 
 
 
CIN = Contrast Induced Nephropathy, SCr = Serum Creatinine, MACE = Major Adverse Cardiovascular Events 
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1.3.2 NOVEL BIOMARKERS FOR THE DETECTION OF CIN 
 
The clinical utility of SCr is limited by the delayed response to the rapid changes in GFR that 
occur in AKI, particularly in patients with normal preceding renal function,57 with increases 
in SCr typically requiring 48 hours to breach a diagnostic threshold. Additionally renal 
function must decrease by more than half before a significant increase in SCr is observed, 
limiting its sensitivity considerably. Numerous renal biomarkers have been developed that 
aim to provide earlier and more sensitive diagnosis, including neutrophil gelatinase associated 
lipocalin (NGAL)58, urine albumin creatinine ratio (UACR), cystatin c59, urinary Kim-160, IL-
1861 and L-FABP62. Although promising results have been demonstrated in small clinical 
trials, these novel biomarkers have yet to be translated into clinical practice and they await 
validation in the early diagnosis of AKI and as predictors of adverse clinical outcomes in 
larger studies. 
 
1.3.2.1 Neutrophil gelatinase associated lipocalin (NGAL) 
 
NGAL is a small (25 kDa) protein secreted by many organs (including the kidney) in response 
to ischaemia, whose role is to scavenge free extracellular iron released from injured tissues. 
Liberated iron is a noxious substance and is responsible for catalysing hydrogen peroxide 
into hydroxyl anion, a reactive oxygen species (ROS) involved in ongoing cellular injury. 
McCullough et al demonstrated that NGAL is a sensitive, although somewhat less specific 
biomarker useful in the early detection of CIN63, especially useful in patients who develop a 
subclinical kidney injury, as defined by a SCr rise of 0-25% above baseline. Acute elevation 
in NGAL is detectable in both serum and urine samples within a few hours of renal injury 
that makes this biomarker a promising tool for the early detection of AKI. Point of care 
(POC) testing equipment is available to further reduce the diagnostic lead time, enabling 
prompt risk stratification and therapeutic interventions. 
30 
 
 
 
 
1.3.2.2 Urine Albumin Creatinine Ratio (UACR) 
 
Spot UACR, a widely available and cost effective investigation, measures the ratio of urine 
albumin to urine creatinine at a given time point. This measure takes into account variations 
in urinary concentration and is a surrogate for 24-hour urine albumin excretion, albeit 
assuming constant serum creatinine concentration. Micro-albuminuria, defined as an UACR 
≥3.5 mg/mmol (female) or ≥2.5 mg/mmol (male), can be a manifestation of endothelial 
dysfunction resulting from hypertension and diabetes and is proportional to the severity of 
kidney disease and strongly correlated with CVD and mortality64. Microalbuminuria is a 
recognized risk factor for AKI as well as for progression of CKD, mediated by mechanisms 
including inhibition of podocyte regeneration at the glomerular tuft65. Development of new 
or worsening microalbuminuria secondary to acute glomerular injury leads to proximal 
tubular toxicity and dysfunction, mediated by reactive oxygen species (ROS) and protein 
kinase C (PKC)66. UACR has been shown in clinical trials to predict the progression and 
severity of AKI following cardiac surgery67 and has been suggested as a sensitive marker for 
CIN at a threshold below the sensitivity of observed changes in SCr or eGFR68.  
1.3.2.3 Cystatin C 
 
Cystatin C is a small (13 kDa), non-glycosylated basic protein belonging to the cysteine 
protease inhibitor family and is produced by all nucleated cells. It is a useful marker of renal 
function as it is freely filtered at the glomerulus, almost completely reabsorbed and is not 
secreted by the proximal renal tubular cell; as such the plasma concentration of Cystatin C is 
almost exclusively determined by the GFR. In addition it is not affected by muscle bulk or 
age which complicate the interpretation of SCr. Briguori et al59 demonstrated that  Cystatin 
C elevation of >10% from baseline was a more sensitive test than SCr, with diagnosis of 
CIN possible at 24 hours following CM exposure rather than at 48 hours as with SCr. In 
addition Cystatin C elevation also correlated well with major adverse events at one year. 
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1.3.2.4 Urinary Kidney Injury Molecule 1 (KIM-1) 
 
KIM-1 is a transmembrane protein upregulated in proximal tubular cells following ischaemic 
injury and is subsequently shed into the urine. It has been shown to be specific for ATN 
over other forms of renal injury based upon renal biopsy analysis69. Torregrosa et al recently 
demonstrated that urinary KIM-1 elevation at 12hours is a useful predictor of AKI following 
coronary angiography although at a lower sensitivity and specificity than NGAL70. 
  
1.3.2.5 Interleukin 18 (IL-18) 
 
Interleukin 18 is a pro-inflammatory cytokine produced by macrophages and other 
leukocytes in response to a wide range of triggers, including ischaemia, and is involved in 
activation of the cell mediated immunity response. Variable predictive accuracy has been 
reported with urinary IL-18 as a marker of AKI, however a well conducted recent meta-
analysis by Liu et al suggested that urinary IL-18 is a useful predictor of AKI and is consistent 
with SCr measurement in a broad cohort of patients, including those post CA/PCI, post 
CABG and on intensive care units71 
 
1.3.2.6 Liver type fatty acid binding protein (L-FABP) 
 
Urinary excretion of liver type fatty acid binding protein (L-FABP) is a biomarker of tubulo-
interstitial damage arising from ischaemic and toxic renal injury, with peak levels rising within 
24 hours after contrast administration, enabling early detection of CIN.  Igarashi et al62 
demonstrated that RIPC attenuated urinary L-FABP after CA in patients at low to moderate 
risk of CIN, albeit without significant differences in SCr between control and RIPC groups. 
Correlation with adverse clinical outcomes following CIN is yet to be established. 
32 
 
 
 
 
1.3.3 ADVERSE OUTCOMES FOLLOWING CIN 
 
 
Although CIN is often considered a transient event, with up to 80% of patients recovering 
renal function within one to three weeks72, observational clinical studies have demonstrated 
that it is associated with adverse clinical outcomes over the short and long term73.  In-hospital 
mortality after CIN has been shown to be up to five times greater, even after adjusting for 
co-morbidities74 and longer term mortality risk at one and five years has been found to be 
four times higher75, with some studies revealing a one year mortality risk of between 20%55 
and 38%76. Of those patients who develop CIN, up to 20% suffer persistent worsening renal 
function (WRF)5, with acute renal replacement therapy becoming necessary in 0.7%74 to 7%76 
of patients (Table 7).  
 
Not surprisingly, the additional healthcare costs incurred due to CIN are considerable55. 
However drawing conclusions from these observational studies is problematic as they cannot 
establish a direct causal relationship between CIN and mortality.  For example, a severe 
cardiac insult, which itself carries a poor prognosis, is likely to be associated with an increased 
risk of CIN and thus CIN may only function as a marker of adverse events. James et al77 
performed a meta-analysis on 39 observational studies investigating CIN and demonstrated 
increased mortality, cardiovascular events, persistent WRF and prolonged hospital stay, 
although strong confounders were present in the clinical characteristics that predispose to 
both CIN and mortality. Even after appropriate adjustment for these confounders, the 
authors advise caution in making any firm conclusions regarding causality. 
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There are several conceivable pathological mechanisms that might explain causality between 
CIN and major adverse cardiac events (MACE). During the acute phase of CIN, acute 
volume overload, uraemia, electrolyte imbalance and the pro-inflammatory and pro-
thrombotic milieu associated with AKI may result in an acute cardiac insult, otherwise 
described as type 3 cardio-renal syndrome. In addition there is an added risk of complications 
arising from invasive therapies such as haemofiltration or dialysis. Those patients that suffer 
persistent worsening of renal function may develop type 4 cardio-renal syndrome due to 
progressive atherosclerosis, vascular calcification and left ventricular hypertrophy21. 
However in the majority of patients with only minimal or transient changes in renal function 
it remains speculative how CIN might lead to increased MACE.  
 
If well designed interventional studies are able to demonstrate that effective CIN prevention 
strategies reduce MACE, without using therapies that might provide an independent 
cardiovascular benefit, the question of causality between CIN and MACE may finally be 
answered. An alternative approach, which side steps some of the confounders that exist 
between CIN and MACE, is for clinical trials to concentrate on adverse renal outcomes, such 
as persistent WRF, proteinuria and progression to ESRD. Regardless of direct causality, CIN 
is a worrying clinical occurrence that should when and wherever possible be pre-empted 
with appropriate prophylactic measures. 
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Table 7: Cardiovascular adverse outcomes following CIN 
 
Adverse Event Outcome 
CIN vs no CIN 
 
In-Hospital Mortality 
 
 
 
7.1% vs 1.1% (P<0.0000001) 
McCullogh et al74, N=1826 
 
1 Year Mortality 
 
 
 
37.7% vs 19.4% (P=0.001) 
Gruberg et al76, N= 439 
 
Persistent Worsening Renal Function 
(eGFR>25% baseline at 3/12) 
 
 
18.6%  vs 0.9% (P=0.0001) 
Maioili et al5, N=1490 
 
Haemodialysis 
 
 
 
0.7% McCullogh et al74 
7% Gruberg et al76 
 
CM = Contrast media exposure, CIN = Contrast Induced Nephropathy, eGFR= Estimated glomerular filtration Rate  
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1.3.4 PATHOPHYSIOLOGY OF CIN 
 
 
Radio-opaque CM are concentrated tri-iodinated benzene compounds that have an 
associated iodine moiety. By their nature, all CM compounds have cytotoxic effects related 
to the ionic strength, osmolality, or viscosity of the agent78. The first CM agents to be utilised 
were ionic ‘hyper-osmolar’ solutions however these have been withdrawn due to significant 
nephrotoxicity79. Safer non-ionic ‘low-osmolar’ (LOCM) and ‘iso-osmolar’ (IOCM) solutions 
were developed although these compounds are significantly more viscous than blood 
plasma80 (Table 8). It is believed that the physicochemical properties of CM, in addition to 
additional vasoconstrictive and cytotoxic effects, are causative in CIN 81.  
 
The tissues of the kidney that exist under high metabolic and osmotic stress, supplied by a 
delicate microvascular circulation, are at high risk of ischaemic injury. This is particularly 
pertinent within the outer renal medulla where active sodium resorption in the ascending 
loop of Henle requires large amounts of oxygen despite a very low partial pressure of oxygen 
(10-20mmHg82),  a result of poor tissue perfusion from the descending vasa recta (DVR), 
which is a vessel with a high vascular resistance commonly compromised by arterio-venous 
shunting83. In CKD, the greater metabolic burden placed upon a reduced number of 
functional nephrons, commonly supplied by a diseased micro and macro-vascular 
circulation, lowers the threshold for renal ischaemic injury further more84. 
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A comprehensive pathophysiological model of CIN remains the focus of ongoing research, 
however ischaemia in the outer medullary region of the kidney is believed to be a critical 
factor83.  The cytotoxicity of CM has been shown to induce the vascular endothelium to 
release local vasoactive substances, including nitrous oxide (NO)85, adenosine, endothelin86, 
prostaglandins and reactive oxygen species (ROS) which cause profound vasoconstriction in 
critical vessels such as the DVR87.  The onset of renal ischaemia in turn leads to a further 
release of vasoactive substances and a prolonged period of vasoconstriction when tissue 
damage is observed.  
 
Compounding this, the greater viscosity of the CM and blood mixture within the DVR 
results in reduced medullary blood flow88 and capillary obstruction may occur as a result of 
hyperosmolar red cell distortion and aggregation89.  On restoration of normal vascular tone 
and blood flow, reperfusion of the ischaemic tissue is believed to exacerbate the tissue injury 
mediated via a number of complex pathways which will be the focus of discussion in 
following sections. Finally, CM is concentrated within the tubular filtrate to a degree where 
it may cause hyper-viscous tubular obstruction and a cytotoxic release of ROS resulting in 
acute tubular necrosis (ATN)90(Figure 1). 
 
Elderly patients and those with diabetes or CKD, are at an increased risk of CIN due to 
inherent endothelial dysfunction causing an exaggerated vasoconstrictive response to CM91. 
Patients with congestive cardiac failure (CCF), reno-vascular disease, dehydration and 
hypotension are also at increased risk of CIN due the additional effect of renal 
vasoconstriction on outer medullary blood flow in the context of low renal preload.  If the 
oxygen carrying capacity of blood is also reduced, as seen in anaemia or hypoxia, any 
reduction in renal blood flow will compound the ischaemic injury92.  
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Table 8: Comparison of CM agents by osmolality and viscosity93 
 
 
 Blood Plasma Iso-Osmolar 
Visipaque  
Low-Osmolar  
Omnipaque 
High-Osmolar 
Hypaque  
Osmolality 
mosmol/L 
290 290 844 2076 
Viscosity, 37o 
Centipoise 
3-4 11.8 10.4 8.4 
CIN risk - Low Low High 
 
CM = Contrast Media, CIN = Contrast Induced Nephropathy 
 
 
Figure 1: Proposed pathological mechanism of CIN 
 
 
 
CM = Contrast Media, NO = Nitric Oxide, ROS = Reactive Oxygen Species      
Adapted from Seeliger et al, Eur Heart J 2012
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1.3.5 RISK FACTORS FOR CIN 
 
 
An individually tailored CIN risk assessment including review of the indications for any CM 
based investigation should be reviewed prior to any procedure involving CM. Pre-procedural 
CIN risk factors are obtainable from the clinical history, physical examination and usual 
laboratory investigations and additional risk factors may be estimated and identified peri-
procedurally.  
 
1.3.5.1 Chronic Kidney Disease 
 
The European Society of Urogenital Radiology (ESUR) Consensus Working Panel95 in 1999 
stated that “CIN risk becomes clinically significant when baseline SCr concentration is ≥1.3 
mg/dL (≥115 mmol/L) in men and ≥1.0 mg/dL (≥88.4 mmol/L) in women”.  This 
approximates to CKD stages III - V (when eGFR is <60 mL/min/1.73m2) and is recognised 
as the most important clinical risk factor for CIN96. Although this common biochemical 
investigation provides a cost effective screening tool, other risk factors are highly 
contributory to CIN, with many cases of CIN occurring in patients without pre-existing 
CKD45.   
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1.3.5.2 Diabetes Mellitus and acute hyperglycaemia 
 
During the 1970’s diabetes mellitus (DM) was recognised as an independent risk factor for 
the development of CIN97. This has since been convincingly demonstrated in a number of 
clinical trials52, 98, with significantly increased risk observed when co-existent with CKD99. 
The pathophysiological basis for increased susceptibility to renal ischaemia-reperfusion 
injury (IRI) in patients with DM can be explained by a number of factors: the presence macro 
and microvascular atherosclerotic disease affecting the renal vasculature, endothelial 
dysfunction and imbalance of vasoactive mediators, chronic tubulo-interstitial changes and 
regional hypoxaemia, increased oxygen demands due to additional tubular transport activity 
as well as increased generation of reactive oxygen species100. 
 
 In non-diabetic patients presenting with MI pre-procedural elevation of blood glucose prior 
to CM exposure has recently been shown to increase the risk of CIN in a large retrospective 
study performed by Alpert et al101. Interestingly there was no association found between CIN 
and pre-procedural glucose levels in diabetic patients, even after adjustment for confounding 
factors.  Importantly the relationship between acute hyperglycaemia and CIN in non-diabetic 
patients persisted after accounting for disease severity indicators such as infarct size, which 
suggested that hyperglycaemia was not simply a marker of stress response to acute 
cardiovascular compromise and thus indirectly associated with CIN.  The mechanism for 
this phenomenon remains unclear although may be related to acute hyperglycaemia mediated 
endothelial dysfunction102, increased oxidative stress103 and decreased levels of nitric oxide104. 
However the results may also be attributable to unrecognised pre-existent diabetes in the 
non-diabetic cohort, less aggressive acute blood sugar control and lack of appropriate pre-
hydration in these patients, all known factors that increase the risk of CIN. 
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1.3.5.3 Congestive cardiac failure (CCF) 
 
CCF is a complex syndrome that results from failure of the heart to adequately perfuse the 
tissues, either due to functional or structural abnormalities of the myocardium, cardiac valves 
or pericardium that leads to disruption of the systolic and/or diastolic phase of the cardiac 
cycle. Patients with moderate to severe CCF symptoms (classified according to New York 
Heart Failure Association (NYHA) III or IV), a recent history of pulmonary oedema52, MI49, 
or those with a left ventricular ejection fraction (LVEF) of less than 45% are at increased 
risk of developing CIN98, 105. A number of complex pathological processes and clinical factors 
are responsible for the increased risk of CIN in this patient cohort.  
 
Due to the overlap of aetiological factors in both renal and cardiac disease, as well as the 
complex interactions inherent in the cardio-renal syndrome, CKD and CCF often co-exist, 
significantly compounding the risks of CIN. Despite severe CKD commonly being an 
exclusion criterion in the landmark CCF trials, observed CCF/CKD co-prevalence rates 
were between 32% and 50% (Table 9). In addition, many of the cornerstone medications 
used in CCF, such as diuretics, ACE inhibitors and aldosterone antagonists may lead to 
hypovolaemia and hypotension resulting in renal hypo-perfusion. Clinicians may also be 
disinclined to prescribe prophylactic intravenous fluid to patients with CCF prior to CM 
exposure, due to the risk of precipitating an acute decompensation of CCF. 
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Table 9: Prevalence of CKD in landmark CCF trials106  
 
Study Treatment Exclusion SCr 
(µmol/l) 
CKD prevalence 
eGFR<60ml/min/1.73m2 
 
SOLVD107 
 
 
Enalapril 
 
>177 
 
32% 
 
CIBIS-2108 
 
 
Bisoprolol 
 
>300 
 
33% 
 
CHARM109 
 
 
Candesartan 
 
>265 
 
36% 
 
CARE-HF110 
 
 
CRT 
 
N/A 
 
50% 
 
 
Adapted from “Implications of kidney disease in the cardiac patient”, Rear et al, Interventional Cardiology 
Clinics, 2014. 
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1.3.5.4 Advanced age 
 
Advanced age, specified as age >75 years, is independently associated with an increased risk 
of CIN52, and is an important contributor to the increasingly frequent incidence of CIN, due 
to the cohort of cardiovascular patients generally being more elderly and the high number of 
CM based procedures now performed on these patients. In animal models and in humans, 
advanced age itself is associated with a physiological reduction in the total number of 
glomeruli, vascular morphological and functional abnormalities, glomerulo-sclerosis and 
interstitial fibrosis which are together responsible for the progressive age related fall in GFR 
and an increased risk of AKI111.  
 
The cumulative exposure to disease processes affecting the kidney, including hypertension, 
diabetes and vascular disease as well as CCF, anaemia and nephrotoxic medications also 
significantly increases the incidence of CIN in the elderly. In addition, due to reductions in 
muscle bulk found in this population, measurement of SCr alone may not alert the clinician 
to the presence of underlying CKD unless formal eGFR calculation is performed112. 
 
 
  
43 
 
 
 
 
1.3.5.5 Female gender 
 
Although female patients are traditionally considered to be at higher risk of CIN than men, 
this is often attributed to the presence of confounding factors. However a large retrospective 
analysis suggested that women over the age of 65 years are indeed at greater risk of CIN than 
men of the same age with similar co-morbidity113. One explanation is that men have both 
larger and more numerous glomeruli than similar aged women, which is likely to be 
protective against renal IRI114. In addition females undergoing CA or PCI have been shown 
to have a higher incidence of CKD (74% vs 45%)115, anaemia and a higher risk of vascular 
and bleeding complications92, all known risk factors for CIN. Hormonal differences, 
including lower intramedullary prostaglandin production and increased platelet aggregation115 
may also be responsible for the observed increased CIN risk observed in women. 
 
1.3.5.6 Anaemia 
 
Anaemia, defined as a haematocrit (HCT) of less than 0.39 in males or 0.36 in females is 
known to increase the risk of CIN; as demonstrated in a large registry study by Nikolsy et 
al92. Baseline anaemia was shown to be an independent predictor of CIN in patients with and 
without CKD (23% and 11% respectively). Patients with the lowest eGFR and HCT were 
found to be at highest risk (28.8%), however interestingly those patients with similarly low 
eGFR but normal HCT were relatively less vulnerable (15.4%). A peri-procedural fall in HCT 
of >5.9% was also shown to almost double the incidence of developing CIN (38.9%). This 
was most commonly due to acute haemorrhage either from traumatic vascular injury or from 
gastrointestinal blood loss attributable to anti-platelet and anti-thrombin therapy. Renal 
hypo-perfusion secondary to acute volume loss as well as the reduced oxygen carrying 
capacity of blood are likely to further compound medullary hypoxaemia and thus CIN.  
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1.3.5.7 Nephrotoxic medications 
 
Co-administration of CM in the presence of nephrotoxic agents with direct tubular toxicity 
effects (Table 10) is thought to increase the risk of CIN, although this is variably documented 
in clinical studies116.  Withdrawal of these agents, where clinically appropriate, for 24 hours 
prior to CM exposure is recommended. A particular area of interest pertains to concurrent 
treatment with angiotensin converting enzyme inhibitors (ACE-I) and Angiotensin receptor 
blockers (ARB’s). Although not nephrotoxic per se, some small RCT’s have reported that 
withholding ACE-I or ARB prior to CM exposure reduces the rate of CIN117, whereas other 
studies have not found any beneficial effect118.  Current guidelines recommend that if these 
medications are part of established therapy, continuation is considered safer than the risk of 
withdrawal and that if initiation of ACE-I or ARB therapy is being considered this should 
be delayed until after CM exposure and CIN has been excluded96. 
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Table 10: Nephrotoxic medications requiring withdrawal prior to CM exposure 
 
 
Drug Class Examples 
Non-Steroidal  
Anti-Inflammatory drugs (NSAIDs)  
 
Naproxen, Ibuprofen, Diclofenac 
Celecoxib119 
Non-selective risk > Cox-2 selective risk 
Antibiotics Aminoglycosides: Gentamycin, Amikacin120  
Antifungal drugs Amphotericin B121 
Antiviral drugs Acyclovir, Tenofovir, Foscarnet122 
Immuno-modulatory drugs Cyclosporin A123 
Anti-neoplastic chemotherapy agents Cisplatin, Ifosfamide, Mitomycin124 
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1.3.5.8 Procedural factors 
 
The total volume of CM administered is one of the most important risk modifiable factors 
in the development of CIN and has been shown to be the leading independent predictor for 
emergency dialysis125. In patients with CKD, administration of more than 125-140 ml of CM 
results in a 5-10 fold increase in CIN, irrespective of preventive measures74.  Current ESC 
guidelines recommend limitation of contrast volume to 3 ml/kg. More specifically, Laskey 
et al126 have identified that the maximum safe volume of contrast is dependent a ratio of the 
volume of contrast media to creatinine clearance (V/CrCl) of less than 3.7:1.  
 
Other procedural factors such as total previous CM exposure within 72 hours51  are directly 
related to the development of CIN. In addition the presence of peri-procedural 
haemodynamic instability, defined as a systolic blood pressure below 80mmHg for more 
than 60 minutes, use of inotropic agents or intra-arterial balloon pump (IABP)52 therapy are 
all high risk factors. A recent meta-analysis failed to demonstrate any difference between 
rates of CIN following CM administered via the intra-arterial (IA) route as against the 
intravenous (IV) route, despite the long held assumption that an IA bolus might have a 
greater potential for toxicity127. 
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1.3.6 CIN RISK ASSESSMENT TOOLS 
 
 
 A commonly used CIN risk scoring system has been validated in a large cohort study by 
Mehran et al that incorporates weighted pre-procedural and peri-procedural risk factors52 
(Figure 2). Tziakas et al128 have also developed a similar tool, albeit with a slightly different 
set of variables, including metformin use, previous PCI, peripheral arterial disease and >/= 
300 ml of CM. Both scoring systems are limited by estimation of CIN risk only after CM has 
been administered, when there is a clear clinical need to predict CIN pre-procedurally when 
prophylactic measures are most effective. As such, a pre-procedural CIN risk score has been 
validated in a prospective cohort by Maioli et al51 (Table 11). 
 
Several novel CIN risk factors have recently been identified, such as pre-procedure serum 
glucose129, 130 and LDL-C131 however these have not yet been integrated into a validated risk-
scoring tool. Commonly used cardiovascular risk scoring systems, such as the Global 
Registry of Acute Coronary Events (GRACE) score in AMI patients, have been shown to 
predict risk of CIN in patients with normal renal function and a GRACE inpatient risk score 
of greater than 140 (>3% mortality)132. Bio-Impedance Vector Analysis (BIVA), an 
investigative measure of total body hydration, has also been shown to correlate with the risk 
of developing CIN in a proof of concept clinical trial133 and shows promise of being 
incorporated into a CIN risk scoring system and guided hydration strategy. 
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Figure 2: The Mehran CIN risk score52  
 
 
Hypotension = SBP<80mmHg >1hr/ inotropic support, IABP = IABP within 24hrs of procedure, CHF =NYHA III-IV or history of 
pulmonary oedema, Anaemia = Male: HCT<0.39,   Female: HCT<0.36     
 
 
Table 11: A Pre-procedural Risk score for CIN, adapted from Maioli et al51 
 
 
Pre-Procedural Risk Factor 
 
       
Score 
Prior CM exposure within 72 hours 3 
Left Ventricular Ejection Fraction <45% 2 
Pre-procedure SCr > Baseline SCr 2 
Baseline SCr >1.5mg/dl 2 
Diabetes Mellitus 2 
Creatinine Clearance (eGFR) <44ml/min 2 
Age>73 years 1 
Score       0 - 3          4 - 6         7 - 8 >9 
CIN risk   Low  1.1%  Moderate 7.5%   High 22.3% Very High 52.1% 
 
CM = Contrast Media, SCr = Serum Creatinine, eGFR = Estimated Glomerular Filtration Rate 
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1.3.7 PREVENTATIVE STRATEGIES AGAINST CIN 
 
 
The following sections will summarise recent evidence based guidelines that provide a 
framework for the prevention of CIN, as published in the European guidelines (ESC134, 
ESUR96), national (NICE) and local (UCLH) guidelines. Optimisation of the patients 
circulating volume prior to and during CM exposure remains the most effective single 
intervention, although the strategy for achieving this remains controversial135. In addition a 
number of other important considerations and interventions have been shown to be 
effective. 
 
1.3.7.1 CIN Risk Assessment 
 
A CIN risk assessment should be performed on all patients referred for CM based 
investigations, including baseline measurement of SCr and calculation of eGFR using an 
appropriate formula (e.g. Modification of Diet in Renal Disease (MDRD). Patients that are 
identified as being at increased risk of CIN should be considered for a non-CM based 
procedure if clinically acceptable. If a ‘follow on’ CM procedure is necessary after initial CM 
exposure, this should ideally be delayed until adequate clearance of CM or normalisation of 
renal function has occurred, in non-urgent cases after two weeks or in urgent cases as long 
as is clinically appropriate.   
 
Due to mutual risk factors and interaction between CKD and cardiac disease, patients 
identified as being at risk of CIN are also at higher risk of poor cardiovascular outcomes and 
thus clinician concern about the risk of CIN should not prevent or unnecessarily delay 
prognostic CM based procedures.  
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1.3.7.2 Pre-procedural medication review 
 
All patients should discontinue non-essential nephrotoxic medications (Table 10) as well as 
loop diuretics for 24 hours before and 48 hours after CM exposure, restarting these only 
once SCr measurement excludes CIN. Patients taking Metformin who receive intra-arterial 
CM with an eGFR<60ml/min/1.73m2, or who receive intra-venous CM with an 
eGFR<45ml/min/1.73m2, should ideally discontinue Metformin for 48 hours pre-procedure 
and restart once CIN has been excluded. Although Metformin is not nephrotoxic in itself, 
some studies have shown an increased risk of lactic acidosis following CIN although 
significant inconsistencies between studies mean that only a low level of evidence exists for 
this recommendation136. It is important to note that elevated pre-procedural serum glucose 
levels are themselves implicated in the development of CIN and so must be taken into 
account when considering Metformin withdrawal. 
 
1.3.7.3 Choice of CM and radiographic considerations 
 
Use of HOCM agents are now contra-indicated in patients at risk of CIN, however it is less 
clear whether IOCM formulations are preferable over LOCM. A number of meta-analyses 
have been performed which present conflicting results93, 137. Current guidelines recommend 
the use of either IOCM or LOCM, as long as the amount of CM required for diagnostic 
accuracy is kept to a minimum and is under the threshold of 3ml/kg or a V/CrCl <3.7:1. In 
experienced centres, the use of biplane imaging during CA may reduce CM volumes as 
simultaneous orthogonal views can be acquired138. Novel automated contrast injection (ACI) 
devices have also been shown to reduce the volume of CM used and may reduce the 
incidence of CIN139. 
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1.3.7.4 Pre-hydration strategies 
 
Ensuring that patients are adequately hydrated prior to CM exposure is the single most 
effective prophylactic measure to prevent CIN. Optimising intravascular volume maintains 
renal blood flow and dilutes CM in blood and tubular filtrate. In low risk ambulant patients 
oral hydration is acceptable if adequate fluid intake is possible. In higher risk patients or those 
unable to tolerate oral hydration, intravenous (IV) crystalloid is preferred as it guarantees 
appropriate fluids are delivered and is superior to oral hydration in clinical trials140.  
 
There continues to be debate regarding which formulation of crystalloid is optimal, with 
some centres favouring intravenous ‘normal saline’ (0.9%) and others favouring  intravenous  
sodium bicarbonate (1.26%) which is believed to be superior due both to its additional ROS 
scavenging ability141 and lack of chloride ions that may exacerbate renal vasoconstriction142. 
Although some meta-analyses have suggested a slight reduction in CIN rates with sodium 
bicarbonate, no clear mortality benefit has been demonstrated143, 144 Owing to a considerable 
cost difference between the two therapies, many centres continue to favour the use of normal 
saline. However, one practical advantage of sodium bicarbonate is that most studies 
demonstrated equivalence to normal saline with shorter administration times and a lower 
fluid volumes, which may be useful for elective patients and those who are unable to tolerate 
large amounts of i.v. fluid, such as elderly patients and those with CCF145. (Table 12) 
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Table 12: Intravenous pre-hydration regimes, updated ESUR guidelines 201196 
 
IV Fluid Pre Hydration Post Hydration 
Isotonic Saline  
(0.9%) 
6-12 Hours, 
1-1.5ml/Kg/Hr  
6-12 Hours 
1-1.5ml/Kg/Hr 
Sodium Bicarbonate 
(1.26%) 
1 Hour 
3ml/Kg/Hr 
6 Hours  
1ml/Kg/Hr 
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1.3.7.5 Pharmacological prophylaxis against CIN 
 
Few pharmacological agents have proven efficacy against CIN, however N-Acetyl-Cysteine 
(NAC), an inexpensive and well tolerated antioxidant and vasodilator, given at dose of 600mg 
BD for 24 hours pre and post procedure has been shown to reduce the incidence of CIN in 
several large RCT’s 146, 147. Despite these findings, recent meta-analyses148, 149 have been 
equivocal, most likely as a result of wide heterogeneity, variable reporting and publication 
bias in the included studies150. As such it is not recommended that NAC is used alone, 
although it may be a useful additional agent and is rarely harmful when added to conventional 
therapy in high-risk patients151.  
 
1.3.7.6 Post procedure renal monitoring and management of AKI 
 
All patients at risk of CIN should have repeat SCr levels measured from 48 to 72 hours 
following CM exposure. In addition those at very high risk should have urinary output 
measured, often requiring insertion of an indwelling urinary catheter connected to an 
urometer. If CIN occurs (see Table 6) then recommended AKI management guidelines, such 
as included in the recent European Best Practice position statement on AKI151, should be 
implemented. This consists of serial SCr measurements, withholding nephrotoxic 
medications and loop diuretics, optimisation of electrolyte and hydration status, nutritional 
input, and if severe early hospitalisation with input from specialist nephrology teams. 
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1.3.8 NOVEL PHARMACOLOGICAL PROPHYLAXIS AGAINST CIN 
 
 
A number of pharmaceutical agents with antioxidant and vasodilatory properties have been 
investigated and although some have shown promise, further evaluation is required (Table 
13). The three agents with the most supportive evidence are theophylline/aminophylline, 
high dose statins and ascorbic acid. 
 
1.3.8.1 Theophylline & Aminophylline 
 
The use of competitive adenosine antagonists, such as theophylline and aminophylline, as 
prophylaxis against CIN stems from the rationale that inhibiting adenosine mediated renal 
vasoconstriction (section 1.4.2.4) should offer protection against renal IRI. Theophylline and 
aminophylline are also non-specific competitive phosphodiesterase inhibitors which may 
also contribute to reno-protection through anti-inflammatory pathways. Initial evidence for 
efficacy was limited, as shown in an early meta-analysis by Ix et al, who demonstrated a small 
difference in post procedure mean SCr between groups (11.5 µmol/l). A larger and more 
recent meta-analysis by Dai et al152, consisting of 1412 patients in 14 RCT’s, has found a 
more pronounced effect with an overall CIN relative risk (RR) of 0.48 (95% CI 0.26-0.89, 
P=0.02) and a significant reduction in post procedure SCr in the treatment group (27.4 
µmol/l). Nevertheless the included studies showed significant heterogeneity and so no firm 
conclusions can be made until further large RCT’s are performed.  
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1.3.8.2 High dose Statins 
 
Hydroxymethylglutaryl CoA reductase inhibitor (statin) therapy is an important component 
in the treatment of ACS and CVD which significantly improves both short and long term 
cardiovascular outcomes153, particularly so when initiated prior to PCI154 and at high doses153. 
This effect is mediated via lipid profile optimisation as well as by pleiotropic effects including 
improvements in endothelial function155, anti-inflammatory156 and anti-oxidative properties157 
and inhibition of thrombin formation and platelet aggregation158.  
 
The recent PRATO-ACS study159 demonstrated that high dose rosuvastatin pre-treatment 
(40mg then 20mg od) in statin naïve ACS patients was protective against CIN (6.7% vs. 
15.1%; OR 0.38; 95% CI 0.20 - 0.71; p = 0.003) in addition to improving cardiovascular 
outcomes. A follow up meta-analysis by Marenzi et al160, including 5212 patients in 9 RCT’s, 
conformed reduction in the rate of CIN when treating statin naïve ACS patients (5.5% vs 
15%, RR 0.37; 95% CI 0.25 to 0.55; P<0.0001) however this benefit did not extend to non-
ACS patients, although there was a non-significant trend towards benefit. Importantly 
another meta-analyses by Thompson et al161 did not show benefit in treating statin  naïve 
patients with stage III CKD, although this may be explained by the limited number of trials 
that specifically include this group of patients. As such further specifically designed RCT’s 
are required to elucidate whether statin pre-treatment can reduce the incidence of CIN in 
high-risk patients.  
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1.3.8.3 Ascorbic Acid 
 
The rationale of antioxidant therapy in CIN prophylaxis is derived from the evidence 
supporting NAC and the role that ROS is believed to play in CIN (section 1.4.2.9). Ascorbic 
acid (vitamin C) is well tolerated, has powerful antioxidant properties and was therefore 
proposed as a potentially beneficial agent. However despite promising data supporting its 
protective role against ischaemic AKI in animal models162, clinical trials have been less 
conclusive. An initial pilot RCT performed by Spargias et al163 in 2004 demonstrated that 
pre-treatment with high dose ascorbic acid reduced the incidence of CIN (9% vs 20% OR 
0.38, 95% CI 0.17 to 0.85; P=0.02). However a number of other further RCT’s failed to 
demonstrate benefit164, 165,166. Nevertheless a recent meta-analysis of 9 small RCT’s, 
performed by Sadat et al167, found that ascorbic acid pre-treatment may reduce CIN rates by 
up to 33%, with no significant evidence of heterogeneity or publication bias in the studies 
examined. As such ascorbic acid remains an interesting therapy that warrants further 
investigation in large RCT’s. 
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Table 13: Novel pharmacological prophylaxis against CIN 
 
Drug name Study Outcome: Treatment vs Control 
High dose Statins PRATO-ACS159 
N=504 RCT 
CIN 6.7% vs. 15.1% 
OR 0.38; 95% CI 0.20 - 0.71; p = 0.003 
Marenzi et al160  
N= 1134 
CIN 5.5% vs 15% 
RR 0.37; 95% CI 0.25 to 0.55; P<0.0001 
N-Acetyl Cysteine Gonzales et al148 
Meta-analysis 
N=2746 RCT 
High quality RCTs - no CIN benefit  
RR=0.87; 95% CI 0.68-1.12, p = 0.28  
Low quality RCTs – high CIN benefit 
RR=0.15; 95% CI 0.07-0.33, p < 0.0001 
Limited Evidence 
Ascorbic Acid Sadat et al167,  
Meta-analysis 
N=1561, 9 RCT 
CIN 33% reduction 
RR 0.672; 95% CI 0.466 to 0.969; p = 
0.034 
Theophylline Ix et Al168,  
Meta-analysis 
N= 480 RCT 
Difference in mean SCr  11.5 µmol/l 
95% CI 5.3-19.4 µmol/l, p = 0.004 
Dai et al 
N= 1412 RCT 
Reduction in CIN (Heterogeneity) 
RR 0.48, 95% CI 0.26-0.89, P=0.02 
Iloprost Spargias et al169  
N=208, RCT 
CIN 8% vs 20%  
OR 0.29 95% CI 0.12 to 0.69; P=0.005 
Atrial natriuretic 
peptide 
Morikawa et al170 
N=254, RCT 
CIN 3.2% vs. 11.7% 
OR 0.24; p = 0.016 
Trimetazidine Shehata et Al171 
N=100, RCT 
CIN 12% vs 28%  p <0.05 
Prostaglandin E1 Li et al172 
N=163, RCT 
CIN 3.7 vs. 11.1 % P < 0.05 
Negative or conflicting evidence: Fenoldopam173, dopamine174, calcium channel 
blockers175, L-arginine176, furosemide177, mannitol178, endothelin receptor antagonists179. 
 
CIN = Contrast Induced Nephropathy, RCT = Randomised Controlled Trial, RR = Relative Risk, CI = Confidence 
Interval, OR = Odds Ratio, SCr= Serum Creatinine, PCI = Percutaneous Coronary Intervention, CKD = Chronic Kidney 
Disease, DM = Diabetes Mellitus 
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1.3.9 NOVEL INTERVENTIONAL PROPHYLAXIS AGAINST CIN 
 
Novel interventional therapies may offer further protection when combined with standard 
therapy and can broadly be characterised into three areas: hydration optimisation, CM 
extraction and renal protection. Although numerous small studies investigating novel CIN 
prophylactic strategies have shown promise, no intervention has as yet been proven to be 
effective and successfully translated into clinical practice. 
1.3.9.1 Novel hydration strategies 
 
The optimal volume and rate of i.v. fluid delivery is often difficult to quantify and whilst 
under-hydration increases CIN risk, over hydration may precipitate acute pulmonary oedema 
in patients with severe CKD and CCF necessitating i.v. diuretic use. Two strategies for 
improving peri-procedural hydration have been investigated. 
 
Left ventricular end diastolic pressure (LVEDP) guided volume expansion, using a cardiac 
catheter placed in the left ventricle to attain intra-procedural LVEDP measurements that 
determine the amount of i.v. fluid needed, has been shown to be a safe and effective 
treatment in the POSEIDON RCT180, with a reduced incidence of CIN from 16.3% with 
standard hydration to 6.7% in the LVEDP-guided group.  
 
Creation of a ‘forced diuresis’ by administering a matched fluid and furosemide infusion has 
demonstrated efficacy in the MYTHOS study, reducing CIN from 18.6% to 4.6%181. 
Building upon these results, the RENALGUARD system maintains a high urine output 
(>300ml/hr) using balanced i.v. isotonic saline (0.9%) and i.v. Furosemide infusion 
(0.25mg/kg), plus oral NAC. In the REMEDIAL II study182 this reduced CIN to 11%, 
(16/146) from 20.5% (30/146) in the i.v. Sodium Bicarbonate plus oral NAC control group 
(OR 0.47; 95% CI 0.24 - 0.92).  
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1.3.9.2 Novel CM removal strategies 
 
Removal of CM from the blood pool should in theory show benefit in preventing CIN, 
however prophylactic haemodialysis (HD) after CM procedures has not been shown to 
reduce CIN183, whereas both pre and post procedural hemofiltration (HF)184 and 
simultaneous HF185 have shown limited efficacy, possibly solely due to optimisation of peri-
procedural intravascular volume. HF is a costly intervention with associated risks which 
should therefore be reserved for those patients at the highest risk of CIN, for example in 
those with end stage renal disease (ESRD)186. In order to minimise the amount of CM that 
perfuses the renal vasculature, catheter devices have been developed to filter and extract CM 
from coronary sinus venous blood, which contains high concentrations of CM during CA, 
before it mixes back into the general circulating blood pool187, however this emerging 
technology has yet to be translated into clinical trials. 
 
1.3.9.3 Novel reno-protective strategies 
 
Remote ischaemic conditioning (RIC), a prototypical treatment against ischaemia 
reperfusion injury (IRI) which is pathognomic to CIN, has been shown to be effective in 
animal and clinical studies188. Several proof of concept RCT’s have demonstrated a 60-70% 
reduction in CIN using cycles of brief, non-injurious remote tissue ischaemia induced by 
blood pressure cuff inflation on the upper arm prior to CM exposure 
(preconditioning/RIPC)189. Additionally, brief cycles of myocardial ischaemia induced by 
catheter balloon inflation in the target coronary artery following PCI may also reduce CIN 
after CM exposure (remote ischaemic post-conditioning/RIPostC)190, 191.  RIPC presents a 
novel reno-protective prophylactic strategy that will be examined in depth in the following 
sections and is the focus of the clinical trial presented within this thesis. 
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1.4 ISCHAEMIA-REPERFUSION INJURY 
 
Ischaemia-reperfusion injury (IRI) occurs following injurious reduction in arterial perfusion 
and oxygenation of an organ (ischaemia) followed by restoration of blood flow and re-
oxygenation of the ischaemic tissues (reperfusion). Organs that are most at risk are those 
with high oxygen demand and metabolic activity, most notably the heart, kidney, liver, 
intestine and brain.  Clinical scenarios in which IRI occurs involve acute compromise of an 
organ’s blood supply, as a result of processes such as atheromatous plaque rupture and 
thrombosis, vascular dissection, embolism or vasoconstriction, followed by reperfusion of 
the affected tissues either by spontaneous reflow or following medical intervention, typified 
in conditions such as MI,  CVA and CIN.   
 
Renal IRI typically occurs following injurious systemic hypo-perfusion in conditions such as 
cardiogenic shock, sepsis, major haemorrhage and anaphylaxis and is a component of the 
systemic inflammatory response syndrome (SIRS)192 and  multi organ dysfunction syndrome 
(MODS)193, responsible for between 30% and 40% of mortality on intensive care units. It is 
also a common complication during invasive therapies such as PCI (CIN), CABG surgery 
(cardiopulmonary bypass), vascular surgery (aortic cross-clamping) and renal transplantation. 
The development of ESRD and treatment with regular haemodialysis exposes patients to 
recurrent hypovolaemic stress affecting cardiac194, cerebral195 and enteric196 perfusion 
contributing to the increased morbidity and mortality seen  in this patient group197. 
 
The intra-cellular mechanisms involved in IRI are complex and not yet fully understood, 
however a number of proposed pathways will be discussed in depth in the following sections. 
In general the cellular injury that occurs in IRI may be as a consequence of reperfusion 
triggered cell death and/or an event that occurs during ischaemia that manifests during the 
reperfusion process198.   
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Myocardial IRI has been the subject of extensive investigation, however the mechanisms of 
IRI in the kidney will be the focus of the following sections. In particular, due to the pivotal 
role that IRI is believed to play in CIN, specific prophylactic therapies that are believed to 
ameliorate CIN through this pathway will be explored.  
 
 
1.4.1 ISCHAEMIA-REPERFUSION INJURY OF THE KIDNEY 
 
 
IRI of the kidney, either due to pre-renal hypo-perfusion (hypovolaemia, cardiogenic shock 
and major surgery) as well as due to CIN, leads to acute tubular necrosis (ATN) and 
reduction in GFR, the hallmark of AKI. ATN can be clinically and temporally divided into 
four stages; initiation, extension, maintenance and recovery, which directly relate to cellular 
and histological pathological events (Figure 3). 
 
 
Figure 3: Four pathophysiological phases of ATN 
              Ischaemia       Reperfusion 
      
 
              eGFR 
 
 
 
                 Initiation    Extension     Maintenance        Recovery 
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1.4.1.1 Initiation phase 
 
Following injurious renal hypo-perfusion, the initiation phase of ATN is heralded by 
decreased oxidative phosphorylation of adenosine diphosphate (ADP) into adenosine 
triphosphate (ATP) within the mitochondria of the renal vascular epithelium, endothelium 
and smooth muscle cells. In the same way reductions in levels of Guanisine triphosphate 
(GTP) are observed. As a consequence, failure in a wide range of intracellular structural and 
functional processes occurs. ATP degradation leads to disruption of the intracellular 
framework of filamentous actin (F-Actin)199 causing macroscopic loss of the renal brush 
border and disruption of cellular membrane proteins involved in cell signalling, epithelial 
polarity and tight junction formation. Up-regulation of vasoactive mediators, cytokines and 
chemokines occurs, leading to vasoconstriction and activation of the inflammatory 
cascade200.   
 
1.4.1.2 Extension phase 
 
Progression to the extension phase is potentiated by ongoing vasoconstriction of the renal 
vasculature. Lethal and sub-lethal tubular injury occurs which is particularly pronounced in 
the cortico-medullary junction (CMJ) and outer medullary region where tissues exist on the 
brink of hypoxia (10-20mmHg) under normal conditions. Vascular and tubular damage 
occurs due to persistent activation of the inflammatory cascade, leukocyte infiltration201, 
intracellular dysfunction and oxidative stress following reperfusion, leading to a precipitous 
fall in GFR. 
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1.4.1.3 Maintenance phase 
 
The maintenance phase occurs following established reperfusion that leads to initiation of 
cellular repair mechanisms, proliferation, migration and apoptosis of cells in an attempt to 
restore tubular integrity and intracellular homeostasis. GFR generally plateaus at this point, 
lasting from a few days up to two weeks. During this period the tubulo-glomerular feedback 
mechanism causes reduced renal blood flow due to vasoconstriction of the afferent renal 
arterioles in response to detection of an increased salt load in the distal tubules by macula 
densa cells. Uraemic complications are often seen during this phase and diuretic therapy may 
be required to manage salt and water balance. 
 
1.4.1.4 Recovery phase 
 
The recovery phase involves re-establishment of normal cellular function, epithelial polarity 
and differentiation of cells, with recovery of GFR dependent on the degree of tissue injury 
sustained. Diuresis commonly occurs during this period, causing water and electrolyte loss 
and volume depletion, the mechanism of which is not completely understood, although 
delayed recovery of tubular function with increased GFR may account for this phenomenon. 
  
64 
 
 
 
 
1.4.2 PATHOPHYSIOLOGY OF RENAL IRI 
 
 
Multiple vasoactive mediators are involved in the initiation and extension phases of ATN 
that exert complex effects dependent on the location and subtypes of receptor within the 
kidney. The imbalance of vasoactive mediator production consequent to ischaemia of the 
vascular epithelium leads to prolonged medullary vasoconstriction and activation of the 
inflammatory cascade that precedes renal IRI. 
 
1.4.2.1 Norepinephrine, Renin, Angiotensin II 
 
Systemic and renal hypo-perfusion is associated with a strong sympathetic neuronal and 
endocrine response consisting of release of norepinephrine and renin and activation of 
angiotensin II (ANGII). Increased sympathetic tone and release of norepinephrine, renin 
and ANGII causes profound renal vasoconstriction; that compounds pre-renal hypo-
perfusion and worsens renal ischaemia. Renal sympathetic denervation202 has been shown to 
be protective against AKI in animal studies, however renin and angiotensin blockade does 
not seem to confer the same protective effect, with some clinical trials reporting a deleterious 
effect on CIN117 and increased AKI following cardiac surgery203, 204. 
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1.4.2.2 Endothelin 
 
Endothelin is a potent vasoconstrictive molecule that has been shown to be elevated 
following ischaemic AKI205. It interacts with both ET-A and ET-B receptors, activation of 
which results in reduced renal blood flow and GFR. Although a promising target for reno-
protection, clinical trials suggest non-selective endothelin blockade appears to significantly 
exacerbate renal injury due to CIN179. The explanation for this is unclear, however it may be 
related to complex interactions with other vasoactive substances, differing specific function 
of ET-A and ET-B receptors or a preferential renal cortical response to endothelin causing 
a vascular ‘steal’ phenomenon affecting the vulnerable outer medullary region91. 
 
1.4.2.3 Platelet-activating factor 
 
Platelet activating factor (PAF) is a lipid mediator secreted by many organs including the 
kidney in response to ischaemia that causes concentration dependant renal vasoconstriction 
and reduction in GFR. PAF levels are also increased by release of endothelin and renin, 
which support its role in renal vasoconstriction206. PAF antagonists have been also shown to 
be protective against AKI in a number of animal studies207, 208. Despite this, PAF itself has 
been shown to cardio-protective against IRI, mediated through activation of mitochondrial 
KATP channels that are known to protect against cell death
209. 
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1.4.2.4 Adenosine 
 
Impaired Na+ resorption in the proximal tubule in response to ischaemia leads to activation 
of the tubulo-glomerular feedback (TGF) mechanism and the subsequent release of 
adenosine, which in turn causes potent afferent renal vasoconstriction mediated by A1 
receptors210. This effect is more pronounced in the renal cortical regions and may act to shunt 
blood toward the vulnerable medulla and reduce the metabolic load on the kidney, however 
prolonged cortical vasoconstriction, as seen in CIN, leads to tubular injury. Although 
adenosine mediated vasoconstriction might be expected to worsen ATN, animal studies 
suggest it plays a more complex role, including exerting a protective anti-inflammatory effect 
mediated through the A2a receptor
211. Adenosine A1, A2b and A3 receptors are involved in the 
trigger mechanism for activation of protein kinase C (PKC)212 and the reperfusion injury 
salvage kinase (RISK) pathway, consisting of AKT and ERK1/2, which protect against cell 
death by preventing opening of the mitochondrial permeability pore (MPTP) (section 
1.4.2.11).  
 
1.4.2.5 Prostaglandins 
 
As a protective response to ischaemia, renal medullary cells secrete prostaglandins, including 
prostacyclin PGE2, which exert a strong vasodilatory effect on the renal vasculature as well 
as inhibiting production of intracellular adhesion molecules (ICAM), critical for leukocyte 
infiltration. The concomitant use of cyclooxygenase (COX) inhibitors, such as non-steroidal 
anti-inflammatory drugs (NSAIDs), strongly contributes to the risk of CIN213, likely mediated 
through the reduction in COX-2 dependant prostaglandin production in the kidney. In a 
recent small RCT169, the synthetic prostaglandin iloprost demonstrated protection against 
CIN in susceptible individuals. 
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1.4.2.6 Nitric Oxide 
 
Nitric oxide (NO), a potent vasodilator involved in autoregulation of renal blood flow, is 
produced by several isoforms of nitric oxide synthase (NOS) from L-arginine substrate. 
Endothelial NOS (eNOS) and neuronal NOS (nNOS) are found in particularly high 
concentrations in the renal vascular epithelium in the cortico-medullary region214, whereas 
inducible NOS (iNOS) is found predominantly in the glomerulus and renal tubular cells. 
Following AKI, eNOS activity is significantly reduced leading to unopposed 
vasoconstriction from other vasoactive substances such as endothelin and Angiotensin II215.   
However following renal ischaemia, iNOS activity increases and interestingly has shown to 
be detrimental to IRI in the kidney216. This may be explained by the formation of toxic 
metabolites, such as peroxynitrite, from reaction between excessive NO and reactive oxygen 
species (ROS) production within the tubular cells. Non-specific inhibition of NOS in renal 
IRI has been found to be detrimental217, likely due to the vasoconstrictive response to 
reduced eNOS activity, whereas specific inhibition of iNOS has been found to be protective 
in animal models218. 
1.4.2.7 Microvascular thrombosis 
 
Endothelial dysfunction following renal IRI may lead to the formation of thrombotic micro-
emboli within the renal microvasculature, which further exacerbates ischaemic damage. 
Intravascular thrombin and fibrin deposition have been described in animal models of renal 
IRI219 and following renal transplantation in humans. In addition to reduced renal blood 
flow, the loss of cell surface inhibitory modulators such as thrombomodulin and activated 
protein C, with increased expression of pro-thrombotic glycoproteins such as tissue factor 
may explain this phenomenon220. Administration of soluble thrombomodulin has also been 
shown to ameliorate ischaemic AKI in animal models221 
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1.4.2.8 Inflammatory cascade activation and leukocyte infiltration 
 
Leukocyte adhesion to and infiltration across the renal vascular epithelium is characteristic 
of renal IRI and is seen as early as 1 hour following an ischaemic insult201. Accumulation of 
leukocytes within the vascular lumen may cause obstruction in addition to contributing to 
vasoconstriction via the secretion of vasoactive mediators. Once infiltrated across the 
vascular epithelium, leukocytes exert direct cytotoxicity on the renal parenchyma, with the 
ensuing interstitial oedema further reducing renal perfusion by restricting peritubular 
capillary flow and increasing tubular pressure. Endothelial expression of leukocyte adhesion 
molecules, such as ICAM and P-selectin for neutrophil/natural killer T-Cell infiltration and 
fractalkine for macrophage chemo-attraction, are an integral part of the inflammatory 
response to renal ischaemia.  
 
Inactivation of these molecules using specific antibodies has shown some promise in 
ameliorating renal IRI in animal models222, 223. Once infiltrated these activated leukocytes, in 
addition to injured endothelial cells, are responsible for the production of large quantities of 
pro-inflammatory signalling molecules such as interferon gamma (IFNγ), tissue necrosis 
factor alpha (TNFα), and interleukins (IL1, IL6, IL8, IL12, IL18) that further promote the 
cascade of  inflammation224 and apoptosis225 both locally and systemically. 
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1.4.2.9 Reactive oxygen species generation 
 
Excessive reactive oxygen species (ROS) generation, consisting primarily of superoxide 
anion (O2
-), hydrogen peroxide (H2O2), hydroxyl radical (HO) and peroxynitrite, occurs as a 
result of oxidative stress and leukocyte activation and has been identified as playing an 
important role in the pathogenesis of renal IRI226. ROS are highly reactive molecules that 
result from disturbances in intermediary metabolism, ischaemic blockade of the 
mitochondrial electron transport chain227, leukocyte NADPH oxidase activity226 and  catalysis 
of hydrogen peroxide into the hydroxyl radical by free iron.  
 
During ischaemia NADPH dependent xanthine dehydrogenase, which is usually responsible 
for nucleic acid degradation, is converted into xanthine oxidase. Following re-oxygenation, 
xanthine oxidase acts upon excess hypoxanthine and xanthine accumulation resulting from 
ATP depletion and generates superoxide anion and hydrogen peroxide ROS. Excessive NO 
released as a result of ischaemia reacts with superoxide anion to form peroxynitrite, a 
particularly aggressive species of molecule. ROS cause widespread cellular damage by 
reacting directly with DNA, cell membrane lipids (lipid peroxidation), intracellular and cell 
membrane proteins and glycosaminoglycans as well as activating redox signalling. 
 
Cellular antioxidant defence mechanisms, consisting of superoxide dismutase, catalase and 
glutathione-s-transferase, which maintain ROS at non-harmful levels during normoxaemia, 
are variably impaired during IRI, contributing to ROS induced cellular injury228. 
Supplementation with N-acetyl-cysteine, a glutathione precursor, has shown promise in 
animal models of AKI229 however results from clinical trials investigating its protective 
effects against CIN147 and cardiac surgery associated AKI230 are mixed. 
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1.4.2.10 Intracellular biochemical disruption. 
 
Ischaemia affecting the proximal tubular cells and medullary cells of the thick ascending limb 
leads to rapid intracellular ATP depletion, due to the high demand for ATP and limited ability 
to perform glycolysis within these cells, which preferentially use free fatty acid substrate for 
ATP generation. Limited availability of intracellular ATP leads to dysfunction of the 
Sodium/Potassium/ATPase (Na+/K+/ATPase) transporters, which are found on all renal 
cells and extensively on the basolateral surface of proximal tubular (PT) cells231 where they 
are responsible for 70% of cellular oxygen requirements232. The loss of this transporter 
function leads to an influx of Na+ ions and water into the cell and an efflux of K+ ions. As a 
result progressive cellular swelling and intracellular dysfunction occurs and if uncorrected 
results in cellular membrane rupture and necrotic cell death233.  
 
In response to high intracellular Na+ levels the Sodium/Calcium (Na+/Ca2+) exchange 
protein, found particularly on the cortical PT basolateral membranes, reverses its usual 
function and causes significant influx of Ca2+. Dysfunction of sarcolemmal ATPase, which 
is responsible for active transport of Ca2+ into the endoplasmic reticulum for storage, results 
in further disruption of intracellular calcium homeostasis. High intracellular Ca2+ leads to 
dysregulation of the mitochondrial permeability transition pore (MPTP) 234, as well as 
activation of a number of proteases, phospholipases and endonucleases that are responsible 
for necrotic and apoptotic cell death. 
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1.4.2.11 Mitochondrial dysfunction 
 
A cascade of intracellular events, including oxidant stress during reperfusion and disruption 
in intracellular Ca2+ homeostasis, leads to opening of the mitochondrial permeability 
transition pore (MPTP)235. As a result mitochondria are no longer able to maintain a 
transmembrane potential gradient of H+ ions, critical for oxidative phosphorylation and ATP 
production.  Efflux of H+ from the mitochondria is accompanied by increased permeability 
to intracellular ions, proteins and water which causes swelling of the mitochondria236 and 
release of pro-apoptotic molecules into the cytosol. Fission of mitochondria also occurs 
which is thought to contribute to increasing outer membrane permeability and is a precursor 
to cellular apoptosis and necrosis in renal IRI237. Cyclosporine A is a known indirect inhibitor 
of MPTP opening and is cardio-protective against IRI238, however its use in renal IRI is 
limited by its nephrotoxic and vasoconstrictive properties239. 
 
1.4.2.12 Apoptosis, necrosis and autophagy 
 
Apoptosis describes an orderly and active process of programmed cell self-destruction that 
occurs in response to severe cellular injury and which manifests during the maintenance 
phase of ATN. As a number of the enzymes involved in apoptosis require ATP for their 
function, it can only occur in cells following reperfusion and in those that have recovered 
their respiratory function to some degree. The hallmark features of apoptosis are initial 
activation of the ‘intrinsic’ and ‘extrinsic’ caspase pathways, which in turn activate nuclease 
and endonuclease proteins causing nuclear and DNA degradation225, formation of apoptotic 
bodies and cell death. Reduction in the levels of intracellular GTP has also been shown to 
up-regulate a protein known as p53 which exerts a strong apoptotic effect on the cell240 
(Figure 4).  
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The cellular membranes of apoptotic bodies remain intact until phagocytosed by 
macrophages or other leukocytes within the renal parenchyma, which prevents the extrusion 
of intracellular contents into the interstitium and the corresponding inflammatory 
response225.  
 
The intrinsic caspase pathway is activated by intracellular ROS, hydrolysis of the 
phospholipid membrane and generation of ceramide241, structural abnormalities in the ATP 
dependent f-actin cytoskeleton and release of pro-apoptotic proteins such as cytochrome-c 
from the mitochondria in response to increased permeability across the mitochondrial 
membrane242.   The extrinsic caspase pathway is directly activated by a family of TNF-
receptor cell membrane proteins, otherwise known as ‘death receptors’, in response to TNF-
α secreted by activated leukocytes225. 
 
Cells that are not re-perfused or those that are critically injured to a degree where ATP 
production in sufficient quantities is impossible, undergo disorderly necrosis with passive 
swelling and rupture of cellular organelles and the cell membrane. This is followed by 
extrusion of cellular contents into the extracellular matrix, exacerbating local tissue injury 
through activation of inflammatory pathways225. Both apoptosis and necrosis occur 
simultaneously in IRI with differentiation between the two types of cell death largely 
attributable to intracellular ATP concentration following reperfusion. 
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Autophagy is a catabolic determinant of cell viability that involves orderly degradation of 
damaged cellular organelles and proteins by proteolytic lysosomal enzymes. Ischaemia 
induces autophagy following reduced oxidative phosphorylation of ATP, with resulting 
increase in AMP, AMP kinase and inhibition of mTOR activity243. During reperfusion 
autophagic mediators include ROS244, Beclin-1, phosphatidylinositol 3-kinase (PI3K)245, 
AKT246, and heat shock proteins (HSP)247. Autophagy may be protective in renal IRI248 when 
associated with telomerase reverse transcriptase (TerT) activation as TerT deficient mice 
shave been shown to suffer aggravated renal IRI with a reduction in cellular autophagy249. 
This may partially explain the increased susceptibility to AKI in the elderly population who 
have intrinsically lower TerT activity and shorter telomere length. However autophagy has 
been shown to be detrimental when mediated by activation of Beclin-1250, inhibition of which 
can be mediated via IPC activation of the RISK pathway. Activation of autophagy prior to 
IRI is thought to be protective, whereas inhibition of autophagy during reperfusion may be 
beneficial251. 
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Figure 4: Apoptotic pathway in ischaemia-reperfusion injury of the kidney 
 
 
 
 
 
Abbreviations: ANGII = Angiotensin II, PAF = Platelet activated factor, NO = Nitric oxide, ATP = Adenosine triphosphate, GTP = 
Guanisine triphosphate, ROS = Reactive oxygen species, MPTP = Mitochondrial permeability transition pore, TNF = Tissue Necrosis 
Factor 
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1.5 ORGAN PROTECTION AND ISCHAEMIC CONDITIONING 
 
The concept of organ protection against IRI was first proposed in 1986 by Murry, Jennings 
and Reimer252, who described therapeutic attenuation of the extent of myocardial infarction 
in a canine model, beyond that achieved by timely reperfusion alone. This seminal study 
demonstrated that ‘preconditioning’ the heart with transient ischaemia, achieved via 
intermittent ligation of a coronary vessel (four 5 minute cycles of sub-lethal ischaemia 
followed by reperfusion), protected the distal myocardium from a subsequent lethal IRI 
induced by a 40 minute coronary ligation. A dramatic infarct size reduction of 75% was 
observed which confirmed that reperfusion injury was both an observable entity and a 
modifiable process. 
 
1.5.1 ISCHAEMIC PRECONDITIONING 
 
This phenomenon was termed ‘classical’ ischaemic preconditioning (IPC) and is the result 
of direct activation of an endogenous protective response within a target organ, the 
mechanisms of which will be discussed in this chapter. Classical IPC appears to be a 
ubiquitous process that has been reproducibly demonstrated in a wide range of animal 
models and in humans and is capable of conveying protection against IRI in the heart as well 
as in other organs including the kidney253, brain254, intestine255, liver256, lung257, skeletal 
muscle258 and skin259. However the invasive nature of IPC and its restriction to predictable 
models of ischaemia make clinical application limited. The interest generated by IPC 
nevertheless led to investigation of many other forms of conditioning including ‘remote’ 
ischaemic preconditioning (RIPC) applied to a distant organ prior to ischaemia, remote per-
conditioning (RIPerC) applied to a distant organ during ischaemia, ischaemic post-
conditioning (IPostC) applied after ischaemia, remote ischaemic post-conditioning 
(RIPostC) applied to a distant organ after ischaemia and pharmacological conditioning. 
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1.5.1.1 Temporal aspects of ischaemic conditioning 
 
The main clinical limitation of classical IC (and RIPC) is that onset of injurious ischaemia in 
important and potentially amenable conditions (e.g. ACS, CVA and ischaemic AKI) is usually 
unpredictable, rendering pre-treatment impossible. However there may be a role for 
preconditioning in clinical scenarios where IRI is predictable (e.g. myocardial injury during 
elective CABG surgery and CIN in coronary angiography). Nevertheless pre-treatment does 
not appear to be an absolute requirement for organ protection, as benefit has been 
documented during concurrent ischaemia (per-conditioning) and after ischaemia 
conditioning (post-conditioning)260 (Figure 5).  
1.5.1.2 Biphasic response to  ischaemic preconditioning 
 
The protective response against IRI following classical IPC and RIPC is effective in target 
tissues almost immediately following the IC stimulus and persists for up to 4 hours, after 
which time it declines rapidly261. Following this, a ‘second window of protection’ (SWOP), 
otherwise known as ‘late’ or ‘delayed’ preconditioning, occurs at 24 hours and persists for up 
to three days although its effect is of lower magnitude262 (Figure 6). The second component 
of this biphasic response is not fully understood however it is thought to be mediated via 
up-regulation of various proteins including iNOS, COX-2 and heat shock proteins (HSP’s) 
within the target organ tissue. HSP’s are believed to have several functions including 
stabilisation of the intracellular cytoskeleton, protein chaperoning (assisting with assembly 
or repair of newly formed or damaged proteins) and down-regulating non-essential protein 
synthesis in damaged cells263. These temporal considerations have allowed IC to exist as a 
potential treatment strategy for a wide range of predictable and unpredictable IRI conditions 
however it is critical to recognise the importance and limitations of the proven windows of 
efficacy. 
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Figure 5: Temporal considerations in ischemic conditioning  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Biphasic windows of efficacy following ischaemic preconditioning 
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1.5.2 PROPOSED MECHANISM OF  ISCHAEMIC PRECONDITIONING 
 
The resistance to IRI that occurs following an IPC stimulus is mediated through ischaemia 
related ligand activation of cell surface receptor ‘trigger mechanisms’ as well as direct RISK 
pathway activation secondary stimuli such as intracellular acidosis264. Once activated, the 
trigger mechanism initiates a complex signalling cascade within the cell known as the ‘signal 
transduction pathway’ which terminates at an ‘end effector’, ultimately responsible for 
determining cell survival (Figure 7). In addition a ‘memory’ component, likely mediated 
through protein kinase C and post translational modification of intracellular proteins, is 
believed to be responsible for the windows of efficacy seen in early (0-4 hours) and delayed 
(24-76 hours) IPC respectively265. Much of the basic research into this area involves 
myocardial cell pathways, which in general exhibit commonality with other cell types such as 
in the kidney, however where renal pathways have been determined these will be elucidated. 
 
1.5.2.1 Trigger mechanism 
 
Numerous cell surface receptors have been identified as playing a role in the trigger 
mechanism of IC, which can be broadly grouped into Gi Protein-coupled receptors (GPCR), 
growth factor (GF) receptors and ‘other’ ligand receptors266. These receptors known as 
‘preconditioning mimetics’, are believed to trigger an IRI resistant phenotype through 
summative activation beyond a threshold for response267. Ischaemic activation of GPCR and 
GF receptors by their respective ligands, results in activation of receptor associated tyrosine-
kinase, which in turn activates signalling cascades, including the RISK pathway. In addition, 
non-receptor triggering of the RISK pathway by pharmacological agents (section 1.5.3.6), as 
well as direct RISK activation secondary to intracellular acidosis and other metabolic 
imbalances are thought to occur264. 
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In the heart and kidney the GPCR ligand/receptor complexes potentially implicated in IC 
include adenosine A2b
268
, opioid
269, glucagon-like peptide 1(GLP-1)
270 and adrenomedullin271. 
Interestingly there is no evidence for renal involvement of the cardio-protective autacoids 
urocortin272 and bradykinin273, with the latter potentially aggravating renal IRI274.  GF 
ligand/receptors with both cardio and reno-protective effects include insulin275, transforming 
growth factor beta (TGF-β)276, granulocyte colony stimulating factor (G-CSF)277, fibroblast 
growth factor 2 (FGF-2)278, erythropoietin279 and the adiponectin leptin280, 281. Further cardio-
protective GF ligand/receptors with as yet unproven renal effects include insulin-like growth 
factor-1 (IGF-1)282, corticotrophin-1 (CT-1)272 and other adiponectins including visfatin283, 
apelin284, although not resistin285.  Other ligand/receptors include atrial natriuretic peptide
286 
and oestrogen287.  Many of these receptor/ligand entities are suitable targets for 
pharmacological intervention, with appropriate exogenous drug ligands capable of triggering 
a protective response (section 1.3.8).  
 
1.5.2.2 Signal Transduction pathways 
 
Cell surface receptor triggering and parallel signal transduction leads to the activation of a 
number of intracellular protein kinases, e.g. protein kinase-C (PKC)288. Following GPCR or 
GF receptor activation, a complex signalling pathway is initiated via phosphatidylinositol 3-
kinase (PI3-K) activated AKT (protein kinase B), which in turn activates endothelial nitric 
oxide synthase (eNOS). The resulting nitric oxide (NO) production, which may be 
supplemented by EPO mediated activation of Janus kinase (JAK)-signal transducer and 
activator of transcription (STAT) signalling pathway, activates guanylate cyclase (GC) which 
activates cyclic GMP dependant protein kinase (PKG). This pathway results in opening of 
mKATP channels with subsequent mitochondrial K
+ influx. During reperfusion this leads to 
production of mitochondrial ROS which activates PKC288 and inhibits MPTP opening.  
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 This particular pathway may not play an important role in the kidney, as studies have shown 
that mKATP channel opening is not necessary for RISK pathway activation, which instead 
relies on direct PI3K/AKT and A2b receptor/PKC activation
289. In cardio-myocytes, 
adenosine is capable of activating PKC directly via the A1 and A3 receptor, however the role 
of these receptors in the kidney is less clear. Animal models have confirmed the reno-
protective effect of specific A1 agonists
290, however specific A3 agonists have been shown to 
be deleterious to AKI253. Activation of PKC is thought to be a key step responsible for the 
‘memory’ effect that creates the early window effect following the initial trigger. In both 
organs, activated PKC potentiates low affinity A2b receptor activation of both AKT and ERK 
1/2 in the RISK pathway, which in turn leads to inhibition of mitochondrial permeability 
transition pore (MPTP) opening via glycogen synthase kinase-3beta (GSK-3β), ultimately 
protecting the cell against apoptotic cell death291. In cardio-myocytes, IPC mediated RISK 
pathway activation via PI3K/AKT also leads to inhibition of Beclin-1292, which reduces 
cellular autophagy and appears to prevent cell death (section 1.4.2.12). In vitro and animal 
models also suggest Beclin- 1 also plays a role in exacerbating renal IRI293 and is likely to be 
amenable to IPC via the same pathway. 
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1.5.2.3 End effector 
 
The principle target that the signal transduction pathways converge upon is believed to be 
the mitochondrial transition pore (MPTP), the constituents of which remain under 
investigation, however opening of the MPTP ante-cedes cell apoptosis and inhibition of 
opening conveys a resistant phenotype294. One component of this pore is formed from an 
adeninine nucleotide translocator (ANT) protein on the inner mitochondrial membrane and 
a voltage-dependent anion channel on the outer membrane, which when aligned connect the 
matrix directly with the cytosol. This permits efflux of H+ ions from the matrix resulting in 
in loss of the membrane potential and inhibition of oxidative phosphorylation, critical for 
cell survival. In addition efflux of pro-apoptotic mediators such as cytochrome C is thought 
to occur (section 1.4.2.12). 
 
An important component of cellular autophagy known as mitophagy, involves depolarisation 
of mitochondrial membranes and fragmentation of mitochondrial complexes (fission) in 
order to allow degradation of damaged mitochondria.  Ischaemic mitochondrial 
fragmentation is believed to be mediated by mitochondrial fission protein (DRP1)295 and 
mitophagy is then regulated by translocation of cytosolic ubiquitin ligase (parkin) to the 
mitochondrial membrane where it fuses with mitofusin 2 which is then phosphorylated by 
phosphatase and tensin homologue (PTEN) induced kinase 1296. Mitophagy has been shown 
to be cardio-protective against IRI in experimental studies mediated through removal of 
potentially harmful defective mitochondria297. However prevention of mitochondrial 
fragmentation by direct inhibition of DRP1295 and mitofusin 2298 has also been shown to 
prevent MPTP opening and convey cardio-protection, which suggests a wider role of these 
proteins beyond that of mitochondrial fission alone, although it is not known at present 
whether IPC influences these pathways299. 
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Figure 7: Preconditioning mechanism  
 
      
 
 
 
 
 
 
 
 = Cardiac & renal protection pathway      = Cardiac protection pathway only 
 
*= Unknown or deleterious effect in renal IPC, italics = pharmacological conditioning 
 
Abbreviations: GLP-1 = glucagon like peptide-1, EPO = erythropoietin, GPCR = G Protein coupled receptor, 
GF = growth factor receptor, A1, A2b, A3 = adenosine A1, A2b, A3 receptors, Met = Metformin, PI3-K = 
phosphatidylinositol 3-kinase, eNOS = endothelial nitric oxide synthase, NO = nitric oxide,  EPO = 
erythropoietin, JAC-STAT = Janus-activated kinase signal transducer and activation of transcription,  GTN = 
glyceryl tri-nitrate, GC = guanylate cyclase, cGMP = cyclic Guanisine monophosphate, PKG = protein kinase 
G , mKATP = mitochondrial potassium-adenosine triphosphate channel, ROS = reactive oxygen species, PKC 
= protein kinase C,  ERK = extracellular signal-regulated protein kinase, GSK-3b = glycogen synthase kinase-
3b, mPTP = mitochondrial permeability transition pore. Adapted from Downey et al300 & Sivaraman et al301 
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1.5.3 PHARMACOLOGICAL CONDITIONING 
 
The various cell surface receptors, signal transduction pathways and end effectors in IPC 
offer ideal pharmacological targets that are capable of potentiating a similar protective 
response against IRI. 
 
1.5.3.1 Adenosine 
 
Exogenous administration of adenosine is an obvious choice given its interactions with A1, 
A2b and A3 receptors in the IPC trigger mechanism and its A2a mediated anti-inflammatory 
properties. Despite encouraging data in animal models of myocardial IRI302, results in clinical 
studies have been mixed with the Amistad I303 and II304 STEMI trials demonstrating reduced 
infarct sizes but no reduction in MACE, whilst other similar PPCI trials have not shown 
benefit305. This variability might be explained by adenosine’s short in-vivo half-life (<10 
seconds) and lack of specificity, however whilst specific adenosine receptor agonists have 
shown promise in animal models306, translation into benefit in clinical trials has not yet been 
determined.  
 
The ADMIRE study307 which used a novel A1/A2 receptor agonist during PPCI, was only 
able to demonstrate a non-significant trend towards reduction in infarct size. The role of 
adenosine within the kidney is complex (section 1.4.2.4). Adenosine antagonists, such as 
aminophylline and theophylline, have shown equivocal reno-protective effects in CIN 
clinical trials168, with their vasodilatory benefits possibly attenuated by inhibition of 
preconditioning pathways. The sedative dexmedetomidine, a specific A2a agonist, and has 
demonstrated reno-protection in a rat model of AKI, thought to be mediated via modulation 
of autophagy via MAPK p38,  as well as through a preconditioning effect mediated via 
PI3/AKT 308.    
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Other specific A1
309 and A2a 
211 receptor agonists have also been shown confer reno-
protection through anti-inflammatory effects in experimental studies. A retrospective 
analysis of patients receiving dexmedetomidine during CABG surgery has suggested 
improved cardiovascular outcomes310 and a lower incidence of AKI311, however translation 
into prospective clinical studies has yet to occur. 
 
1.5.3.2 Opioids 
 
Exogenous opioids such as Morphine have been shown to be both cardio and reno-
protective312 in animal models, likely through activation of the delta and kappa opioid and 
EGF receptors with transduction via the PI3K/AKT and the mK-ATP pathway (Figure 7). 
Opiates are commonly used during many clinical IRI scenarios (e.g. CABG and STEMI), 
however there is only limited evidence for their efficacy in IRI in clinical trials313.    
 
1.5.3.3 Other exogenous autacoids 
 
 Atrial natriuretic peptide (ANP) is a hormone produced by the cardiac atria which acts on 
the kidney to increase renal medullary blood flow and glomerular filtration rate. It has been 
shown to be cardio314 and reno-protective315 against IRI via activation of guanylate cyclase 
(GC) and increased intracellular cGMP316. A pilot study by Sward et al317 investigated i.v. 
ANP following perioperative AKI in complex cardiac surgery and Mitaka et al318 investigated 
i.v. ANP prior to aortic cross-clamping in abdominal aortic aneurysm (AAA) repair, both 
demonstrating attenuation of AKI, although both studies were unable to distinguish whether 
improved renal haemo-dynamics or a direct protection was responsible.  
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The functional GLP-1 analogue ‘Exenatide’, used in the treatment of diabetes mellitus, has 
shown promising cardio-protective properties in experimental models and proof of concept 
clinical trials319, 320, however it has not been investigated in the setting of AKI. Nevertheless, 
Sitagliptin, which up-regulates production of GLP-1 and receptors has recently been shown 
to protect against AKI in a rat model321.  
 
Other exogenous autacoid ligands with evidence against renal IRI in animal models include 
Insulin275, GCSF277 and Erythropoietin322. Insulin therapy has been shown to be of benefit in 
protecting against AKI in a systematic review of critically ill patients323, however the clinical 
efficacy of GCSF is untested. Erythropoietin has not displayed clinical benefit in cardio-
protection and in fact may be harmful324 whilst efficacy in preventing ischaemic AKI remains 
equivocal325.  
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1.5.3.4 Nitrates 
 
GTN is an anti-anginal vasodilatory medication which is thought to exert its protective effect 
through NO donation and activation of guanylyl cyclase which promotes mKATP opening via 
increased cGMP levels. A historical meta-analysis investigating GTN use during ACS 
demonstrated significant mortality benefits326. In addition, Candilio et al327 recently reported 
in a subgroup analysis that perioperative use of GTN in CABG significantly reduced the 
incidence perioperative MI (PMI) by 38%. They also demonstrated that GTN and RIPC 
were equally effective in preventing PMI, but did not confer additive benefit when used in 
combination, suggesting that both therapies may operate through a common pathway. 
Experimental evidence in a rat model328 also supports the reno-protective role if GTN when 
administered prior to ischaemic AKI, however no effect was seen when administered 
following renal IRI.  No clinical studies have specifically investigated this effect and Candilio 
et al have yet to report on the effect of GTN on AKI in subgroup analysis. 
 
1.5.3.5 Other K-ATP agonists 
 
Nicorandil, another antianginal drug which is a direct KATP channel agonist as well as a NO 
donor with equivocal cardio-protective effects in STEMI329, 330, has shown promise in animal 
models of ischaemic AKI331 however has not been effective in ameliorating CIN in clinical 
trials332 Levosimendan, a calcium sensitising heart failure medication that also has KATP 
agonist effects, has demonstrated reno-protection against IRI in a porcine model333 but has 
yet to be tested in clinical studies. 
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1.5.3.6 Pharmacological targets within the RISK pathway 
 
Volatile anaesthetics such as isoflurane334 have demonstrated both cardio and reno-
protection, thought to be mediated by sphingosine 1-phosphate receptor activation of 
AKT/ERK. One facet of the pleiotropic cardio-protective effects of Statins may be 
attributable to direct activation of the RISK pathway as demonstrated by Bell et al335. As 
described (section 1.3.8.2), statins have been shown to protect against CIN in vitro and in 
clinical studies336. Metformin has also been shown to mediate cardio-protection through 
activation of the RISK pathway337, inhibition of pro-apoptotic caspase pathways and 
upregulation of mitogen activated protein kinases (mAPK) p38. No clinical trials have 
examined the benefit of metformin in ischaemic AKI, almost certainly due to the risk of 
precipitating lactic acidosis. 
1.5.3.7 Pharmacological targets within mitochondria 
 
Cyclosporin-A is known to directly inhibit MPTP opening and small clinical trials have 
shown cardio-protective effects338, with larger RCT’s currently underway339. However its use 
is limited by nephrotoxicity and as such no specific clinical trials have performed in renal 
IRI. Trimetazidine, an anti-anginal medication that inhibits fatty acid oxidation and promotes 
efficient glucose oxidation in ischaemic tissue, is known to preserve mitochondrial 
homeostasis. Clinical trials have demonstrated both cardio-protection during PCI340 and 
reno-protection against CIN341. Diazoxide, an antihypertensive with KATP channel activating 
properties, was traditionally assumed to exert a cardio-protective effect through mK-ATP 
channel activation, however Minners et al found instead that it may be due to mitochondrial 
respiratory inhibition triggered ROS signalling342.  Novel mitochondrial antioxidant drugs 
such as MitoQ, that aim to reduce mitochondrial injury due to excessive ROS production, 
are currently showing promise in animal models of ischaemic AKI343.  
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1.6 REMOTE ISCHAEMIC PRECONDITIONING 
 
The invasive limitations inherent in classical IC were circumvented following the discovery 
in animal models that brief cycles of non-lethal ischaemia and reperfusion in one organ or 
tissue induces protection against subsequent lethal IRI in a distant organ or tissue, a 
phenomenon known as ‘remote’ ischaemic preconditioning (RIPC). In 1993 Whittaker and 
Pryzlenk344 demonstrated in a canine model that intermittent occlusion of the left circumflex 
(LCx) coronary artery protected against subsequent lethal IRI in the neighbouring left 
anterior descending (LAD) coronary artery territory. This discovery led to a mathematical 
model345 that deduced that RIPC had activated, produced, or transported via diffusion, a 
‘protective substance’ within the target organ or tissue, although it was unknown what this 
substance might be. The detection of a communicable intra-organ protective signal led 
investigators to postulate that inter-organ protection might also be possible, communicated 
by either humoral, neural or systemic response pathways. 
 
The first evidence of inter-organ protection was established by McClanahan et al346 in a rabbit 
model, where occlusion of a renal artery for 10 minutes reduced the extent of a subsequent 
myocardial IRI, importantly to the same degree as direct myocardial IPC. Confirming these 
findings, Gho et al347 utilised 15 minutes of non-injurious mesenteric ischaemia to protect 
against subsequent myocardial IRI in a rat model,  again producing similar infarct size 
reduction as 15 minutes of direct myocardial IPC. Additionally this effect appeared to be 
dependent on reperfusion of the mesentery, and that a neuronal pathway was involved in 
relaying a protective signal to the heart, as the protective effect was abolished when 
hexamethonium, a ganglion blocker, was administered. RIPC has since demonstrated clinical 
efficacy in a number of settings utilising both limb ischaemia and inter-organ protection as 
summarised in Figure 8 and Table 14. 
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1.6.1 RIPC AND LIMB ISCHAEMIA 
 
Transient ischaemia of an upper or lower limb has the advantage of being easily applied and 
well tolerated, as limb tissues are relatively resistant to IRI. Intermittent occlusion of the 
vascular supply of a limb is either achieved invasively, e.g. by infra-renal aortic or iliac artery 
cross-clamping, or more commonly by non-invasive methods such as using a tourniquet, or 
more reliably and comfortably by inflating a blood pressure cuff to a supra-systolic pressure.  
 
In 1997 Birnbaum et al348 provided initial experimental data confirming skeletal muscle RIPC 
cardio-protection in a rabbit model, using electrical stimulation of a hind-limb muscle and 
30 minutes of partial occlusion of a femoral artery  to induce ischaemia whilst allowing for 
transport of a hypothesised humoral signal out of the ischaemic zone. As such they 
demonstrated a 65% reduction in myocardial infarct size from a subsequent coronary artery 
ligation. Weinbrenner et al349 examined the effects of varying RIPC occlusion times in a rat 
model using 15 minutes, 10 minutes and 5 minutes of infra-renal aortic occlusion which 
resulted in proportional reductions in subsequent myocardial infarct size of 65%, 30 % and 
20% respectively, which suggested that an optimal RIPC stimulus duration exists. Further 
findings in this study included confirmation that PKC is involved in the intracellular 
signalling pathway (as with IPC) and that the connective pathway between the remote and 
target organs was likely to have a humoral component as hexamethonium neural blockade 
did not abolish the observed protective effect.  
 
Evidence for skeletal muscle RIPC reno-protection in animal models is scarce, with evidence 
from clinical studies vastly outweighing the experimental data. Nevertheless Lazaris et al 
demonstrated in a rat model that infra-renal aortic occlusion for 15 minutes reduced a 
subsequent renal IRI due to 45 minutes of sub-phrenic aortic cross clamping. 
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The first experimental evidence for non-invasive RIPC in large animals was developed by 
Kharbanda et al350 who demonstrated in a porcine model, that 4 cycles of 5 minute hind-
limb ischaemia was capable of reducing subsequent myocardial IRI during cardiopulmonary 
bypass. In the clinical component of this trial they also demonstrated in healthy volunteers, 
that upper limb RIPC using three 5 minute cycles of blood pressure cuff inflation to 
200mmHg, was able to protect against a subsequent endothelial IRI in the contralateral 
forearm caused by a 20 minute blood pressure cuff inflation (200mmHg). This method has 
been adopted as the standard when administering RIPC to patients, and is a well-tolerated 
and safe and inexpensive intervention. Lower limb RIPC is also efficacious, and has the 
potential to provoke a larger response given the increased bulk of ischaemic skeletal muscle, 
however it is more uncomfortable than upper limb RIPC and thus is usually reserved for 
anaesthetised patients. 
 
1.6.2 TEMPORAL CONSIDERATIONS IN RIPC 
 
Evidence in man for early and delayed windows of efficacy in RIPC, as seen in IPC, was 
determined by Loukogeorgakis et al351, who applied RIPC to one arm of healthy volunteers 
and were able to measure an endothelial response, known as ‘flow mediated dilatation 
(FMD)’ in the contralateral arm. This appeared almost immediately following RIPC and 
persisted for up to four hours with re-emergence for further period between 24 and 48 hours. 
The role of a neural signalling pathway was also supported as FMD was abolished by 
autonomic ganglion blockade. Studies utilising organ RIPC often involve continuous periods 
of ischaemia of up to 15 minutes in duration, whereas limb RIPC utilises a fractionated 
approach. The optimal number or length of RIPC cycles remains unknown, with most 
studies empirically using three of four cycles of 5 minutes ischaemia interspersed with 5 
minutes of reperfusion. ‘Hyper-conditioning’ which uses longer ischaemic periods or a 
greater number of cycles is as yet unexplored352. 
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Figure 8: RIC inter-organ protection 
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Table 14: Major clinical and experimental studies in RIC organ protection 
 
 Remote IC →target organ Setting Size & outcome 
1 Upper limb RIPerC → Brain  Traumatic brain 
injury353 
n= 60, ↓ TBI 
biomarker 
2 Upper limb RIPerC → Heart 
Upper limb RIPC → Heart 
STEMI, PPCI354 
CABG327 
n = 197, ↓MI size 
n= 180, ↓TnT 
3a Upper limb RIPC → Kidney 
 
 
Lower Limb RIPostC 
PCI, CIN189 
Cardiac surgery, AKI355 
Renal Transplant356 
PPCI, CIN357 
n= 100, ↓SCr>25% 
n= 240, ↓SCr>25% 
n= 406, ↑eGFR 
n= 97,   ↓SCr>25% 
3b Heart RIPerC → Kidney PCI, CIN191 n= 225, ↓SCr>25% 
3c Liver RIPC →Kidney Rat358 ↑SCr, histopathology 
4a Liver RIPC → Pancreas Rat359 ↓ pancreas 
biomarkers 
4b Renal  RIPC→ Pancreas Rat360 ↑ pancreas 
microcirculation 
5 Lower limb RIPC → Liver Cardiac surgery361 n= 201, ↓ LFT 
6 Lower limb RIPC → Lung Cardiac surgery361 n= 201, ↓ Lung 
biomarkers 
 
Abbreviations: TBI = traumatic brain injury, TnT = troponin T, MACE = major adverse cardiovascular 
event, SCr = serum creatinine, LFT = liver function tests. Adapted from Hausenloy et al362 & Candilio et al363 
LIVER
 
LUNG
 
PANCREAS 
RIC 
3b
b 
HEART
T  
KIDNEY 
BRAIN 
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1.6.3 PROPOSED MECHANISM OF RIPC 
 
Although unified understanding of RIPC is incomplete, several mechanistic pathways are 
believed to be involved, that can be separated into three interrelated components; the initial 
remote organ response to RIC, the message relay pathway between remote and target organs 
and the target organ protective response, thought to be similar to the response observed in 
IPC and IPostC. Specific pathways involving the kidney are not well understood, however 
they are assumed to be similar to those known to be involved in signal communication with 
the heart. Therefore the pathways involved in cardiac relay will be the focus of discussion 
unless specific renal pathways have been elucidated. Two hypothesised routes for this relay 
mechanism exist; namely the humoral and neural pathways. 
1.6.3.1 Humoral pathway 
 
Two seminal studies by Dickson et al indicated a humoral route for the relay mechanism; the 
first demonstrated remote cardio-protection in untreated rabbits using blood transfused 
from those treated with myocardial IPC364; the second involved transfusion of coronary 
venous effluent from classically conditioned rabbit hearts to untreated rabbit hearts365. 
Shimizu et al366 demonstrated inter-species cardio-protection (human to rabbit) was possible, 
mediated by a small (<15kDa) hydrophobic molecule and abrogated by opioid receptor 
blockade with naloxone. A study by Serejo et al367, using transfusion of coronary effluent 
from conditioned rat hearts to untreated rat hearts, also supported these findings and found 
that the relay molecule was small (3.5-15kDa) and activated PKC in the target organ. Using 
the same model, Breivik et al368 postulated a small molecule (<30kDa) activated the RISK 
pathway (PI3K/AKT) in recipient rats. The first evidence for a humoral pathway in skeletal 
muscle RIPC was derived by Konstantinov et al369, who demonstrated cardio-protection of 
transplanted (denervated) donor hearts by hind limb RIPC in the recipient porcine model, a 
process which appeared to be dependent on activation of KATP channels.  
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Numerous candidate molecules within the humoral pathway have been investigated,  
including NO and nitrite370 (generated by RIPC induced endothelial shear stress), stromal 
derived factor-1α371 (SDF1- α) and micro-ribonucleic acid-144372 which is transported in 
blood by liposomal protein complexes and exosomes373. It is not known whether these 
pathways act independently or in concert however it seems likely that multiple humoral 
signals are involved, which act directly on the target organ, or act upon intermediary neural 
pathways that connect with the target organ. Accordingly, Lim et al were able to demonstrate 
that both humoral and neural pathways were involved in cardio-protection in a rat model, as 
femoral vein occlusion and femoral/sciatic nerve transection independently abrogated the 
protective effect of hind limb RIPC 
 
1.6.3.2 Neural pathway 
 
Numerous triggers other than RIPC are capable of activating a protective response through 
direct stimulation of peripheral nociceptive pathways, with evidence for subsequent humoral 
transmission of this signal to remote organs. Experimental data for this phenomenon exists 
for ‘remote ischemic preconditioning of trauma’ (RPCT) using abdominal skin incisions 
(mediated by bradykinin and neuronal PKC activation)374, direct peripheral nerve 
stimulation375, transcutaneous nerve stimulation376, electro-acupuncture377 and chemo-
stimulation of sensory C-fibres with capsaicin375. In these studies, peripheral nerve 
transection, or blockade with local anaesthetic drugs, e.g. lidocaine, abrogated the protective 
effect. This effect is mirrored in a human model, where dialysate from patients with diabetic 
neuropathy receiving limb RIPC showed attenuated cardio-protection in rabbits378 compared 
with dialysate from patients without neuropathy. 
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A neural signal is also believed to be directly relayed from the conditioned limb to the target 
organ by somatosensory (as above), autonomic and spinal cord pathways. The evidence for 
autonomic involvement is derived from experiments utilising autonomic ganglionic blockers 
(e.g. hexamethonium) to abrogate the effect of RIPC in both animal347 and human models351. 
In addition both vagal nerve transection and atropine379 are capable of diminishing the 
cardio-protective effects of hind-limb RIPC in a rabbit model. Southerland et al380 
demonstrated that electrical spinal cord stimulation is cardio-protective against IRI in a rabbit 
model, and involves adrenergic cardiac neurons, with the effect abolished by 
pharmacological α and 𝛽 receptor blockade. Hind limb RIPC induced cardio-protection has 
also been shown to be abrogated by spinal cord transection374, 379 as well as by intrathecal 
opioid receptor blockade381. 
 
1.6.3.3 Post signal relay in the target organ 
 
Although many autacoids and paracrine factors have been shown to initiate IPC, the trigger 
mechanisms involved in RIPC are less well understood, however the two final pathways are 
thought to be broadly similar. Specific evidence for  triggers involved in RIPC exists for 
adenosine via A1 receptors
382, which also interact with opioid  Δ1 & κ receptors383, bradykinin 
via B2 receptors
374, SDF1-α via chemokine receptor 4371 and interleukin 10384 (in delayed 
RIPC). The mechanisms of RIPC reno-protection are less clear with some studies ruling out 
activation of adenosine385, bradykinin, opioid and muscarinic autonomic receptors289, and 
other studies demonstrating involvement of opioid receptors269. The intracellular signal 
transduction pathways in RIPC are similar to IPC involving activation of AKT and eNOS384, 
PKC386, KATP channels
387 and the RISK pathway consisting of PI3K and AKT388,  ERK 1/2389 
and GSK3β390. The end effector in IPC, prevention of opening of the MPTP, is also believed 
to be the final target of RIPC391 which manifests the pro-survival cell phenotype.  
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1.6.4 DEMOGRAPHIC AND CLINICAL FACTOR EFFECTS ON RIPC 
 
 
In 1995 Szilvassy et al392 described attenuation of the preconditioning response in hyper-
lipidaemic rabbits. Following this discovery, the traditional cardiovascular risk factors, 
endemic within patients enrolled into IPC clinical trials, have been shown to abrogate the 
protective effect of all methods of conditioning, mediated via dysfunction in cytosolic 
signalling and mitochondrial responses to conditioning stimuli. 
 
Advanced age has been shown to reduce the efficacy of IPC, as summarised in a 
comprehensive review by Boengler et al393, dependent on reduced activity of the 
AKT/GS3K-β pathway394 and mitochondrial dysfunction from excessive ROS 
production395. The effect of age on RIPC efficacy is less well understood, with some studies 
suggesting increased efficacy of RIPC in healthy elderly volunteers396. Interestingly although 
in general females appear to be relatively resistant to IRI397, elderly female patients appear to 
be more responsive to RIPC than elderly males398, potentially mediated by gender related 
isoforms of PKC and ERK399. 
 
Patients with diabetes mellitus (DM) are at greater risk of cardiovascular and renal 
complications and are more susceptible to organ IRI400. The majority of experimental and 
clinical studies have shown that DM interferes with the protective RIPC response, due to 
the effects of overlapping metabolic comorbidities, inhibition of the protective humoral 
signal in diabetic peripheral neuropathy378 and dysfunction of AKT/ERK1/2 in the RISK 
pathway266 and  JAK-STAT within the SAFE pathway401. In addition pharmacological agents 
used to treat DM402 inhibit the mKATP channel
403 and disrupt AKT signalling404. Nevertheless 
numerous studies have shown DM patients benefit from RIPC in various clinical settings405 
although with conflicting evidence in CIN406, 407 suggesting a threshold to response may exist. 
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Hypertension and LVH has been shown in an aged animal model to raise the threshold for 
IPC of the myocardium and is unaffected by ACE-I co-therapy408. Hyperlipidaemia 
significantly aggravates myocardial IRI and abrogates the effects of RIPC, as summarised in 
a thorough review by Ferdinandy et al409 due to oxidative dimerization of PKG410 as well as 
inhibition of mKATP
411 and matrix metalloprotease (MMP2), a regulator of the extrinsic 
apoptotic pathway and RISK pathway412.  A host of other deleterious genetic and cellular 
responses to hyperlipidaemia exist, including decreased NO and HSP expression and 
increased oxidative stress that may play a role in abrogating IPC.  
 
Despite a strong correlation with adverse cardio-renal outcomes, kidney dysfunction does 
not abrogate the protective effects of IPC413 where RISK and SAFE signalling pathways 
remain intact.  
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1.6.5 RIPC AND RENO-PROTECTION 
 
 
In 1999, Cochrane et al414 were the first to demonstrate in a rat model that hind-limb RIPC 
ameliorated subsequent renal IRI.  However translation of RIPC reno-protection into clinical 
settings, such as the prevention of AKI in patients undergoing major cardiac or vascular 
surgery, renal transplantation and CIN, has yet to be fully established. Many of the clinical 
studies have been small, single centre investigations that have not been adequately powered 
to demonstrate reno-protection. In addition renal and clinical endpoints vary widely between 
studies and patient populations are variably affected by differing co-morbidities and poly-
pharmacy.  
 
1.6.5.1 Reno-protection during non-cardiac surgery 
 
Ali et al415 used intermittent non injurious iliac artery occlusion prior to surgical abdominal 
aortic aneurysm repair and demonstrated reduced serum creatinine in RIPC versus control 
patients. Another randomised trial performed by Walsh et al416 investigated lower-limb cuff 
RIPC prior to endovascular abdominal aortic aneurysm repair (EVAR) and found a reduced 
incidence of subclinical acute kidney injury, indicated by a reduction in the urine albumin 
creatinine  ratio (UACR) and urinary retinol-binding protein levels at 24 hours.  However 
contrary to this a further study by Walsh et al417  did not demonstrate renal protection using 
intermittent iliac artery occlusion prior to open infra-renal abdominal aortic aneurysm repair; 
although a larger retinol-binding protein (a novel marker of kidney injury) increase in control 
versus RIPC patients was found.   
  
98 
 
 
 
 
1.6.5.2 Reno-protection during cardiac surgery  
 
The evidence for perioperative AKI prevention using RIPC prior to CABG surgery is mixed, 
following Zimmerman et al’s28 initial demonstration of efficacy in a small study using lower 
limb RIPC.  Retrospective analysis of two studies using upper limb RIPC prior to CABG 
surgery by Venugopal et al418 found no SCr reduction, although significantly more control 
patients were in AKIN category 1 (Table 3). A prospective study by Thielmann et al419 also 
using upper-limb RIPC prior to CABG, demonstrated lower peak postoperative SCr level in 
RIPC patients but no difference in eGFR.  Two recent studies demonstrated more 
convincing evidence; In 2015 Zarbock et al published a study examining the effect of RIPC 
in 240 high risk patients undergoing CABG and found significant reductions in AKI (37.5% 
vs 52.5%), renal replacement therapy (5.8% vs 15.8%) and ICU stay (3 days vs 4days). 
Candilio327 et al also demonstrated a similar reduction in perioperative AKI (10% vs 21%) in 
180 patients undergoing CABG.  However this evidence is countered by two recent 
multicentre randomised controlled trials ‘ERICCA420’ and ‘RIP-Heart421’ which both 
examined whether RIPC could ameliorate complications resulting from CABG surgery, with 
no differences found in the secondary outcome measure of perioperative AKI between RIPC 
and control groups in either study (ERICCA n=1612, 38% vs 38.3%, p=0.975, RIP-Heart n 
= 1403, 6.1% vs 5.1%, p=0.45).  
 
Although initial pilot studies suggested that RIPC may have a role in ameliorating 
perioperative AKI during cardiac surgery, the neutral secondary outcomes in large clinical 
trials suggest that either RIPC may not be an effective intervention in this setting, perhaps 
due to the complex ischaemic and non-ischaemic injurious processes that occur during 
cardiac surgery, or that significant confounding factors may exist, for example abrogation of 
the preconditioning effect by anaesthetic or cardiovascular medications.   
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1.6.5.3 Reno-protection during kidney transplantation  
 
Macallister et al, in the recent multinational REPAIR trial356, evaluated RIPC prior to living 
donor renal transplantation in 406 donor-recipient pairs. Both short and long term windows 
of efficacy were examined and both donor and recipient received RIPC. Although the 
primary endpoint of Iohexol GFR measurement showed a non-significant trend towards 
benefit in early RIPC, the secondary measurement of eGFR as calculated by SCr at six 
months demonstrated significant improvement in early RIPC (adjusted difference 4.98, 95% 
CI 1.13 to 8.29; p = 0.011). Late RIPC however was not associated with any reno-protective 
benefit. As such this important study demonstrated that RIPC may have an important role 
to play in renal as well as other organ transplantation by extending the duration of donor 
organ survival through minimisation of ischemic organ damage during transplantation. 
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1.6.5.4 CIN prophylaxis during coronary angiography and PCI 
 
Er et al189 were the first to convincingly demonstrate that RIPC, consisting of 4 cycles of 5 
minutes ischaemia/5 minutes reperfusion of the upper limb, versus placebo control, reduced 
the incidence of CIN in high risk patients from 40% to 12% (p=0.002). However, the 
surprisingly high rate of CIN in the control group, three times that seen in similar cohorts 
of patients5, 59, 422, 423, limits translation to widespread clinical use. The patient cohort studied 
had a high degree of LV systolic dysfunction and frequently required peri-procedural diuretic 
therapy, which may partially explain the high rate of CIN. In addition the investigators used 
LOCM (iohexol/omnipaque) which may be associated with greater likelihood of renal injury 
compared to IOCM (iodixinol/Visipaque)424, 425, as well as i.v. NaCl 0.9% hydration and oral 
NAC, which may be inferior to i.v. sodium bicarbonate426. Yamanaka et al427 examined the 
effect of upper limb RIPC on CIN in patients undergoing PPCI for STEMI, a procedure 
conferring significantly increased CIN risk. RIPC was found to reduce the risk of CIN (as 
defined by a rise in SCr of >0.5mg/dL or >25% at 48-72 hours), by 10% vs. 36% in the 
control group (OR 0.1, 95% CI0.05-0.64, p=0.008) as well as reducing short term MACE 
rate, although the study was not adequately powered for MACE outcomes. 
 
Despite numerous small studies providing somewhat conflicting results (Table 15), two 
recent meta-analyses have found overall benefit for RIPC on CIN. Bei et al428 examined 10 
RCTs including 1389 patients undergoing CA or PCI and found that upper arm RIPC 
reduced CIN in all patients regardless of eGFR (OR = 0.52, 95% CI = 0.34-0.77, P = .001), 
as well as 1 year MACE (OR = 0.36, 95% CI = 0.20-0.66, P < .001)., although interestingly 
lower limb RIPC was not effective. Zuo et al429, similarly examined 9 RCT’s and found RIPC 
conferred a reno-protective effect (RR= 0.42; 95% CI, 0.27-0.65; P = 0.000) without 
significant heterogeneity or other bias.  
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Table 15: Summary of clinical trials investigating the effect of RIPC on CIN  
 
 
Study 
 
Setting 
 
RIPC 
CIN 
events 
 
Control 
CIN 
events 
 
Outcome 
RR, 95% CI 
Er et al189 
2012 
Elective CA/PCI, 
eGFR<60ml/min 
6/50 20/50 0.300 (0.132 – 0.684) 
Igarashi et al62 
2013 
Elective CA/PCI, 
eGFR<60ml/min 
2/30 8/30 0.250 (0.058 – 1.081) 
Zagidullin et al430 
2016 
Elective CA/PCI 1/25 7/26 0.14 (0.019 to 1.112) 
Yamanaka et al427 
2015 
PPCI in STEMI 5/47 17/47 0.294 (0.118 – 0.732) 
Savaj et al406 
2014 
Elective CA/PCI in 
DM patients 
1/48  5/48 0.200 (0.024 – 1.649) 
Hoole et al431 
2009 
Elective PCI 6/104 10/98 0.54 (0.19 – 1.54) 
 
Negative or conflicting evidence 
Menting et al432 
2015 
Elective CA/PCI 
eGFR<60ml/min 
 
2/36 2/36 1.000 (0.149 - 6.718) 
Balbir Singh et al407 
2016 
Elective PCI in DM 
eGFR<60ml/min 
7/51 7/51 1.000 (0.373 – 2.679) 
Xu et al433 
2013 
Elective PCI in 
elderly DM patients 
4/102 3/98 1.28 (0.294 – 5.577) 
Luo et al434 
2013 
Elective CA/PCI 2/101 1/104 2.059 (0.190 – 22.36) 
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CHAPTER 2: AUDIT AND QUALITY IMPROVEMENT 
INTERVENTION 
2.1  CLINICAL AUDIT 
In order to assess the feasibility of the study, a clinical audit was performed to assess the 
number of patients likely to meet the inclusion criteria, adherence to the Heart hospital CIN 
guidelines and the subsequent rate of observed CIN and all-cause mortality. This audit was 
carried out at The Heart Hospital from June 2011- May 2012 (12 months) which identified 
1,913 patients as having undergone a coronary angiographic procedure.  
 
The electronic patient record, CDR, was used to determine pre-procedure SCr and eGFR 
and at 48-72 hours afterwards. Further blood results were retrieved from the electronic 
TOMCAT database where data was not available on CDR (i.e. inter-hospital “treat and 
returns”). 312 of 1913 patients had a pre-procedural eGFR<60ml/min/1.73m2 whose 
clinical records were then reviewed to determine whether appropriate CIN consent had been 
obtained, i.v. sodium bicarbonate 1.26% had been administered and repeat (48-72h) blood 
test requested. For all patients, 1 year mortality data was collected from CDR. The CIN rate 
was between 10% in outpatients with follow up blood tests and 22% in all patients, with or 
without follow up 48-72 hour blood tests, which is in keeping with the historical published 
rate of approximately 17%.  Extrapolating from this data, we determined that approximately 
300 patients per year would meet the eligibility criteria and assuming a 50% successful 
recruitment rate from this group, 150 patients per year could be recruited from the Heart 
Hospital alone. The results of this Audit were presented to stakeholders at UCLH and 
recommendations about changes to practice were made including adoption of a WHO style 
checklist. These presentations also served as platform to inform staff about the ERICCIN 
study prior to its commencement. 
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2.2 SAMPLE SIZE CALCULATION 
 
At the time of the study design, the only previous study to evaluate RIPC and its effect on 
CIN suggested that it would be reasonable to expect a 70% reduction in the rate of CIN 
between preconditioned and non-preconditioned patients at 48 hours following contrast 
exposure189. Comparable studies in which RIPC reduces acute kidney injury following CABG 
surgery suggest that RIPC can reduce rates of AKI by up to 57%435.  The rate of CIN in at-
risk patients varies between cardiac centres and can be as low as 7% and as high as 40% in 
some studies189, 436, depending on patient characteristics and peri-procedural factors. From 
the Audit data the local CIN rate was estimated to be between 10% and 20%. 
 
Using a CIN incidence of 15% and a RIPC effect of a 60% reduction in CIN, the 
following power calculation determined optimal sample size: 
 
 
p1, p2 = proportion (incidence) of groups #1 and #2, p1= 0.15, p2= 0.06 
 Δ = |p2-p1| = absolute difference between two proportions  
n1 = sample size for group #1 , n2 = sample size for group #2  
α = probability of type I error (usually 0.05)  
β = probability of type II error (usually 0.2)  
z = critical Z value for a given α or β  
K = ratio of sample size for group #1 to group #2 
 
For a power of 80% and α value of 0.05, the study would need to recruit 362 patients.  
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Potentially much larger numbers were required if the actual CIN rate was lower or the RIPC 
effect size smaller and as such the study was undertaken as a proof of concept, accepting 
that it may be underpowered. As part of the ethical approval for the study the REC requested 
that a Data Monitoring Committee review an interim analysis of the data, identified as after 
100 patients had been recruited to the study, to ensure that the study was adequately powered 
and that no significant adverse events related to RIPC therapy in high risk patients had 
occurred. 
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CHAPTER 3:   EFFECT OF REMOTE ISCHAEMIC 
PRECONDITIONING ON CONTRAST INDUCED 
NEPHROPATHY  
Contrast induced nephropathy (CIN) remains a common iatrogenic complication and is 
associated with adverse cardio-renal outcomes. Despite advances in protective therapies, the 
incidence of CIN in contemporary studies remains unacceptably high. Patients identified as 
being at high risk of CIN are particularly likely to benefit from additional reno-protective 
strategies, which must be administered rapidly and safely during urgent clinical scenarios such 
as acute coronary syndromes (ACS). This clinical trial was designed to evaluate whether a 
novel therapy known as remote ischaemic preconditioning (RIPC) is effective at reducing 
the incidence of CIN. 
   3.1 HYPOTHESIS 
 
Remote ischaemic preconditioning, in addition to optimal preventative therapies and 
procedural approaches, reduces the incidence of contrast induced nephropathy in at–risk 
patients undergoing contrast based cardiac procedures. 
 
   3.2 AIMS AND OBJECTIVES 
3.2.1 Overall aim 
 
To study the effect of RIPC on CIN and short term cardio-renal outcomes in a cohort of 
patients undergoing elective and urgent coronary angiography and PCI, who had been 
identified as being at increased risk of CIN due to persistent reduction in estimated 
glomerular filtration rate (eGFR) below 60ml/min/1.73m2.  
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3.2.2 Objectives 
 
1) To study the effect of RIPC on CIN, defined as a 25% increase in serum creatinine 
(SCr) or eGFR, or an absolute rise in SCr of 0.5g/dl (44µmol/l) from baseline, at 48 
hours post contrast medium exposure, in consecutive at-risk patients undergoing 
elective or urgent coronary angiography and PCI. 
 
2) To study the effect of RIPC on persistent renal injury at 3 months following contrast 
exposure defined by chronic elevation in SCr or UACR. 
 
3) To study the effect of RIPC on cardio-renal outcomes at 3 months following contrast 
exposure, defined as all-cause mortality, non-fatal MI, revascularisation, acute heart 
failure, non-fatal stroke, major haemorrhage, rehospitalisation, haemofiltration or 
haemodialysis during the follow up period. 
 
4) To study the effect of RIPC on a sensitive marker of subclinical renal injury known 
as urine albumin creatinine ratio at 48 hours in consecutive at-risk patients 
undergoing elective or urgent coronary angiography and PCI. 
 
5) To study the effect of RIPC on a novel biomarker of renal injury, known as NGAL 
at an early 6 hour time-point following contrast exposure in consecutive at-risk 
patients undergoing elective or urgent coronary angiography and PCI. 
 
6) To study the effect of RIPC on CIN, novel biomarkers of renal injury, persistent 
renal dysfunction and short term cardio-renal outcomes in subgroups of patients 
with specific risk factors such as diabetes mellitus. 
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CHAPTER 4: METHODS 
4.1 ETHICAL APPROVAL AND INFORMED CONSENT 
 
The study protocol and associated documents were drawn up in accordance with the 
International Conference on Harmonisation, Good Clinical Practice guidance which were 
subject to approval by the UCL Partners Joint Research Office (UCLP–JRO) committee for 
the ethics of human research. Approval was also sought, via the online IRAS application 
system, from NHS R&D as well as the Research Ethics Council (REC) and all study 
documents including consent forms, patient information leaflets and correspondence were 
submitted for review. Once approved, a local review was performed by the Heart Hospital 
research committee and a site specific information form was signed. Subsequent major 
amendments were individually submitted to UCLP JRO and REC for approval and local SSI 
forms at Basildon and East Surrey hospitals were also signed upon the commencement of 
multi-centre involvement. 
 
Trial Management: 
 
The Chief Investigator, Professor Derek Yellon was responsible for the day to day 
monitoring and management of the study at all sites and the UCLP JRO, on behalf of UCL 
as the Sponsor, was responsible for monitoring and auditing studies in its clinical research 
portfolio. The trial management committee consisted of Professor Derek Yellon, Dr Rob 
Bell and Dr R. Rear and the data monitoring committee (DMC) (see below). Auditing was 
conducted in accordance with the Department of Health Research Governance Framework 
for Health & Social Care (April, 2005), in accordance with the Sponsor’s monitoring and 
audit policies and procedures. The study was enrolled onto the NIHR portfolio which 
supported clinical research nurse (CRN) activities. 
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Data Monitoring Committee: 
 
A condition for ethical approval by the REC was that a data monitoring committee (DMC) 
was to be formed in order to analyse the interim dataset of the first 100 patients recruited, 
to ensure that the study was appropriately powered and to investigate RIPC safety in high 
risk groups. This was chaired by Dr Malcolm Walker, Clinical Director of the Hatter 
Cardiovascular Institute, Professor Raymond Macallister, an independent expert at UCL and 
Dr Tim Clayton, an independent statistical expert at the London School of Hygiene and 
Tropical Medicine. 
 
Safety issues: 
 
RIPC is known to be a low risk intervention with no major adverse events demonstrated in 
a number of clinical trials, although there is a small risk of minor bruising or transient skin 
discoloration to the area of the limb on which the cuff is placed. There is a very small risk 
during venepuncture for the transmission of blood borne diseases. 
 
Patient Withdrawal 
 
We ensured that participants knew that they were free to withdraw their consent at any time 
during the trial, without reason and without prejudicing their usual care. Although not an 
occurrence during the study, patients losing the ability to consent during the trial would have 
been withdrawn, however samples and data collected whilst they remained able to consent 
may have been used.  
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UCL Indemnity Statement: 
 
“UCL holds insurance against claims from participants for harm caused by their participation in this clinical 
study. Participants may be able to claim compensation if they can prove that UCL has been negligent. 
However, if this clinical study is being carried out in a hospital, the hospital continues to have a duty of care 
to the participant of the clinical study. University College London does not accept liability for any breach in 
the hospital’s duty of care, or any negligence on the part of hospital employees. This applies whether the hospital 
is an NHS Trust or otherwise.” 
 
Reporting Serious Adverse Events 
 
All Serious Adverse Events (SAE’s) in the study were reported immediately to the sponsor 
by email as well as via the UCLH ‘Datix’ system, and were documented from the point of 
enrolment until the patient had exited from study including a comprehensive description of 
the event. 
 
 
Registration of Clinical trial 
 
 
Following successful REC (13/LO/0502) and local NHS R&D (12/0578) approvals 
ERICCIN was registered with ISRCTN, registry no. 49645414.  
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4.2 STUDY DESIGN AND PATIENT RECRUITMENT 
 
The study was initially conceived as a single centre double blinded randomized placebo 
controlled trial at the Heart Hospital, UCLH, and was subsequently expanded to a multi-
centre study including two further research centres, Basildon Hospital and East Surrey 
Hospital.  Consecutive patients awaiting elective coronary angiography or PCI for stable 
anginal symptoms or urgent PCI for NSTEMI were screened by a member of the patient’s 
usual cardiology team based upon the study inclusion and exclusion criteria, using elective 
and emergency cardiac procedure lists and the electronic patient records for demographic 
and biochemical data (Figure 9). 
 
Patients received verbal and written information about the study from their usual cardiology 
team in the form of a face to face or telephone introduction and patient information sheet 
(Appendix 1). Patients waiting for an elective procedure were given approximately 1 week 
and those waiting for urgent procedures at least 24 hours to consider participating in the 
study. For those interested in participating, an interview with a researcher was conducted on 
the day of the procedure in order to collect demographic and clinical data and to answer any 
questions.  If the patient was willing and able to provide informed consent this was 
documented using the study consent form by a researcher with a current certificate in Good 
Clinical Practice. For non-English speakers, this interview took place with an independent 
interpreter present or via a telephone service. A copy of the consent form was given to the 
patient, another filed in the clinical notes and the original was stored securely in the 
participants study folder. No monetary payment of participants or researchers occurred other 
than the occasional reimbursement of travel costs. Following enrolment a standard letter was 
sent to patients GP’s confirming participation in the study. 
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Figure 9: ERICCIN study design diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCI – Percutaneous coronary intervention, eGFR – estimated glomerular filtration rate, CCF – congestive 
cardiac failure, SCr – serum creatinine, NGAL – neutrophil gelatinase associated lipocalin, ACR – albumin 
creatinine ratio 
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4.3 INCLUSION AND EXCLUSION CRITERIA 
 
Inclusion Criteria: 
 
 Age 18 to 85.  
 Male or Female gender. 
 Awaiting elective or urgent coronary angiography or PCI  
 eGFR <60ml/min/1.73m2 (MDRD) 
 
 
Exclusion criteria: 
 
 Age less than 18 or over 85 
 Inability to give written informed consent. 
 Pregnancy 
 Patients receiving haemo or peritoneal dialysis 
 Significant upper limb peripheral arterial disease  
 Other contraindication to BP cuff inflation (friable skin/axillary lymph node 
clearance etc.) 
 Coagulopathy with INR >2.0 
 Participation in another interventional clinical trial within 3 months. 
 Intravascular contrast exposure within one month prior to study date. 
 ST elevation MI/Cardiac arrest/Cardiogenic shock during admission. 
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4.4 RANDOMISATION METHOD & BLINDING 
 
Minimised randomisation was utilised with minimisation factors of stratified eGFR 
(<20ml/min, 20-40ml/min, 40-60ml/min), age (<75yr, >75yr), diabetes, NYHA III/IV 
heart failure and haematocrit (<0.36 females, <0.39 males) as the pre-procedural weighted 
predictors of CIN identified by Mehran et al52. This ensured that the study and placebo 
groups were evenly matched in terms of the pre-procedure risk of CIN. Patients were 
assigned in a 1:1 ratio to either RIPC or placebo.  This was performed by a researcher using 
a freeware computer programme ‘MinimPy 0.3’ on a secure laptop (0). A study number and 
a treatment group letter (A or B) was generated and these results were documented on a 
confidential list to allow future data analysis or unblinding during the study if necessary.  
 
To ensure blinding, the researcher was not aware which group letter corresponded with the 
RIPC treatment or placebo arms and the automated RIPC device (DERIC) administered a 
predetermined therapy based on this letter, again unknown to the researcher. The placebo 
arm involved 5 minute cycles of sub-therapeutic inflation of the blood pressure cuff to 
10mmHg followed by deflation to 0mmHg. As such the researcher, clinical team and patient 
were blinded as to whether RIPC therapy or placebo had been delivered. All data analysis 
was carried out by a blinded fellow and no serious adverse events occurred necessitating un-
blinding of the researchers or patients. 
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Figure 10: ‘Minimpy’ minimised randomisation software 
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4.5 CIN PREVENTION PROTOCOL 
 
The established UCLH CIN prevention protocol (Figure 11) was used for all enrolled 
patients, which included encouragement of oral hydration, diuretic and nephrotoxic 
withdrawal for 24 hours (NSAID, aminoglycoside, cyclosporine, and amphotericin B), 
metformin withdrawal for 48 hours, intravenous pre-hydration with Sodium Bicarbonate 
1.26% at 3ml/kg/hour for 1 hour pre-procedure and 1ml/kg/hour for 6 hours post 
procedure, use of iso-osmolar ‘Visipaque’ contrast medium, minimisation of contrast volume 
and use of biplane imaging where appropriate.  
 
Figure 11: CIN prevention protocol at UCLH 
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4.6 TRANSIENT LIMB ISCHAEMIA PROTOCOL 
 
The RIPC or sham procedure was performed by a blinded researcher aiming for a window 
two hours prior to contrast exposure, although an exact pre-treatment window was not 
possible due to the constraints of variable caseloads and emergencies in the catheter 
laboratory. The patients’ right arm was inspected and a baseline blood pressure reading was 
made to ensure it did not exceed 200mmHg. The RIPC protocol involved inflation of a 
standard size BP cuff on the right upper arm to 200mmHg for five minutes, followed by 5 
minutes cuff deflation to 0 mmHg. A total of four cycles of inflation and deflation was 
performed. The sham procedure involved cuff inflation to 10mmHg for five minutes, 
followed by deflation to 0mmHg for five minutes with four cycles. The RIPC and sham 
therapies were visually and audibly indistinguishable to the researcher and clinical team.  This 
upper limb RIPC protocol has been widely used in many studies and is known to be a safe 
and tolerable intervention, as demonstrated in a recent RCT performed by Sharma et al437 
where patient reported pain scores were between 4 and 5 on a ‘likert’ pain scale ranging 
between 0 (least) and 10 (greatest). 
 
4.7 CORONARY ANGIOGRAPHY AND PCI PROCEDURE 
 
Coronary angiography or PCI was performed as per usual by blinded clinicians. Relevant 
data was collected including the volume and type of contrast used, whether the procedure 
included diagnostic coronary angiography alone, LV/Aortogram, PCI procedure and any 
intra-procedural complications such as hypotension (Systolic BP<90mmHg) or intra-arterial 
balloon pump (IABP) therapy. The use of biplane imaging was left to the discretion of the 
blinded coronary angiography operator. 
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4.8 CIN BIOMARKERS & CLINICAL OUTCOMES 
 
Prior to i.v. sodium bicarbonate 1.26% administration and contrast exposure, a blinded 
researcher or phlebotomist at the Heart Hospital collected venous blood for baseline SCr 
and serum NGAL tests during insertion of an intravenous cannula, and urine sample was 
collected for dipstick analysis and UACR. Following the procedure a blinded researcher or 
phlebotomist at The Heart Hospital/UCLH subsequently collected a 6 hour serum NGAL 
sample. A small cohort of patients also had ‘point of care’ NGAL samples measured at 0 and 
6 hours. The 48 hour and 3 month SCr, serum NGAL and UACR samples were collected at 
the Heart Hospital or UCLH. For patients with poor mobility these samples were collected 
at nominated satellite research sites including the North Middlesex, Whittington and 
Homerton hospitals and couriered immediately for analysis at the UCLH laboratory.  
 
SCr analysis was performed using the Roche Cobas modular analyser series (Roche 
Diagnostics, Burgess Hill, UK). A rate blanked, compensated Jaffe method was used for all 
samples. UACR was analysed using quantitative particle enhanced immune-inhibition 
method (Dade Behring aca IV® analyser, Dade Behring Inc., Wilmington, DE). NGAL 
point of care analysis was performed using Alere Triage® fluorescence immunoassay NGAL 
Test strips and Alere Triage® Meter. 
 
At 3 months a blinded researcher performed telephone interviews with patients and the 
patients’ GP to document changes to medications and identify cardio-renal endpoints that 
may have occurred. 
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4.9 PRIMARY OUTCOME MEASURE 
 
The incidence of CIN, as defined by a relative 25% increase, or 0.5g/dl (44µmol/l) absolute 
increase in serum Creatinine from baseline at 48 hours post contrast medium exposure. 
 
4.10 SECONDARY OUTCOME MEASURES 
 
The change in serum creatinine, eGFR and urine albumin creatinine ratio (UACR) from 
baseline to 48-hours and 3 months post contrast medium exposure.  
 
The change in serum neutrophil gelatinase-associated lipocalin (NGAL) from baseline to 6 
hours, 48 hours and 3 months post contrast exposure. 
 
The assessment of short term cardio-renal endpoints including death, non-fatal MI, 
revascularisation, acute heart failure, non-fatal stroke, major haemorrhage, rehospitalisation, 
haemofiltration or haemodialysis during three months follow-up. 
 
 
 
 
  
119 
 
 
 
 
4.11 DATA COLLECTION, HANDLING & RECORD KEEPING 
 
A blinded fellow or research nurse used a case report form (CRF) to perform data collection. 
This confidential document identified the patient with a unique study number, initial, date 
of birth, documented fulfilment of the inclusion and exclusion criteria, randomisation data, 
baseline demographic and medical history and medications. Numerical data was entered onto 
the CRF for serum creatinine, serum NGAL, and urine dipstick/UACR at the various time 
points. The CRF was then transcribed by a blinded researcher or research nurse onto a secure 
UCL database, known as ‘Redcap’ to allow for data collection across the multicentre research 
sites and to facilitate analysis (Figure 12).  
 
For each participant, the CRF was stored in an individual patient folder with separate patient 
identifiable information such as name, address, GP details and contact telephone number. 
The folders were secured in a locked room at The Heart Hospital and subsequently at The 
Hatter Cardiovascular Institute, UCL. Patient identifying information was not used in data 
analysis after participants were allocated a unique study number. All computerized data was 
stored on password-protected computers in encrypted drive partitions. Some routine patient 
data, such as blood test results, was available to the clinical team via password-protected 
electronic patient record.  
 
In accordance with its current Records Retention Schedule, research data is retained by UCL 
as sponsor for 20 years after the research has ended. The UCL Records Office provides a 
service to UCL staff and maintains records in a safe and secure offsite location and access to 
stored records is strictly controlled. 
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Figure 12: Online ‘Redcap’ case report form database 
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4.12 STATISTICAL ANALYSIS 
 
Variables were tested for normal distribution using the Shapiro Wilk test, data that 
conformed to a normal distribution were summarised as means (SD) and otherwise as 
median and first and third quartiles (Q1–Q3). The effect of RIPC treatment on CIN was 
evaluated using logistic regression, adjusted for the minimization factors, as well as other 
covariates of interest (gender, volume of contrast, peri-procedural hypotension and Intra-
Arterial Balloon Pump (IABP) use). The effect of RIPC treatment on serum creatinine 
change, eGFR(MDRD) change, serum NGAL and UACR compared at the two  time points 
was evaluated using the Mann-Whitney U test.  Statistical analyses were performed with SPSS 
22.0. A 2-sided probability value of 0.05 was considered to indicate statistical significance. 
 
The data analysis was performed blinded and the results were summarised in in tables and 
box and line graphs. The tables include demographical, clinical and procedural data, as well 
as the results of blood and urine tests taken at the three time points. A table displays data 
relating to the primary and secondary outcomes as well as subgroup analysis of patients with 
higher CIN risk. Line graphs have been used to display surrogate measures for CIN at 
different time points in study patients and control patients. Missing data due to withdrawal 
or non-compliance has been documented in the results. 
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4.13 MAJOR AMENDMENTS TO THE PROTOCOL 
 
22/11/13 – Version 1.2 Approved by REC 
 
 The study inclusion criteria were amended to include patients with impaired renal function 
undergoing biventricular pacemaker insertion using intravascular contrast medium. This 
amendment was aimed to increase the number of potentially eligible patients for the study. 
Clarification of the recruitment and randomisation methods was made and the analysis of 
serum Cystatin C and urinary NGAL was removed from the protocol given that neither 
investigation added significantly to the scientific validity or safety of enrolled participant and 
incurred significant costs. Three satellite blood test collection centres were included in the 
study to facilitate 48-hour and 3-month sample collection for patients with impaired mobility, 
namely the North Middlesex, Homerton and Whittington hospitals. 
 
 
29/5/14 Version 1.3 approved by REC 
 
In order to increase recruitment and to widen participant demographics, the study was 
expanded to a multicentre trial including Basildon Hospital (PI Dr Reto gamma) and the 
East Surrey Hospital (PI Dr Shrilla Banerjee). The London Chest Hospital, The Royal Free 
Hospital and Barnet Hospital were also approved for inclusion into the study however were 
unable to participate due to difficulty in securing staff for NIHR nursing support. Site-
specific patient information sheets, consent forms and GP letters were approved. Grant 
funding of £37,266 from the NIHR UCL Biomedical Research Centre was confirmed.  
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15/5/15 Version 1.3.1 Amendment to laboratory NGAL analysis 
 
A small cohort of patients (n=10) had a ‘point of care’ (POC) serum NGAL testing at 0 and 
6 hours post procedure in order to assess whether changes in serum NGAL from baseline 
might predict CIN at the bedside. It was initially planned that these results were to be 
correlated with formal laboratory NGAL samples collected on all patients to ensure validity. 
Following the DMC review of the study and the conclusion that the study was underpowered 
and had not demonstrated any significant difference in the primary outcome measure 
between groups, it was decided that formal laboratory NGAL analysis on all patients would 
not add significantly to findings of the study. It would however have increased study costs 
substantially and therefore the formal laboratory NGAL results were not processed.  The 
results from the NGAL point of care tests have been presented in the results section below. 
No patients who had POC NGAL analysis went on to develop CIN. 
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4.14 DEVELOPMENT OF THE ‘DERIC’ DEVICE 
 
In order to facilitate the administration of the RIPC or sham procedure by a blinded 
researcher and to allow for precise delivery of the RIPC protocol, an automated RIPC device 
was designed and built in collaboration with the UCL biomedical department. The initial 
design of this device consisted of dual blood pressure cuffs that would uniquely enable the 
automated delivery of RIPC at two different limb sites simultaneously thus potentially 
halving the time needed for effective treatment. This device was named the ‘Dual electronic 
remote ischaemic conditioning’ device, or ‘DERIC’ (Figure 13).  
 
This particular ‘dual conditioning’ ability was not specifically utilised in the ERICCIN trial 
although it was hoped that this would be of benefit in future studies. Much of the hardware 
of the DERIC device was derived from existing automated blood pressure measurement 
machines, as well as utilising ‘off the shelf’ electronics, which greatly reduced the cost and 
time involved in developing the prototype (Figure 14). The hardware is controlled by a laptop 
PC with a user-friendly graphical user interface (Figure 15) that allows the researcher to easily 
configure the therapy that is required and allows objective data collection on the treatment 
that has been delivered (Figure 16). Although the DERIC device was not submitted for CE 
marking, not being for commercial use, the device underwent a formal safety assessment, 
performed by Medical Engineering Solutions Ltd prior to its use in the study (see Appendix).  
 
Two further single pump laptop controlled devices were manufactured based upon the 
original specification for use at Basildon Hospital and East Surrey Hospital research sites and 
it is hoped that these devices will also be utilised in future RIPC research studies at the Hatter 
Cardiovascular Institute, UCL. 
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Figure 13: Illustration and picture of the ‘DERIC’ device 
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Figure 14: Block diagram of the ‘DERIC’ device 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: DERIC graphical user interface control 
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Figure 16: Database for the DERIC RIPC/Sham delivery 
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4.15 PARTICIPANT FOCUS GROUP 
 
In order to optimise recruitment to the study a patient focus group meeting was held at the 
midpoint of the study in order to assess participant experience and to receive feedback. 42 
participants recruited to date were approached and two separate small group meetings for 
both control (n=7) and RIPC (n=6) participants were held at the Hatter Cardiovascular 
institute on the 17th July 2014. By holding separate meetings, participants were prevented 
from comparing their treatment regimens with one another and in doing so blinding was 
maintained. The meeting was chaired by two independent researchers, Dr R. Bell and Ms K 
Bavnbek, and participant responses to structured questions and an open feedback session 
were recorded to audio tape and transcribed.  
 
 
A) Initial contact with research team and Information sheet 
 How were you initially approached by the research team? 
 Was this convenient for you and was the team member polite and helpful? 
 Was the information given to you clear and concise? 
 Was the need to return to hospital for blood tests after your procedure explained to 
you? 
 Did we offer blood test collection at your local hospital? 
 Were you given an opportunity to ask questions or raise any concerns? 
 Did you feel under any undue pressure to participate in the study? 
 Were you given the contact details of the research team? 
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B) On the day of the procedure 
 
 Was the study re-explained to you and were you given the opportunity to ask 
questions? 
 Were the research team polite and helpful? 
 How did you find the remote ischaemic conditioning procedure? 
 Did you notice any ill effects afterwards? 
 Were you given clear information about how to have your blood tests collected? 
 Were you given the contact details of the research team in case of any problems? 
 
C) Follow up after your procedure 
 
 How convenient for you was the 48 hour and 3 month blood collection? 
 Did you know when and where to have your blood collection? 
 Did you experience any problems whilst attending for your blood collection? 
 If so were you able to communicate these to the research team? 
 How could we improve this process for you? 
 Was there anything you wished you had been told before joining the study? 
 Were you told you would receive feedback on the results of the study? 
 
D) Open feedback session 
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4.16 REPORTING AND DISSEMINATION OF RESULTS 
 
An anonymised data summary sheet will be offered to participants and the Sponsor at the 
end of the study. The anonymised data has also been summarised and presented at internal 
meetings at the Hatter Cardiovascular Institute as well as at the participating hospitals. It is 
hoped that in addition to the benefit of this thesis, the anonymised data will be used by the 
author for submission to peer-reviewed journals for publication, as well as being presented 
at local and national Cardiovascular and Renal conferences. The rationale for the study was 
published in a peer reviewed journal at the outset of the clinical trial. 
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CHAPTER 5: RESULTS 
5.1   CLINICAL AUDIT 
 
 1,913 patient events encoded “Coronary angiography” identified. 
 Mean patient age was 64, 71% were male. 
 25.3% were “treat and returns” with no recorded blood test data on the UCLH CDR 
(half of these patients had data recorded on the ‘TOMCAT’ angiographic database 
and therefore could be included in the audit). 
 1,773 had no follow-up within the UCLH NHS trust. 
 312 patients were identified as having an eGFR<60 (giving a prevalence of 19%). 
 Case notes of 221 patients with an eGFR<60ml/min (72%) were reviewed. 
 Of the 312, only 141 had a 48h blood test within the Trust, however this identified 
31 cases of contrast induced nephropathy. 
 Overall rate of CIN in the eGFR<60 ml/min group was 10%. 
 CIN rate for those with repeat blood within the trust was 22%. 
 The 1 year survival rate for patients with an eGFR<60ml/min and CIN was 69%, 
compared with 87% for patients with an eGFR<60ml/min and no CIN and 97% for 
those with an eGFR>60ml/min (Figure 17). 
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Figure 17: Kaplan-Meier Cumulative 1 Year Survival Plot 
All-cause mortality of patients undergoing coronary angiographic procedures at UCLH,      
June 2011 to July 2012 (n=1,913) 
 
 
 
 
 
 
 
 
 
 
Figure 18: Results of 2012 Audit case note review 
  
If eGFR<60, the relative risk of dying within 1 year 
compared to those with an eGFR>60 is 4.58 (CI 3.09 - 
6.78) (χ2 p<0.0001)  
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5.2  PATIENT RECRUITMENT 
 
Figure 19: Study CONSORT diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Patients with 0 hour eGFR >60ml/min, despite a screening eGFR<60ml/min, were 
excluded due to the definition of CKD, requiring two sequential eGFR measurements of 
<60ml/min within 3 months 
5 excluded, 0 hour 
eGFR>60ml/min* 
244 consecutive patients assessed for eligibility 
Angiography 
144 excluded 
113 declined participation 
31 did not meet inclusion criteria 
50 patients 
Control  
50 received sham 
50 patients RIPC 
50 received RIPC 
8 lost to 48 hour 
follow up (DNA) 
2 lost to 3 month 
follow up (DNA) 
37 completed 
48hr follow up 
41 completed 
48hr follow up 
35 completed 
3 month follow up 
 
38 completed 
3 month follow up 
100 
Randomised 
37 analysed at 48 hr 
35 analysed at 3 mo 
 
41 analysed at 48 hr 
38 analysed at 3 mo 
5 excluded, 0 hour 
eGFR>60ml/min* 
4 lost to 48 hour 
follow up (DNA) 
3 lost to 3 month 
follow up (DNA) 
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5.3 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS  
Table 16: Demographic, clinical and angiographic characteristics  
 
 Control Group 
(n=37) 
RIPC Group  
(n=41) 
 P 
value** 
Age, years (SD) 71.68 (+/-8.54) 72.12 (+/-8.137) 0.81 
Age > 75* 13 (35.1%) 16 (39%) 0.54 
Gender (Male) 26 (70.3%) 26 (63.4%) 0.52 
Body Mass Index,  
Kg/m2 (SD) 
30.39 (+/-6.31) 29.16 (+/-3.41) 0.28 
Hypertension 29 (78.4%) 35 (85.4%) 0.42 
Smoking History 27 (72.9%) 27 (65.9%) 0.49 
Dyslipidaemia 27 (72.9%) 33 (80.5%) 0.43 
Diabetes Mellitus* 18 (48.6%) 19 (53.7%) 0.84 
Peripheral Arterial Disease 3 (8.1%) 3 (7.3%) 0.89 
Acute Coronary Syndrome 4 (10.8%) 6 (14.6%) 0.61 
Previous MI 15 (40.5%) 12 (29.3%) 0.29 
Previous PCI 16 (43.2%) 11 (26.8%) 0.12 
Previous CABG 4 (10.8%) 10 (24.4%) 0.12 
Angina <1 month CCS I-IV 18 (48.6%) 10 (24.3%) 0.03 
0 hour MDRD eGFR,  
ml/min, median(Q1-Q3) 
51.2 (40.3-56.9) 47.5 (40-54.2) 0.24 
0 hour Creatinine mg/dl,  
median (Q1-Q3) 
123 (113-158) 126 (119-140) 0.59 
eGFR 40-60 ml/min* 27 (72.9%) 29 (70.7%) 0.83 
eGFR 20-40 ml/min* 10 (27.1%) 12 (29.3%) 0.83 
eGFR <20 ml/min* 0 0 - 
CCF, NYHA III-IV* 4 (10.8%) 5 (12.1%) 0.85 
LV Ejection Fraction >50 17 (46.0%) 23 (56.1%) 0.37 
LVEF 35-50 6 (16.2%) 5 (12.2%) 0.61 
LVEF<35 2 (5.4%) 3 (7.3%) 0.73 
Unknown LVEF 12 (32.4%) 10 (24.4%) 0.43 
Haematocrit <0.39M/0.36Fs* 12 (32.4%) 18 (43.9%) 0.29 
Blood Pressure, mmHg (SD) 132/76 
(+/-19/10) 
139/75 
(+/-24/10) 
0.16 
Heart Rate, bpm (SD) 67 65 0.54 
Contrast Volume ml 
(median/quartiles) 
120 (81.5-200) 110 (90-156) 0.87 
Hydration Volume, ml (SD) 750.29 (+/-169.1) 714.9 (+/-101.59) 0.26 
Mehran Score <5 (SD) 11 (29.7%) 9 (21.9%) 0.19 
Mehran Score 6-10 (SD) 18 (48.6%) 20 (48.7%) 0.99 
Mehran Score 11-15 (SD) 6 (16.2%) 11 (26.8%) 0.26 
Mehran Score >16 (SD) 2 (5.4%) 1 (2.4%) 0.49 
   
* CIN risk factors used as minimisation factors during randomisation 
 
** Independent t-test used for normally distributed variables, Man Whitney U test was used 
for non-parametric continuous variables and chi square test for categorical variables. 
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Table 17: Baseline medication history  
 
 
 Control (N=37) RIPC (N=41)      P Value* 
Aspirin 33 (89.2%) 32 (78%) 0.18 
Clopidogrel/ P2Y(12) inhib 30 (81.1%) 25 (61%) 0.05 
B-Blocker 26 (70.3%) 33 (80.5%) 0.12 
Ca Channel Blocker 12 (32.4%) 13 (31.7%) 0.94 
Nitrate 19 (51.4%) 9 (22%) 0.007 
Statin 33 (89.2%) 33 (80.5%) 0.29 
ACE-I/ARB 23 (62.2%) 31 (75.6%) 0.20 
Insulin 6 (16.2%) 6 (14.6%) 0.85 
Sulphonylurea 7 (18.9%) 12 (29.3%) 0.28 
Metformin 11 (29.7%) 12 (29.3%) 0.96 
Glitazone 2 (5.4%) 1 (2.4%) 0.49 
Gliptin 2 (5.4%) 1 (2.4%) 0.49 
Warfarin 3 (8.1%) 7 (17.1%) 0.24 
Diuretic 14 (37.8%) 17 (41.5%) 0.74 
Nephrotoxic (NSAID etc.) 2 (5.4%) 1 (2.4%) 0.49 
 
* chi square test was used for categorical variables. 
  
136 
 
 
 
 
5.4  SERUM CREATININE RESULTS 
 
 
Table 18: Serum creatinine values at 0 hours, 48 hours and 3 months  
 
Creatinine (µmol/l)  Control Median (Q1-3) n= 37 RIPC Median (Q1-3)  
n= 41 
0 hour   123 (113-157) 126 (118.5 – 140) 
48 Hour   133 (105 -153) 128 (114 – 152) 
  Control   n= 35 RIPC n= 38 
3 Month Median   126 (114-150) 124.5 (106 – 147) 
 
 
 
Figure 20: Serum creatinine values at 0 hours, 48 hours and 3 months 
 
 
 
 
 
 
137 
 
 
 
 
Figure 21: Individual participant serum creatinine change at 48 hours 
 
 
 
 
Figure 22: Individual participant serum creatinine change at 3 months 
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5.5  EGFR RESULTS 
 
Table 19: eGFR values at 0 hours, 48 hours and 3 months  
 
eGFR  ml/min  Control  n= 37 RIPC n= 41 
0 hour Median (Q1-3) 51.2 (40.3 – 56.9) 47.5 (40.1-54.2) 
48 Hour Median (Q1-3) 48.7 (41.2 – 58.6) 46.8 (39.8 – 56.46) 
  Control   n= 35 RIPC n= 38 
3 Month Median (Q1-3)* 47.13 (39.9 – 56.6) 47.8 (37.8- 587.5) 
 
 
 
 
Figure 23: eGFR  values at 0 hours, 48 hours and 3 months 
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Figure 24: Individual participant eGFR change from 0 to 48 hours 
 
 
 
 
Figure 25: Individual participant eGFR change from 0 hour to 3 months 
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5.6  URINE ALBUMIN CREATININE RATIO RESULTS 
 
Table 20: UACR  values at 0 hours, 48 hours and 3 months  
 
Urine Albumin Creatinine Ratio 
mg/mmol 
 Control  n= 32 RIPC n= 37 
0 hour Median (Q1-3) 2.1 (0.5 -9.1) 1.6 (0.4 – 5.8) 
48 Hour Median (Q1-3) 1.8(0.6 – 13.1) 1.7 (0.5- 4.9) 
  Control   n= 25 RIPC n=28 
3 Month Median (Q1-3) 1.7 (0.2 – 11.7) 1.3 ( 0.7 - 4.2) 
 
 
 
Figure 26: UACR values at 0 hours, 48 hours and 3 months  
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Figure 27: Individual participant UACR change from 0 to 48 hours 
 
 
 
 
Figure 28: Individual participant UACR change from 0 hour to 3 months 
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5.7   ‘POINT OF CARE’ NGAL RESULTS 
 
Table 21: NGAL values at 0 and 6 hours and creatinine at 0 and 48 hours 
 
 
NGAL (ng/l)  Control Median (Q1-3) n= 6 RIPC Median (Q1-3) n= 4 
0 hour  246 (143 to 317.5) 110 (77.3 to 226.0) 
6 hours 177.5 (111.8 to 233.8) 127 (70.8 to 147.3) 
SCr (µmol/l)   
0 hour 170 (144.3 to 201.5) 128.0 ( 97.8 to 137.3) 
48 hours 169 (97.7 to 137.2) 127 (96.5 to 134.8) 
 
 
Figure 29: NGAL and SCr values at 0 and 6 hours and SCr at 0 and 48 hours 
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5.8  PRIMARY AND SECONDARY OUTCOME MEASURES 
 
Table 22: Primary and Secondary outcome measure analysis 
 
Primary Outcome Control Group 
(n=37) 
RIPC Group 
(n=41) 
Odds Ratio & 
Significance 
 
CIN  
 
(25% or 44 µmol/l 
increase in 
Creatinine) 
 
n, (%) 
 
2 (5.4%) 
  
 2 (4.8%) 
 
 
OR 1.1  
(CI 0.15 to 8.33) 
p = 0.916 
 
Adj. OR 1.9 * 
(CI 0.19  to 20.5) 
p = 0.575 
 
Secondary 
Outcomes 
Control Group  
Median (Q1-Q3) 
RIPC Group  
Median (Q1-Q3) 
Significance** 
0-48 hour SCr   Δ 
µmol/l 
 1 (-13.5 to 13.5) 0.5 (-6.8 to 10.5) p = 0.97 
0-48 hour eGFR   Δ 
ml/min 
0.9 (-4.3 to 8.4) 
 
-0.3 (-3.4 to 3.3) p = 0.834 
0-48 hour  UACR   Δ 
mg/mmol 
0.7 (-0.2 to 4.5) 0 (-1.3 to 0.3) p = 0.09 
0-3 month SCr   Δ,  
µmol/l 
2.0 (-12.0 to 9.5) 2.0 (-14.3 to 9.8) p = 0.703 
0-3 month eGFR   Δ, 
ml/min 
-1.1 (-5.2 to 2.2) -1.1 (-5.6 to 8.5) p = 0.703 
0-3 month  UACR   Δ 
mg/mmol 
0.1 (-0.9 to 3.7) 0.0 (-1.4 to 0.6) p = 0.206 
0-6 hour NGAL   Δ  
ng/l 
-59.5 (-98.7 to -19.5) -4.0 (-85.2 to 21) p = 0.394 
Secondary 
Outcome 
Control Group 
(n=37) 
RIPC Group 
(n=41) 
Odds Ratio & 
Significance 
 
Cardio-renal 
Endpoints 
 
n, (%) 
 
 
 
        3 (8.1%) 
 
1 Death (Non-CV) 
1 ACS 
1 Readmission with 
haemorrhage 
 
2 (4.8%) 
 
1 Haemorrhage 
1 Acute LVF 
 
OR 1.7 
(CI 0.27 –to 16.8) 
p=0.565 
 
Adj. OR 2.2* 
(CI 0.29 to 18.2) 
p = 0.437 
 
 
* Multivariate regression analysis adjusted for variables including Age>75, eGFR  (ranges: 
<20, 20-40, 40-60), diabetes, CCF or LVEF<50%, anaemia, hypotension and contrast volume. 
 
** Mann-Whitney U-test used for non-parametric analysis 
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5.9 SUBGROUP ANALYSIS 
 
Table 23: Subgroup analysis of patients aged> 75  
 
AGE>75 
n=28 
Control Group 
Med(Q1-Q3) 
n = 12 
RIPC Group  
Med(Q1-Q3) 
n= 16 
Significance** 
0-48 hour SCr   Δ 
µmol/l 
5.0 (-3.5 to 23.2) 1.5 (-6.8 to 14.0) p = 0.285 
0-48 hour eGFR  Δ  
ml/min 
-2.0 (-11.2 to 1.2) -1.2 (-5.2 to 2.3) p = 0.246 
0-48 hour  UACR  Δ 
mg/mmol 
-4.1 (-2.1 to 8.0) 0.23 (-3.2 to 1.0) p = 0.535 
0-3 month SCr  Δ  
µmol/l 
3.0 (-8.0 to 22.0) -2.0 (-21 to 18.0) p = 0.232 
0-3 month eGFR  Δ 
ml/min 
-5.5 (-9.6 to -0.4) 1.03 (-6.4 to 8.9) p = 0.082 
0-3 month  UACR  Δ 
mg/mmol 
-1.6 (-35.8 to 1.0) -0.53 (-15.6 to 0.3) p = 0.643 
 
** Mann-Whitney U-test used for non-parametric analysis 
 
 
Table 24: Subgroup analysis of patients with an eGFR<40ml/min 
 
 
eGFR<40ml/min 
n=22 
Control Group  
Med(Q1-Q3) 
n = 10 
RIPC Group  
Med(Q1-Q3) 
n =12 
Significance** 
0-48 hour SCr  Δ  
µmol/l 
2.5 (-13.5 to 10.3) -3.5 (-6.75 to 11.8) p = 0.792 
0-48 hour eGFR  Δ  
ml/min 
1.96 (-2.9 to 4.9) 0.99 (-2.64 to 2.2) p = 0.742 
0-48 hour  UACR  Δ 
mg/mmol 
0.61 (-1.9 to 10.5) 0.19 (-1.47 to 1.3) p = 0.657 
0-3 month SCr  Δ  
µmol/l 
-10 (-15.5 to 1.5) 7 (-31.5 to 13.2) p = 0.744 
0-3 month eGFR  Δ 
ml/min 
1.28 (-5.9 to 3.8) -1.65 (-4.9 to 12.5) p = 0.624 
0-3 month  UACR  Δ 
mg/mmol 
1.61 (-25.5 to 13.2) -0.37 (-1.3 to 0.4) p = 0.631 
 
** Mann-Whitney U-test used for non-parametric analysis 
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Table 25: Subgroup analysis of patients with CCF or an LVEF<50%  
 
 
CCF or LVEF<50% 
n=20 
Control Group  
Med(Q1-Q3) 
n= 9 
RIPC Group  
Med(Q1-Q3) 
n= 11 
Significance** 
0-48 hour SCr  Δ 
µmol/l 
-7.0 (-10.0 to 6.5) -4.0 (-7 to 5.0) p = 0.648 
0-48 hour eGFR  Δ  
ml/min 
2.6 (-1.8 to 8.9) 1.3 (-1.3 to 3.8) p = 0.676 
0-48 hour  UACR  Δ 
mg/mmol 
2.1 (0.4 to 5.9) 0.0 (-1.3 to 0.3) p = 0.009 
0-3 month SCr  Δ  
µmol/l 
-3.0 (-15.0 to 2.0) -4.0 (-22.5 to 8.0) p = 0.682 
0-3 month eGFR  Δ 
ml/min 
-0.2 (-1.1 to 7.1) 1.5 (-6.3 to 10.3) p = 0.870 
0-3 month  UACR  Δ 
mg/mmol 
-0.2 (-1.2 to 30.8) -0.15 (-1.8 to 0.5) p = 0.482 
 
** Mann-Whitney U-test used for non-parametric analysis 
 
 
 
Figure 30: UACR change at 48 hours and 3 months in CCF or LVEF<50%  
(No CIN occurred in either group) 
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Table 26: Subgroup analysis of patients with type 2 diabetes  
 
 
Type 2 Diabetes 
n=37 
Control Group  
Med(Q1-Q3) 
n =18 
RIPC Group  
Med(Q1-Q3) 
n =19 
Significance** 
0-48 hour SCr  Δ  
µmol/l 
4.0 (-15.6 to 10.3)  3.0 (-4.0 to 14.5) p = 0.484 
0-48 hour eGFR  Δ  
ml/min 
-2.32 (-6.2 to 9.7) -1.45 (-4.0 to 1.6) p = 0.584 
0-48 hour  UACR  Δ 
mg/mmol 
0.87 (-1.5 to 13.5) 0.1 (-1.63 to 1.1) p = 0.265 
0-3 month SCr  Δ  
µmol/l 
1.0 (-11.5 to 10.5) 9.0 (-7.0 to 19.5) p = 0.188 
0-3 month eGFR  Δ 
ml/min 
-3.1 (-5.1 to 3.8) -4.55 (-7.6 to 3.4) p = 0.222 
0-3 month  UACR  Δ 
mg/mmol 
2.4 (0.5 to 11.6) -.05 (-3.2 to 1.3) p = 0.095 
 
** Mann-Whitney U-test used for non-parametric analysis 
 
 
Table 27: Subgroup analysis of patients with anaemia  
 
 
Anaemia 
n=24 
Control Group  
Med(Q1-Q3) 
n =12 
RIPC Group  
Med(Q1-Q3) 
n =18 
Significance** 
0-48 hour SCr  Δ  
µmol/l 
0.0 (-10.0 to 17.0) 0.5 (-6.0 to 14.0) p = 0.966 
0-48 hour eGFR  Δ  
ml/min 
1.10 (-7.6 to 4.4) -0.39 (-4.4 to 2.8) p = 0.641 
0-48 hour  UACR  Δ 
mg/mmol 
0.52 (-0.78 to 
11.5) 
0.0 (-4.73 to 0.4) p = 0.066 
0-3 month SCr  Δ  
µmol/l 
-1.0 (-10.8 to 
14.3) 
-0.5 (-18.0 to 13.8) p = 0.672 
0-3 month eGFR  Δ 
ml/min 
0.6 (-8.6 to 3.0) 0.2 (-5.9 to 7.5) p = 0.611 
0-3 month  UACR  Δ 
mg/mmol 
-0.2 (-47 to 3.9) -0.5 (-15.6 to 1.2) p = 0.928 
 
** Mann-Whitney U-test used for non-parametric analysis 
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Table 28: Subgroup analysis of patients, Mehran score >6 (Moderate CIN risk) 
 
 
Mehran score >6 
n=58 
Control Group  
Med(Q1-Q3) 
n =26 
RIPC Group  
Med(Q1-Q3) 
n =32 
Significance** 
0-48 hour SCr  Δ  
µmol/l 
4.5 (-8.0 to 18.0) 2.5 (-6.0 to 13.2) p = 0.827 
0-48 hour eGFR  Δ  
ml/min 
-0.6 (-6.2 to 4.9) -1.1 (-3.8 to 2.1) p = 0.737 
0-48 hour  UACR  Δ 
mg/mmol 
0.7 (-1.2 to 5.8) 0.0 (-1.8 to 0.7) p = 0.059 
0-3 month SCr  Δ  
µmol/l 
1.0 (-12.0 to 8.5)  5.0 (-17.8 to 14.8) p = 0.886 
0-3 month eGFR  Δ 
ml/min 
-1.1 (-5.9 to 2.9) -1.7 (-6.8 to 7.5) p = 0.813 
0-3 month  UACR  Δ 
mg/mmol 
0.2 (-1.2 to 4.0) -0.3 (-1.6 to 0.9) p = 0.261 
 
** Mann-Whitney U-test used for non-parametric analysis 
 
 
Table 29: Subgroup analysis of patients, Mehran score>11 (High CIN risk) 
 
 
Mehran score>11 
n=20 
Control Group  
Med(Q1-Q3) 
n =8 
RIPC Group  
Med(Q1-Q3) 
n =12 
Significance** 
0-48 hour SCr  Δ  
µmol/l 
5.0 (-3.5 to 22.3) 4.5 (-3.75 to 14.0) p = 0.670 
0-48 hour eGFR  Δ  
ml/min 
-3.7 (-11.2 to 0.8) -1.2 (-6.3 to 2.1) p = 0.247 
0-48 hour  UACR  Δ 
mg/mmol 
2.0 (-1.6 to 15.2) 0.4 (-2.6 to 1.2) p = 0.195 
0-3 month SCr  Δ  
µmol/l 
1.5 (-6.8 to 34.0) 8.0 (-17.0 to 19.0) p = 0.710 
0-3 month eGFR  Δ 
ml/min 
1.1 (-4.0 to 20.1) -2.1 (-6.7 to 8.9) p = 0.283 
0-3 month  UACR  Δ 
mg/mmol 
-2.0 (-70.9 to 
19.3) 
0.0 (-8.7 to 1.0) p = 0.602 
 
** Mann-Whitney U-test used for non-parametric analysis 
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5.10 QUALITY ASSURANCE OF RIPC THERAPY 
 
Time from Sham/RIPC to contrast exposure  Control  n= 37 RIPC n= 41 
Hour : min (SD) 1:46 (0:57) 1.49 (0:55) 
 
 
Figure 31: Time from sham/RIPC treatment to contrast exposure 
 
 
 
 
100% of all Sham/RIPC treatments were delivered as per protocol (4 cycles of 5 minute 
inflation to 10mmHg/200mmHg followed by 5 minute deflation) as recorded in the DERIC 
device software log. 
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5.11 SIGNIFICANT ADVERSE EVENTS 
 
No SAE’s were recorded relating to blood pressure cuff inflation in either group 
 
Control group  
 
1. One patient without CIN was readmitted to hospital with suspected ACS with no 
ECG changes, negative Troponin T and no acute obstructive lesion on repeat 
coronary angiography. 
2. One patient without CIN died during follow up due to complications during elective 
cancer surgery   
3. One patient without CIN was readmitted to hospital during follow up with an upper 
gastrointestinal bleed requiring blood transfusion. 
 
 
RIPC group 
 
1. One patient suffered a femoral haematoma and hypotension post procedure and 
developed CIN 
2. One patient without CIN was readmitted to hospital with decompensated heart 
failure during follow up. 
3. One patient developed an allergic contrast reaction and required oral steroids but did 
not develop CIN. 
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5.12   PATIENT FOCUS GROUP RESPONSES 
 
Audio recordings from the two separate open question and answer sessions involving 6 
control group participants and 6 RIPC group participants were analysed and summarised. 
 
A) Initial contact with research team and Information sheet 
 
The majority of patients (67% in both groups) recalled being initially approached by a 
member the research team in person on the day of their procedure, with 33% Control, 17% 
RIPC recalling the introductory phone call with a member of the research team, and 17% of 
the RIPC group unsure. All participants were satisfied with the initial contact although 33% 
in both groups wished they had been approached earlier. 50% of patients in both groups felt 
anxiety about their cardiac procedure made understanding the PIS more difficult although 
no participants reported that they were placed under undue pressure to participate in the 
study. 100% of patients in both groups understood the research activities and follow up 
process and were given contact details of the research team. 50% of patients in both groups 
learned about their renal dysfunction for the first time during the initial contact and all felt 
they had been adequately counselled about this finding. 
 
B) On the day of the procedure 
 
100% of all participants felt that the research procedure had been adequately explained to 
them and found the research team to be polite and helpful.  No patients reported adverse 
effects from the RIPC/Sham procedure and none felt that the research procedures had 
interfered with their usual care. RIPC patients reported only mild discomfort from the cuff 
inflation, in one example a participant reported “you get used to it”. 
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C) Follow up after your procedure 
 
100% of participants reported receiving adequate instructions about where and when the 
blood tests were to be collected. However 17% of patients in both groups attended the 
wrong location for blood tests although this was quickly rectified after contacting the 
research team. 33% of participants in both groups attended satellite hospitals for blood 
sample collection and found this process to be straightforward and convenient. 33% of 
participants in both groups would have liked to attend their GP for follow up blood tests 
although recognised that this may have been difficult due to high GP workload. 
 
D) Open feedback session 
 
83% of patients in both groups expressed interest in receiving feedback from the outcome 
of study in the form of a newsletter, with 17% expressing interest in feedback via a website. 
67% of patients in both groups wished they had been approached about the study at the 
initial Coronary Angiography pre-assessment clinic. The challenge of identifying suitable 
participants, many of whom would have an unknown eGFR prior to pre-assessment was 
discussed with participants in both groups and early involvement of GP’s was recognised as 
a potential solution. 
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CHAPTER 6: CIN RE-AUDIT 
 
 
In order to close the audit loop, a re-audit of patients at undergoing CA or PCI at 
UCLH/The Heart Hospital was undertaken over a 3-month period from 1st March – 31st 
May 2014, identifying a total of 614 patients. 
 
 The CDR database was used to determine the eGFR and creatinine prior to the 
procedure and, where available, at 48-72 hours and at 3 months afterwards 
 Further blood results were retrieved from the TOMCAT database where data was 
not available on CDR (i.e. inter-hospital “treat and returns”) 
 Clinical records were ordered to determine if:  
o  i.v. sodium bicarbonate had been prescribed and administered 
o Appropriate consent to include CIN had been obtained 
o A repeat (48-72h) blood test had been requested  
o The new WHO check list had been carried out and the form completed 
 
  Mean age was 63; 68% were male 
  15% were “treat and returns” 
  83% had no follow-up bloods within UCLH NHS trust 
  16% (100  patients) had an eGFR<60 ml/min 
  Rate of CIN in this high-risk cohort: was 6-14% 
  30-day mortality rate was 1.95% (no significant difference from 2012) 
 A WHO check list was present in 27% of case notes analysed 
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Figure 32: UCLH CIN audit 2012 compared with re-audit 2014 
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CHAPTER 7: DISCUSSION 
7.1  CLINICAL AUDIT 
 
The most striking finding to emerge from the Clinical Audit in 2012 was that in patients 
undergoing CA or PCI at UCLH, those with at least moderate pre-existing renal impairment 
had a five-fold increase in mortality at 30 days compared to patients with normal renal 
function, with the development of CIN leading to a further doubling mortality in this high 
risk group. The onset of CIN may not have played a causal role in all cases, perhaps acting 
as a marker of severe multi-organ injury, although an extensive body of evidence clearly 
demonstrates that CIN is independently associated with poor cardio-renal outcomes (section 
1.3.3). The principle finding of the Audit was that compliance with the UCLH CIN 
prevention protocol was markedly suboptimal, which catalysed conception and design of the 
clinical trial in tandem with a reinvigorated educational programme and audit cycle, in order 
to improve standards of care and patient outcomes. 
 
7.2  ERICCIN OUTCOMES 
 
In this multicentre double blinded randomised controlled trial, enrolling 100 patients at risk 
of CIN undergoing CA or PCI, standard CIN prophylaxis plus RIPC (4 cycles of 5 minute 
upper limb ischaemia and reperfusion) did not reduce the incidence of CIN at 48 hours 
(5.4% vs 4.8%, OR 1.1 (CI 0.15 to 8.33), p = 0.91) even when adjusted for the main CIN 
risk factors of age>75, eGFR, diabetes, CCF, anaemia, hypotension and contrast media 
volume (Adjusted OR 1.9, CI 0.19  to 20.5, p = 0.575). There were no significant differences 
in SCr, eGFR or UACR at 48 hour or 3 months between control and RIPC groups and no 
effect was observed on cardio-renal endpoints.  
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A small but non-significant trend towards abrogation of median SCr increase at 48 hours 
after RIPC was seen. No significant change in SCr occurred between pre-angiography and 3 
month sample points within either group, which is not surprising given the low incidence of 
CIN and minimal deterioration in renal function expected in CKD over the short course of 
the study. 
 
Subgroup analysis of patients with CCF receiving RIPC demonstrated a small but significant 
abrogation in UACR increase at 48 hours (2.1 vs 0 mg/mmol, Z = -2.598, r = 0.63, p=0.009), 
which did not persist at 3 months. This was observed in the context of a general but non-
significant trend towards abrogation in UACR increase at 48 hours in all patients treated with 
RIPC, particularly in those with anaemia or Mehran scores >6. However it is important to 
recognise that these findings are significantly underpowered and cannot establish a 
conclusive relationship, but may provide a hypothesis-forming basis for future CIN studies.  
 
7.2.1  LOWER THAN EXPECTED CIN INCIDENCE 
 
In trial enrolled patients, where CIN prophylaxis was 100% compliant with pre-hydration, 
Visipaque use and minimised administered contrast volumes (mean 120ml, SD 88.5-200ml) 
a precipitous reduction in the incidence of CIN(5%) was observed. Due to the much lower 
than expected incidence of CIN at interim data analysis, the DMC for the study deemed that 
the trial was significantly underpowered and recommended halting further recruitment on 
grounds of futility. With a CIN incidence of approximately 5% and an assumed RIPC effect 
of a 60% reduction in CIN, 1176 participants would have been required to achieve a power 
of 80% and an α value of 0.05. This was felt to be well beyond the scope of a proof of 
concept investigation, although might be achievable in a larger clinical trial should a 
supportive body of evidence accumulate from similar pilot studies.  
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Changes in serum NGAL were not assessed due to resource constraints in the context of a 
neutral study outcome, with the DMC recommendation that NGAL analysis was unlikely to 
yield further useful information. Point of care NGAL could not be fully assessed due to the 
small number of tests performed, with the sole intention at the outset to correlate a small 
panel of these results with laboratory NGAL samples at the close of the study. 
 
7.3  POTENTIAL CAUSES FOR LOW CIN INCIDENCE 
 
 FEASIBILITY ERROR 
 
The initial CIN audit in 2012 suggested that a CIN rate of 15% was to be expected in the 
control group, however a much lower incidence of approximately 5% CIN was observed. 
This disparity may have been attributable to sampling bias in the audit, leading to 
overestimation of the true CIN incidence. Only 37% of patients at risk of CIN subsequently 
had 48-hour SCr results documented at UCLH, with the vast majority of this cohort requiring 
a prolonged inpatient stay following their procedure, potentially due to procedural 
complications, severity of illness or comorbidity and thus were more likely to have developed 
CIN. Of the remaining 63% at-risk patients with no documented 48 hour creatinine results 
at UCLH, most were referred to their GP or referring hospitals for follow up, and in some 
repeat SCr may not have occurred within 72 hours. However a lower rate of CIN is more 
likely in this group when compared to inpatient group, although to what extent it is difficult 
to quantify and inclusion of the missing GP data was beyond the scope of the initial audit. 
As a result the initial power calculation for the study is likely to have underestimated the 
recruitment target that was necessary to achieve appropriate power. 
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 PARTICIPANT SELECTION 
 
A degree of selection bias may have occurred favouring inclusion of lower risk patients, as 
higher risk patients were more likely to decline participation, be subsequently excluded, or 
experience difficulties attending follow up at the nominated time points. Of the 244 patients 
eligible for inclusion to the study, over 46% declined participation at the outset, most 
frequently patient due to inability or reluctance to travel to the various research sites for 
sample collection at 48 hours and 3 months.  Unfortunately the study was unable to provide 
subsidised transportation or community CRN support for the majority of participants that 
were located across a very wide geographical area.  
 
Almost all participants were discharged or repatriated to their referring hospitals within 48 
hours of their coronary angiogram, often precluding direct interaction with the research team 
beyond this point. Some participants with impaired mobility were assisted with travel 
arrangements to their nearest participating hospital for follow up, with telephone support 
provided for others when necessary. GP involvement had been considered during the study 
design process, but was not implemented due to the complexity of REC and NIHR approval 
for the numerous GP practices that would have been required to participate, in addition to 
anticipated difficulties with sample collection and processing. Of the 100 patients enrolled 
in the trial, 10 were excluded prior to the 48 hour time point as 0 hour eGFR was > 
60ml/min, despite an initial screening eGFR of<60ml/min. The labile nature of eGFR 
results, largely attributable to necessary provision of adequate oral hydration and withdrawal 
of diuretics pre-procedurally was unavoidable in the study. A total of 12 patients were lost 
to follow up at 48 hours and another 5 patients at 3 months, mainly due to participant non-
attendance and sampling errors, and as such it is possible that CIN and longer-term renal 
sequelae were not detected in these excluded participants. 
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The lower than expected accrual rate resulting from the various logistical and clinical 
challenges ultimately negatively impacted on the projected recruitment target of 364 patients, 
whilst there was concern that patients at higher risk of CIN may not have been adequately 
represented in the study due to the inherent difficulties involved in recruiting patients with 
poor health or restricted mobility. Despite early recognition of these issues and significant 
efforts to address them, including learning from participant feedback in focus group 
meetings and two major amendments to the protocol expanding recruitment to multiple 
research centres, these intrinsic difficulties persisted until the close of the study. 
 
In order to examine whether a lower risk cohort of study participants had inadvertently self-
selected, the predicted CIN risk of all enrolled participants was calculated using the widely 
adopted CIN risk score proposed by Mehran et al, which was compared with observed CIN 
incidence in both the audit and clinical trial. 
 
Table 30: Predicted CIN incidence based on Mehran risk score  
 
Mehran Score 
& Risk of CIN 
Control group, n=37 
 
RIPC group, n=41 
(assuming no RIPC 
effect) 
 n Predicted CIN, n n Predicted CIN, 
n 
<5 
(5% risk) 
11 0.55 
 
9 0.45 
6-10 
(14% risk) 
18 2.52 20 2.8 
11-15 
(26.1% risk) 
6 1.56 11 2.87 
>15 
(53.1% risk) 
2 1.06 1 0.53 
Predicted CIN 
Total 
37 
 
5.69 (15.4%) 41 6.65 (16.2%) 
Observed CIN 
Total 
37 2 (5.4%) 
 
41 2 (4.8%) 
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Interestingly the calculated CIN risk in both the control (15.4%) and RIPC (16.2%) groups 
closely matches that seen in the clinical audit (~15%), compared with the much lower 
observed rate of CIN (5.4% and 4.8%) in the clinical trial. This suggests that the Mehran 
score may not be applicable to the ERICCIN study population who received significantly 
more efficacious CIN prophylaxis than the population studied by Mehran et al and indeed 
the cohort included in the initial CIN audit at UCLH.  
 
Data from the audit revealed that only 55% of at-risk patients received i.v. sodium 
bicarbonate pre-hydration and only 74% received iso-osmolar contrast agents, whereas 100% 
of participants in the study received both prophylactic interventions. It is also worth noting 
that a significant number of patients included in the audit would not have been eligible for 
the clinical trial, including those aged over 85 years, those undergoing PPCI for STEMI and 
those with previous contrast exposure within one month, all high risk factors for CIN 
deemed to be too complex to have included in the study. 
 OPTIMAL CIN PROPHYLAXIS  
 
Rigorous adherence to the ‘best practice’ CIN prevention protocol brought about a dramatic 
improvement in CIN incidence and patient outcomes, beyond that easily achievable in 
routine clinical practice or as seen in prior observational studies. This was achieved by strict 
adherence to nephrotoxic medication withdrawal peri-procedurally, pre and post hydration 
with i.v. bicarbonate 1.26% and use of low volumes of iso-osmolar CM with extensive use 
of biplane imaging techniques (section 1.3.7).  
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 CIN DEFINITION 
 
Serial SCr measurements collected over a broader 48 -120 hour timeframe may have included 
later CIN presentations which were not detectable at the 48 hour time point, although the 
intensive nature of blood sample collection required would not have been feasible to achieve 
in this predominantly outpatient study group.  Equally measurement of urinary output, the 
most sensitive early marker of CIN requiring invasive urinary catheterisation, would not have 
been appropriate in our study population.  Other validated markers of CIN such as Cystatin 
C, Urinary Kim-1 and L-FABP may have been of interest to study, although their correlation 
with adverse clinical outcomes following CIN is less well established. 
 
 PARTICIPANT FEEDBACK GROUP  
 
Confounders may have existed during the feedback process as the group of patients who 
had devoted additional time and effort to attend were part of a cohort of patients who had 
already consented to be part of the trial. Although results from the feedback sessions were 
largely favourable and did not suggest a major revision of the trial design was required, it is 
impossible to know the opinions of those who did not wish to participate in the study at the 
outset. The attending participants were further sub-selected into a group who were self-
motivated to attend the meeting and other non-attending participants’ views remain 
unknown. As such any conclusions drawn from the feedback exercise should be interpreted 
with a degree of caution. 
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7.4  RE-AUDIT 
 
The start of the ERICCIN trial brought with it an educational campaign at participating 
research centres as the trial mandated 100% compliance with existing best-practice standards 
defined in the study protocol. Re-audit of clinical practice at UCLH, 12-months after the 
start of the trial, demonstrated improved compliance with CIN guidelines (60% compliance 
with pre-hydration, 91% compliance with Visipaque usage and mean contrast volume 
reduction from 160ml to 147ml in at-risk patients). Improved compliance was associated 
with a concomitant fall in the rate of CIN to between 6-14%, from a previous rate of 10-
20%.  As such it is possible to draw the conclusion that strict adherence with CIN guidelines 
is extremely effective at reducing the rates of CIN and that the trial functioned as an effective 
basis for an excellent quality improvement programme. 
 
7.5  OTHER FINDINGS 
 
Remote ischaemic conditioning was found to be both safe and easy to apply, with no 
reported adverse events directly related to RIPC administration. The trial allowed robust 
assessment of the novel ‘Deric’ device, paving the way for use of the device in ongoing RIPC 
trials at UCLH. ERICCIN was a well-run, NIHR CRN approved multicentre clinical trial, 
which encouraged participant involvement throughout the study, receiving positive feedback 
from participants and members of the research teams.  
 
 
  
162 
 
 
 
 
7.6   POTENTIAL CAUSES FOR NON-SUPERIORITY OF RIPC  
 
The neutral outcome of the ERICCIN study suggests that RIPC may not be an effective 
prophylactic treatment against CIN, although the study was not adequately powered to draw 
firm conclusions. This is in contrast to a number of previous pilot studies suggesting the 
efficacy of RIPC against CIN, the prototypical example being that performed by Er et al. 
However important differences exist between ERICCIN and this previous study, which 
enrolled a population at significantly higher risk of CIN with a median Mehran Score of 13 
(Q1-3, 10 - 17) as compared with a Mehran score of 8 (Q1-3, 5 - 11) in the ERICCIN trial. 
Er et al also utilised a different CIN prevention strategy (PO NAC and i.v. 0.9% NaCl 
1ml/kg hr for 12 hours pre and post CA with non iso-osmolar contrast agent use) and had 
higher rates of acute heart failure necessitating i.v. diuretic administration. This suggests that 
RIPC may be an effective intervention against CIN in higher risk patient groups and to a 
lesser degree in lower risk patients receiving effective standard prophylaxis. 
 
The recently published RIPCIN study432 (n=76), which followed a similar protocol to 
ERICCIN, also demonstrated no significant reduction in CIN at 48 hours after RIPC (2 
sham vs 2 RIPC). However subgroup analysis of patients with Mehran risk scores ≥11, 
showed a significant reduction in SCr from baseline to 48 - 72 hours in the RIPC group ( Δ 
SCr -3.3 ± 9.8 μmol/L) vs control group ( Δ Scr +17.8 ± 20.1 μmol/L). Subgroup analysis 
of ERICCIN study patients with Mehran scores >11 unfortunately did not reflect this 
finding ( Δ Scr +5.0 vs +4.5 μmol/L), however the small number of patients in both groups 
(RIPCIN n=11, ERICCIN n=20) limits direct comparison and interpretation. It is 
reasonable to hypothesise that the highly effective CIN protocol used in ERICCIN, in 
addition to various confounders, may have led to under-powering of the study, suppression 
of a significant RIPC effect and a neutral outcome.  
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7.6.1 CLINICAL DIFFERENCES BETWEEN STUDY GROUPS 
 
The minimised randomisation process robustly ensured that no significant differences 
existed between the control and RIPC groups with respect to the most important CIN risk 
factors, namely age>75 (35.1% vs 39%, p=0.54), diabetes mellitus (48.6% vs 53.7%, p=0.84), 
CCF (10.8% vs 12.1%, p=0.85) and low haematocrit (32.4% vs 31.4%, p=0.29). Contrast 
media volumes were equivalent in both groups (120ml vs 110ml, p=0.87) as were total i.v. 
bicarbonate hydration volumes (750 ml vs 714ml, p=0.26) and time to procedure after sham 
or RIPC which was performed largely within the 2 hour therapeutic window (80%). Apart 
from three variables which had not been expected nor accounted for in the study design, 
there were no significant differences in other demographic or clinical characteristics between 
the two groups:. 
 
By chance the control group had a significantly higher proportion of patients with CCS I-IV 
anginal symptoms (48.6% vs 24.3%, p=0.03) and perhaps unsurprisingly increased use of 
nitrate medications (51.4% vs 22%, p=0.007) and P2Y(12) receptor antagonists (81.1% vs 
61% p=0.05). It is reasonable to postulate that, by chance, a beneficial set of confounders 
existed in the control group resulting in reduced risk of CIN when compared with the RIPC 
group, as discussed below.  
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7.6.1.1 Myocardial Ischaemia 
 
The potential for myocardial ischaemia to subsequently induce RIPC on the kidney has not 
been extensively investigated. Defterios et al191 demonstrated that in 225 patients undergoing 
PCI following NSTEMI, brief cycles of myocardial ischaemia induced by intermittent 
balloon inflation within the acutely stented coronary artery (RIPostC) significantly reduced 
the incidence of CIN (29.5% vs 12.4%, p=0.002) and suggested a trend towards reduced 
mortality and rehospitalisation at 30 days.   In light of this fascinating result, the higher 
burden of myocardial ischaemia present in the control group might theoretically have exerted 
a RIPC effect on the kidney, potentially via the ‘second window of protection’ phase, thus 
conferring reno-protection against CIN.  
 
7.6.1.2 Nitrate use 
 
The increased use of nitrate medications in the control group may have led to unintentional 
pharmacological conditioning against CIN (section 1.5.3.4). This phenomenon was proposed 
by Peguero et al438 in 2015, following a retrospective analysis of 199 patients undergoing PCI 
following NSTEMI, where peri-procedural nitrate use was independently associated 
significantly lower rates of CIN (OR 0.334, CI 0.16-0.7, p= 0.03), particularly when 
administered intravenously. The ERIC-GTN trial439 is currently investigating the role of 
intravenous glyceryl trinitrate (GTN) as a cardio-protective agent during cardiac surgery and 
may determine whether GTN interferes with RIPC cardio-protection. Further investigation 
in large randomised studies is required to determine whether this simple and cost effective 
therapy can be successfully employed as prophylaxis against CIN. 
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7.6.1.3 P2Y(12) receptor antagonist use 
 
The effect of P2Y(12) receptor antagonists (Clopidogrel, Prasugrel and Ticagrelor) on CIN 
is as yet unknown. Clopidogrel inhibits expression of platelet activation markers and platelet-
leukocyte aggregation and has been shown to exert independent cardio-protective effects 
against myocardial IRI to the same magnitude as conferred by IPostC following PPCI in 
STEMI440. Both Ticagrelor and Cangrelor (an intravenous P2Y(12) receptor antagonist), 
have been shown to  induce cardio-protection in animal models and do not confer additional 
benefit  when used in combination with IPC441. This suggests  P2Y(12) pharmacological 
conditioning and IPC may share a common pathway, recently suggested by Cohen et al442 to 
be mediated by sphingosine kinase, rather than via platelet inhibition per se. Further studies 
are required to determine if the pharmacological conditioning effect of P2Y(12) receptor 
antagonists extends to the kidney and is effective against CIN.  
 
7.6.2 RIPC RESISTANCE  IN DIABETES MELLITUS 
 
A large proportion of diabetic patients were enrolled the study (48.6% control group, 53.7% 
RIPC group) which may have led to significant abrogation of any RIPC effect. A number of 
studies have demonstrated that the pro-survival pathways critical to IC efficacy are impaired 
in diabetes mellitus443. Although most studies have investigated resistance to IC cardio-
protection, it is reasonable to hypothesise that this inhibitory effect extends to reno-
protection. In order to summate any resistance to RIPC in diabetic patients, the protocol 
deliberately utilised 4 cycles of RIPC, as opposed to 3 cycles as commonly used in previous 
studies, although it is unknown if increasing the number of RIPC cycles is sufficient to 
overcome this phenomenon. In practical terms, a higher number of RIPC cycles beyond that 
used in the study may lead to both logistical and tolerability limitations for the treatment. 
166 
 
 
 
 
7.7  CIN AND MICROALBUMINURIA  
 
Few previous studies have directly examined the relationship between CIN and an acute 
changes in UACR, with most focusing on elevated UACR as a pre-procedural risk factor444, 
or associated more generally with AKI. Tzakias et al445 compared the prognostic ability of 
three novel biomarkers of renal injury (NGAL, Cystatin C, IL-18) with UACR to detect AKI 
in patients hospitalised with MI. Acute elevation in UACR (> 66.7 μg/mg at 48 hours) was 
found to be an independent marker of AKI (Sensitivity 68%, Specificity 76%) with superior 
discriminating ability over urine NGAL, urine Cystatin-C and serum Cystatin-C across a wide 
variety of clinical sub-groups.  Although not powered to determine an association of UACR 
with clinical outcomes, development of AKI was associated with prolonged hospitalisation, 
increased morbidity during hospital admission, persistent worsening of renal function and 
increased mortality at follow-up.  
 
 Animal models have shown that UACR increases as early as 4 hours after intrinsic renal 
injury (ischemia–reperfusion, nephrotoxicity and rhabdomyolysis) although not in pre-renal 
(endotoxin) or post-renal (obstructive uropathy) injury446. These findings suggest that acute 
elevation in UACR is specific to intrinsic causes of AKI such as CIN and precedes changes 
in SCr. As such this simple bedside test appears to be a practical and cost effective tool to 
safely rule-out or predict the onset of CIN.  
 
ERICCIN is the first clinical trial to examine the effect of RIPC on CIN using UACR as a 
biomarker of renal injury, however it was not designed to assess whether UACR could 
predict CIN, as defined by elevation in SCr. Although no significant reduction in UACR was 
demonstrated following RIPC despite a general trend towards benefit, subgroup analysis in 
patients with CCF showed significant benefit and a near significant benefit was seen in 
patients with anaemia and a Mehran score >6.  
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This interesting finding may be worthy of future study, not least due to the fact that UACR 
is an established biomarker for predicting adverse cardiovascular events and mortality447. This 
subgroup of patients with established higher cardiovascular risk, inherent to conditions such 
as CCF, might potentially have more to gain from therapeutic interventions designed to 
minimise elevation in UACR. Large adequately powered RCT’s are required to establish 
whether RIPC is effective at preventing CIN and acute elevation of UACR in higher risk 
groups and whether this correlates with improved short and long-term cardio-renal 
outcomes. 
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CHAPTER 8: CONCLUSION & FUTURE DIRECTIONS 
 
At the outset of the study, CIN was established to be a common and serious complication 
occurring in high risk patients undergoing CA or PCI at UCLH, in keeping with the wealth 
of supporting evidence from previous studies within this area. Adherence to the local and 
national standard of care for CIN prophylaxis was found to be suboptimal, prompting a local 
educational programme and audit cycle whilst inspiring development of the randomised 
controlled trial ERICCIN, designed to examine whether RIPC, a safe, easily applied and non-
invasive therapy, in addition to standard care was capable of further minimising the incidence 
of CIN, a prototypical example of renal ischaemia reperfusion injury.  
 
Out of a target of 362 patients at risk of CIN following CA or PCI, 100 participants were 
recruited across three hospital research sites in London and South East of England and 
randomly allocated to RIPC (four 5 minute cycles of upper limb ischaemia-reperfusion) plus 
standard therapy vs standard therapy alone, with renal injury biomarkers (SCr and UACR) 
and cardio-renal endpoints assessed over 48 hour and 3 month time points. Due to an 
unexpectedly low incidence of CIN in the control group, the study was significantly 
underpowered and was closed prematurely by the study DMC, with no significant difference 
in CIN rate, novel biomarkers or cardio-renal endpoints between groups occurred by close 
of study. 
 
Whilst the ERICCIN trial was unable to demonstrate the efficacy of RIPC against CIN 
within the study cohort, it was found that optimal management of high risk patients 
consistent with 100% compliance with evidence based local and national guidelines, all but 
eradicated the excess kidney injury associated with contrast administration in the study 
cohort.  
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Implementation of the comprehensive education and audit cycle in parallel with the study 
brought about significant improvements in standards of care and improved patient 
outcomes.  This of itself was an unexpected but welcome finding, which fully justifies full 
implementation of current clinical guidance in this field of practice.  
 
Despite the neutral outcome of the study, several hypothesis-forming findings were 
uncovered, including whether RIPC might be more efficacious in patients at very high-risk 
of CIN and the potential for minimisation of UACR elevation. Despite optimal CIN 
prophylaxis in very high-risk groups, cardio-renal outcomes remain predictably poor and 
often necessitate costly and harmful interventions. RIPC may offer a simple and cost neutral 
therapy for carefully selected very high risk patients, where even a modest beneficial effect 
has the potential to dramatically improve patient outcomes and reduce healthcare costs. The 
concept of a threshold for RIPC reno-protection is raised by the high number of participants 
with diabetes mellitus within the study group who may not have been responsive to the RIPC 
protocol, perhaps requiring greater frequency or longer duration of limb ischaemia 
reperfusion cycling or even combination with alternative forms of conditioning. It is possible 
that inadvertent myocardial RIPC or pharmacological conditioning of the control group by 
nitrate medications and P2Y(12) inhibitors may have conferred a similar protective effect 
against CIN as that of RIPC in our study group.  
 
These phenomenon are worthy of further study in their own right, with the latter currently 
the focus of ongoing basic and clinical research at UCLH. Development and validation of 
the novel ‘DERIC’ device is also expected to significantly enhance, homogenise and simplify 
the delivery of RIPC in these future clinical trials. The results of our study do not rule out 
RIPC as a prophylactic adjunct against CIN, but suggests that it may only be of benefit in 
certain populations and clinical scenarios, the recommended primary foci for future studies.  
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APPENDIX 
1. DERIC safety certificate 
 
 
 
 
 
 
 
                                                                          
 
Electrical Safety Report:     
 
 
Account Name: UCL - DERIC 
Address : Room 3.23, Dept. Medical Physics and Bioengineering, 
Malet Place Engineering Building, University College 
London, Gower Street, LONDON, WC1E 6BT 
Contact name: Dr Nick Everdell/Roger Rear 
 
Medical Equipment information: 
 
Manufacturer: UCL Model: DERIC System Serial Number: N/A 
Description: A laptop with control software, controlling DERIC system for 
controlled operation of inflation pumps. 
Class: Class I BF 
 
  
ES14010 
    
  
 W3  
 
    
 
    
201 
 
 
 
 
1. Block Diagram 
 
 
 
Electrical Safety Conditions: 
 
Mains Voltage: 
 
L1-earth 239V 
L2-earth 0.5V 
L1-L2 240V 
 
 
Protective Earth Resistance (<0.20 Ω): 
 
0.11 Ω Pass 
 
 
Insulation Resistance (>20.00 MΩ) 
 
>99.99 MΩ Pass 
 
Earth Leakage Current: 
 
Normal: 0.041mA Pass 
nP: 0.060mA Pass 
rP: 0.100mA Pass 
rEu: 0.098mA Pass 
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Enclosure Leakage Current 
 
Normal: 0.040mA Pass 
nE: 0.040mA Pass 
nP: 0.040mA Pass 
rP: 0.040mA Pass 
rEu: 0.040mA Pass 
rE: 0.086mA Pass 
 
 
Patient Leakage Current (AC) 
 
Normal: 0.004mA Pass 
nE: 0.004mA Pass 
nP: 0.004mA Pass 
rP: 0.004mA Pass 
rEu: 0.004mA Pass 
rE: 0.004mA Pass 
Patient Leakage Current (DC) 
 
Normal: 0.004mA Pass 
nE: 0.004mA Pass 
nP: 0.004mA Pass 
rP: 0.004mA Pass 
rEu: 0.004mA Pass 
rE: 0.004mA Pass 
 
 
Patient Auxiliary Current (AC) 
 
Normal: 0.004mA Pass 
nE: 0.004mA Pass 
nP: 0.004mA Pass 
rP: 0.004mA Pass 
rEu: 0.004mA Pass 
rE: 0.004mA Pass 
 
 
Patient Auxiliary Current (DC) 
 
Normal: 0.004mA Pass 
nE: 0.004mA Pass 
nP: 0.004mA Pass 
rP: 0.004mA Pass 
rEu: 0.004mA Pass 
rE: 0.004mA Pass 
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Patient F-type Current 
 
Normal: 0.025mA Pass 
nE: 0.025mA Pass 
nP: 0.025mA Pass 
rP: 0.025mA Pass 
 
 
Load 
 
<0.06 KVA (239V) Pass 
 
 
Polarity 
 
Open Pass 
 
 
 
 
 
Comments: 
 
The above readings all fall within safety limits. Appropriate electrical safety should be 
repeated if equipment transported to different location. 
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